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ABSTRACT 
 
 
Lantibiotics are polycyclic antimicrobial peptides that are ribosomally synthesized 
and posttranslationally modified to their biologically active forms. The recently 
discovered lantibiotic epilancin 15X produced by Staphylococcus epidermidis 15X154 is 
active against several pathogenic bacteria, including methicillin-resistant S. aureus and 
vancomycin-resistant Enterococci. Epilancin 15X contains an unusual N-terminal lactate 
group (Lac) that could be important for its bioactivity. To understand its biosynthesis, the 
epilancin 15X gene cluster was identified. The Lac group is introduced by dehydration of 
a Ser residue in the first position of the core peptide by a lantibiotic dehydratase (ElxB), 
followed by proteolytic removal of the leader peptide by a serine-type protease (ElxP), 
and hydrolysis of the resulting N-terminal dehydroalanine residue. A pyruvyl group thus 
formed is finally reduced to Lac by a dehydrogenase (ElxO). Using substrate analogs 
synthesized by solid-phase peptide synthesis or heterologously expressed in 
Escherichia coli, the enzymatic activities of ElxO and ElxP and their substrate 
specificities were investigated in vitro. Furthermore, the dehydratase activity of ElxB 
was demonstrated in vivo. ElxO tolerates several structural modifications along the 
substrate sequence and can catalyze the NADPH-dependent reduction of diverse 
pyruvyl- and oxobutyryl-containing peptides, such as the lantibiotic lactocin S, to the 
corresponding alcohols. The reaction mechanism of ElxO was proposed based on its 
x-ray crystal structure and a mutagenesis study. The characterization of ElxP 
demonstrated that the protease can cleave the unmodified precursor peptide and relies 
on the C-terminal residues of the leader region for substrate recognition. Finally, the 
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stereochemical configuration and the importance of the N-terminal Lac for peptide 
stability against bacterial aminopeptidases were determined. Understanding the 
biosynthetic route to epilancin 15X opens the door for engineering of novel lantibiotics 
with more potent biological activities or different spectra of action. 
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CHAPTER 1. INTRODUCTION* 
 
 
1.1. LANTIBIOTICS AND THE PROBLEM OF BACTERIAL RESISTANCE  
Over the last several decades, bacterial resistance to known classes of 
antibacterial agents has been rising at an alarming rate, mainly due to the widespread 
overuse of antibiotics. The exclusive dependence on broad-spectrum antibiotics has 
intensified the problem by inducing the development of multidrug-resistant pathogens. 
For instance, 60% to 70% of all Staphylococcus aureus strains isolated in hospitals are 
currently multidrug-resistant (1). In recent years, the number of fatalities due to 
infections caused by this microorganism in the United States was larger than the 
number of deaths attributed to AIDS (1). Furthermore, the rising prevalence of 
methicillin-resistant S. aureus (MRSA) increases the likelihood that vancomycin-
resistant S. aureus (VRSA), which is more challenging to treat, will become a new 
scourge in hospitals (2). Despite the rise of resistant pathogens, the rate of discovery 
and approval of new antibiotics has been dramatically decreasing. Indeed, during the 
last five decades, only four new classes of antibiotics have been introduced, in part due 
to high rediscovery rates of old scaffolds and to the unfavorable economics of antibiotic 
development compared to other drugs (2, 3). In order to prevent potential epidemic 
outbreaks, new antibacterial drug classes not affected by existing resistance 
mechanisms are therefore much needed.  
Lantibiotics are ribosomally synthesized and posttranslationally modified 
polycyclic peptides that contain thioether cross-links and that demonstrate promising 
                                                            
* Reproduced in part with permission from: “Velásquez, J. E., and van der Donk, W. A. (2011) Genome mining for 
ribosomally synthesized natural products, Curr. Opin. Chem. Biol. 15, 11-21.” Copyright © 2010 Elsevier Ltd. 
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activity against pathogenic bacteria due to their high potency, low frequency of 
antimicrobial resistance, and lack of significant cytotoxicity (4). In addition to the 
characteristic lanthionine and methyllanthionine rings, members of this family are 
commonly characterized by the presence of the dehydrated amino acids 
dehydroalanine (Dha) and dehydrobutyrine (Dhb) and several other unnatural amino 
acids, such as lysinoalanine and hydroxy-aspartate in cinnamycin; S-aminovinyl-D-
cysteine, hydroxyproline, and chlorinated tryptophan in microbisporicin; and D-alanine 
and N-terminal pyruvyl (Pyr) in lactocin S (Figure 1.1). Nisin, the most studied lantibiotic 
(Figure 1.2), has been used in food preservation and treatment of bovine mastitis during 
the last 40 years in more than 80 countries without the development of natural bacterial 
resistance (5), possibly as a consequence of its multiple modes of action (6). The N-
terminal portion of nisin, as well as several other lantibiotics, recognizes the membrane-
bound cell wall precursor lipid II, inhibiting peptidoglycan biosynthesis (Figure 1.3) (7-9). 
Once the molecule is docked to the membrane, the C-terminal portion generates stable 
pores that result in membrane damage and depolarization (10).  
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Figure 1.1. Posttranslational modifications in lantibiotics. 
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Figure 1.2. Structures of the epilancin-group of lantibiotics (epilancin K7, epilancin 15X, and 
SWLP1) using the shorthand notation from Figure 1.1. The non-conserved residues are 
highlighted with an asterisk in the structure of epilancin K7. The structures of nisin A and 
paenibacillin with considerably homology with the C- and N-terminus of the epilancin-group of 
peptides, respectively, are also shown. 
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Figure 1.3. A dual mode of action of the lantibiotic nisin A. By using the pyrophosphate moiety 
of lipid II as a docking molecule, the N-terminal rings of nisin inhibit polymerization of murein 
subunits in bacterial cell wall biosynthesis (A), while the C-terminal portion forms pores in the 
plasma membrane (B) leading to cell death. Reproduced in part with permission from (5). 
 
Lantibiotics have been known for decades and many of them are active against 
pathogenic bacteria at nanomolar levels (11-13). For instance, as early as 1952, nisin A 
(Figure 1.2) was shown to be as effective as penicillin in the treatment of mice infected 
with Mycobacterium tuberculosis, Streptococcus pyogenes, and S. aureus (14). 
Moreover, despite the short half-life and rapid clearance of nisin A from the blood, the 
peptide was shown to be more effective than vancomycin in an S. pneumoniae mouse 
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infection model (15). However, lantibiotics have not been extensively tested for their 
potential utility in the treatment of infectious diseases and no lantibiotics are currently 
approved in this area. Previous attempts have failed mainly due to the difficulty of 
obtaining these molecules in sufficient, cost effective amounts to enable their testing 
and commercialization (16). Standard fermentations methods, such as those used to 
make a variety of other antibiotics, have been rarely successful (16), with only a few 
cases, such as for the staphylococcal lantibiotics epidermin and gallidermin (17-20), 
being produced in significant amounts (more than 400 mg/L). Furthermore, in cases in 
which large amounts of lantibiotics are produced, such as for nisin A, the peptides have 
limitations due to chemical/biological stability under physiological conditions or the purity 
standards required for clinical testing have not been achieved (21). Thus, current 
challenges in the field include the identification of lantibiotics with increased stability that 
are effective against pathogenic bacteria and the development of alternative 
approaches for their production in a cost effective manner. The in vitro reconstitution of 
the biosynthetic machinery using purified Escherichia coli recombinant expression 
products, as demonstrated for lacticin 481 (22, 23), or the in vivo heterologous 
expression in a manageable host, as recently shown for three different peptides (24), 
have opened a door for more efficient production and purification strategies of 
lantibiotics. Furthermore, the recent discovery of several lantibiotics, such as the 
epilancin-group of peptides (Figure 1.2), with remarkable antimicrobial activity against 
pathogenic bacteria, including MRSA and vancomycin-resistant Enterococci (VRE), may 
aid in the development of novel peptide-based drug therapies. 
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1.2. THE EPILANCIN-GROUP OF ANTIMICROBIAL COMPOUNDS 
At present more than 60 different lantibiotics have been structurally characterized 
and they have been classified in two groups based on the topology of their rings (5, 13). 
The type A lantibiotics, such as the well studied nisin A and Pep5, have a propensity to 
form elongated amphipathic screw-shaped membrane depolarizing structures and have 
a net positive charge, whereas type B lantibiotics, as in the case of cinnamycin or 
mersacidin, are more globular and compact in structure and are less charged (5). Within 
the type A lantibiotics, the epilancin-group is characterized by an N-terminal linear tail 
composed of 11 residues including several dehydrated amino acids and capped by the 
unusual N-terminal 2-hydroxypropionyl group (lactate, Lac) (Figure 1.2). The C-terminus 
of the polypeptides contains two intertwined MeLan rings, with a spacing of two 
residues between the bridging residues. Interestingly, two of the dehydrated amino 
acids in the N-terminus are neighbors, which may impose certain conformational 
restrictions (25). 
Epilancin K7 was the first member of this group of peptides to be characterized 
(25, 26). It was isolated from S. epidermidis K7 and it is a large (31 residues, 3032 Da), 
elongated, and basic peptide due to the presence of six positively charged amino acids. 
The structure was determined by extensive two-dimensional and three-dimensional 
NMR spectroscopy and contains one lanthionine (Lan) and two 3-methyllanthionine 
(MeLan) bridges, one 2,3-didehydroalanine (Dha), three (Z)-2,3-didehydrobutyrine 
(Dhb), and an unprecedented N-terminal Lac. Epilancin K7 adopts an extended, flexible 
structure in water, although the rings likely have defined conformations (25). However, 
after interaction with membranes, or under conditions that mimic such situations, the 
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peptide may adopt a more ordered structure than in water, as evidenced by NMR 
spectroscopy experiments with dodecylphosphocholine micelles (25). 
The lantibiotic epilancin 15X was isolated from S. epidermidis 15X154 and highly 
resembles epilancin K7 with 68% sequence identity (27). It also contains 31 residues 
(3175 Da), including ten amino acids that are posttranslationally modified and seven 
positively charged residues. The primary and tertiary structures were determined by 
mass spectrometry and NMR spectroscopy confirming the presence of the unusual N-
terminal Lac group (Figure 1.2). Finally, the lantibiotic SWLP1 was isolated from S. 
warneri DSM16081, also known to produce the class II lantibiotic nukacin ISK1 (28), 
and its structure was determined by mass spectrometry (2999 Da) (29). As epilancin K7 
and 15X, SWLP1 also contains an N-terminal Lac (Figure 1.2).  
The epilancin-like lantibiotics are active against several strains of pathogenic 
bacteria, including MRSA, VRE, and S. epidermidis. Indeed, epilancin 15X has minimal 
inhibitory concentration (MIC) values against MRSA and VRE among the lowest 
reported for lantibiotics (27, 30) and epilancin K7 is approximately tenfold more active 
against S. simulans 22 than the staphylococcal lantibiotics Pep5, epidermin, and 
gallidermin (25). In addition, this group of peptides may possess considerable stability 
against acid/alkali treatment as evidenced for epilancin 15X in the current work. 
Moreover, the multiple positively charged residues make these peptides quite soluble in 
water. In contrast, the solubility and efficacy of nisin A are highly pH dependent and it 
loses activity sharply in the neutral pH region limiting its application to acidic 
environments (31, 32). 
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Currently, the mode of action of the epilancin-group of lantibiotics is unknown. 
The bactericidal activity of the cationic type-A lantibiotics, such as nisin A, subtilin, 
epidermin, and Pep5, is thought to be a consequence of their ability to induce pore 
formation in cell membranes. Indeed, the C-terminal B and C rings of the epilancin-like 
peptides are structurally similar to the D and E rings of nisin A (Figure 1.2) that are 
believed to be involved in pore formation (10). Furthermore, experiments with 
phosphatidylcholine liposomes suggested that epilancin K7 can penetrate into the 
hydrophobic carbon region of the lipid bilayer permeabilizing the membranes of 
susceptible cells (33). Interestingly, members of the epilancin family of peptides, with six 
to seven charged residues at neutral pH, together with Pep5, are the most positively 
charged lantibiotics reported so far (34). The electrostatic interactions between the 
peptides and the negatively charged bacterial membrane are likely important for the 
initial binding. Indeed, experiments with nisin A suggested that the sensitivity of the 
target bacteria is dependent on the charged state of the cell wall and membrane (35, 
36). Moreover, all the conserved positively charged residues in the epilancin-group of 
peptides (Lys6, Lys10, Lys13, Lys14, Arg17, and Lys31 in epilancin 15X) are expected 
to be located on one side of the molecule and the hydrophobic residues on the other 
side, as suggested by helical wheel projections of the unmodified core peptides. The 
hydrophobic side may face the lumen of the pore while the hydrophilic part could 
interact with the membrane leading to the leakage of charged ions, amino acids, small 
metabolites, and ATP with a simultaneous drop in membrane potential as suggested for 
Pep5 (37, 38). Thus, the efficacy of the epilancin-like peptides may be correlated with 
their cationic charge. 
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However, formation of pores by itself would not explain the low MIC values of 
epilancin 15X, epilancin K7, and SWLP1. While a number of cationic peptides, such as 
those produced by mammals or insects, have antimicrobial activities in the micromolar 
(µM) range, some lantibiotics, including nisin A and the epilancin-like peptides, have 
been shown to be active at nanomolar (nM) concentrations. In the case of nisin A, the 
potent antibacterial activity is a consequence of docking onto lipid II by the A and B 
rings (39), which greatly enhances the pore forming ability (8). However, the epilancin- 
family of peptides does not contain the A and B-rings found in nisin, and lipid II does not 
serve as a docking molecule for epilancin K7 (7). Thus, the N-terminal portion of this 
group of peptides and the unusual lactate group may be involved in a currently unknown 
alternative mechanism. Indeed, additional posttranslational modifications beyond the 
Lan or MeLan rings are often important for biological activity of lantibiotics. In the case 
of cinnamycin, a β-hydroxylated aspartate residue and a lysinoalanine ring are 
important for recognition of its target (40, 41). In another example, the lantibiotic 
microbisporicin, which has a very similar ring topology as epidermin, is two orders of 
magnitude more potent than the latter compound against several strains of S. aureus, 
presumably because of the posttranslationally modified hydroxylated proline and 
chlorinated tryptophan residues that are absent in epidermin (42). Thus, the N-terminal 
lactate group in the epilancin family of peptides might also be important for the 
antimicrobial activity. Interestingly, the lantibiotic paenibacillin produced by the food-
borne bacterial strain Paenibacillus polymyxa OSY-DF that contains an N-terminal 
acetyl group, instead of a Lac group, (43, 44) shares considerable N-terminal sequence 
similarity with the epilancin-group of peptides, suggesting convergent evolution for 
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interaction with a similar bacterial target (Figure 1.2). Contrary to nisin, paenibacillin has 
shown considerable thermal and acid/alkali stability even after long incubation periods 
(43). Despite the potential of the epilancin-group of lantibiotics for treatment of infectious 
diseases, their biosynthetic routes and the role of the Lac group in bioactivity have not 
been determined. The elucidation of their biosynthesis may support the development of 
more efficient production strategies and facilitate the introduction of modified amino 
acids to generate compounds that are more potent or target specific bacteria. 
 
1.3. THE BIOSYNTHESIS OF LANTIPEPTIDES 
Lantipeptides are defined by their characteristic lanthionine and/or 
methyllanthionine thioether crosslinks (45); lantipeptides with confirmed antimicrobial 
activity are called lantibiotics. A classification scheme for this family of posttranslational 
modified peptides has been previously proposed based on the enzymes responsible for 
ring formation (Figure 1.4) and the biosynthetic genes have been designated with the 
generic locus symbol lan (or Lan for the encoded proteins), with a more specific name 
for each lantibiotic (such as nis in nisin A biosynthesis) (4). In all cases, lantipeptides 
are synthesized as precursor peptides (LanA) that contain an N-terminal leader region 
that is not modified and a C-terminal core peptide encoding the backbone of the final 
product. The core peptides in class I lantipeptides are modified by two distinct enzymes 
designated LanB and LanC that catalyze the dehydration of serine and threonine 
residues and the subsequent intramolecular addition of cysteine thiols onto the 
dehydrated amino acids, respectively, resulting in the formation of the thioether 
crosslinks (Figure 1.4). For class II, III, and IV precursor peptides, bifunctional enzymes 
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designated LanM, RamC-like (or LabKC in labyrinthopeptin biosynthesis, a group of 
peptides with additional carbacyclic side-chain linkages) (46-48), and LanL (45), 
respectively, are responsible for both dehydration and cyclization steps of the core 
peptide (Figure 1.4) (4, 45, 47). All the lanthionine forming enzymes (LanC, LanM, 
RamC-like/LabKC, and LanL) share significant homology at the C-terminus and are 
members of a protein superfamily designated LanC-like, while the LanB dehydratases 
bear no homology with other known proteins. After ring formation, and in some cases 
further modifications, the lantipeptides are secreted and the leader peptides are 
removed by the protease domain of transporters (LanT) or dedicated proteases (LanP), 
generating the biologically active compound. The biosynthetic routes to several 
lantipeptides have been characterized with nisin A and lacticin 481 the most studied 
class I and class II members, respectively (Figure 1.5). These pathways possess 
several advantages for bioengineering, including the direct link between precursor 
peptide gene and natural product structure and the relatively short biosynthetic 
pathways. Furthermore, many of the biosynthetic enzymes have demonstrated 
substrate promiscuity. In the following sections, the different families of enzymes are 
described in more detailed. 
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Figure 1.4. Biosynthesis of lantipeptides by four classes of lanthionine-forming enzymes. (A) 
After ribosomal synthesis of the precursor peptides (LanA), different enzymes denotated LanB, 
LanM, RamC-like (LabKC), or LanL can catalyze dehydration of the Ser or Thr residues to 
generate the dehydrated amino acids Dha or Dhb, respectively. For class II, III, and IV 
lantipeptides, this modification proceeds through a two-step process, phosphorylation of Ser/Thr 
and subsequent β-elimination of the phosphate to generate Dha/Dhb. Following dehydration, 
LanC, LanM, LanL, or RamC-like/LabKC enzymes can catalyze intramolecular addition of Cys 
thiols onto the dehydro amino acids generating the thioether-containing residues Lan and 
MeLan. The conserved zinc-ligands are missing in RamC-like/LabKC proteins and the 
mechanism of cyclization is currently unknown. (B) Schematic representation of the domain 
architecture of class I−IV (methyl)lanthionine-forming enzymes. The positions of the expected 
active site residues are shown in darker colors (49). 
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Figure 1.5. Biosynthetic route to the lantibiotics nisin A (A) and lacticin 481 (B). 
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Dehydration 
The dehydration of the Ser and Thr residues in the core peptide leading to the 
formation of Dha or Dhb is the first key reaction in lantipeptide biosynthesis and can be 
performed by different enzymes. The LanB proteins from class I lantipeptides possess 
about 1000 residues and seem to be associated with the membrane, possibly as part of 
a biosynthetic membrane-associated complex, which may explain the failure of previous 
attempts for the reconstitution of their enzymatic activity in vitro. LanB proteins do not 
show any significant similarity to the N-terminal domains of the lanthionine synthetases 
(LanM, RamC-like/LabKC, and LanL) that catalyze the dehydration reaction in other 
classes of lantipeptides and therefore both groups of proteins are unlikely to be 
evolutionary related. Dehydration by LanB seems to be an organized directional 
process that starts at the N-terminus of the core peptide and continues towards the C-
terminus, as suggested for NisB (50). Further details regarding the reaction mechanism, 
cosubstrates, and the structure of the LanB proteins remain unknown. These 
dehydratases contain nine short segments with significant homology that may have 
functional significance (51). However, prediction of the residues involved in catalysis or 
other functions remains challenging because more than 40 residues are highly 
conserved in this family of proteins, with only one residue (Pro612 in NisB) being fully 
conserved based on the alignment of 66 putative LanBs (51). The mechanism for 
substrate recognition is also unknown, but the N-terminal part of the leader peptide, 
including a partially conserved FDLD motif, was shown to be important for the 
interaction of NisA and NisB (52-54). Furthermore, NisB possesses low substrate 
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specificity, as demonstrated by the in vivo dehydration of nonlantibiotic peptides fused 
to the NisA leader peptide (55).  
Three independent domains have been identified in LanB proteins based on 
sequence alignments: an N-terminal Lant_dehyd_N domain (PF04737), a central 
Lant_dehyd_C domain (PF04738), and a C-terminal thiopep_ocin domain (TIGR03891) 
that will be designated as α, β, and γ domains for simplicity (Figure 1.4). Interestingly, 
genes encoding for LanB dehydratase homologs are also present in the biosynthetic 
gene clusters of thiazolyl peptides. In this case, the dehydratase is split in two proteins, 
one consisting of the α and β domains (TsrC for thiostrepton using the nomenclature in 
(56)) and the other possessing only the γ domain (TsrD) (56-59). A split dehydratase 
(GodF and GodG) is also encoded by the goadsporin biosynthetic gene cluster (60). 
Although dehydrated residues derived from Ser and Thr are also found in numerous 
NRPS-derived products, such as syringomycin (61), syringotoxin B (62), or microcystin 
(63-65), the enzymatic mechanism of dehydration remains elusive. However, single or 
multiple putative dehydratases containing the α and β domains, but not the γ domain, 
are present in several gene clusters encoding for putative non-ribosomal peptides 
identified by genome mining (Figure 1.6), suggesting that this family of proteins may 
also be involved in the dehydration of Ser/Thr residues of NRPS-derived metabolites. 
Importantly, the α and/or β dehydratase domains can be fused to adenylation (A) or 
thioesterase (TE) domains, as evidenced for gene clusters from Micromonospora 
aurantiaca and Salinispora arenicola (Figure 1.6). This NRPS-domain architecture has 
not been reported in the literature to the best of my knowledge. The conservation of the 
γ domain in biosynthetic proteins from different families of ribosomal peptide 
17 
 
(lantipeptides, thiazolyl peptides, and goadsporin) and the absence of this domain in 
NRPS-related biosynthetic proteins suggests that the γ domain may function as a 
docking protein that recognizes the leader peptide allowing dehydration by the α and β 
domains. A similar role was proposed for McbD, SagD, and the C-terminal domain of 
PatD in the biosynthesis of the thiazole/oxazole-containing ribosomal peptides microcin 
B17, streptolysin S, and patellamides, respectively (66-68).  
The N-terminal catalytic domain of LanM proteins is responsible for dehydration 
in class II lantipeptide biosynthesis as demonstrated by the in vitro reconstitution of the 
enzymatic activity of LctM (the synthetase involved in lacticin 481 biosynthesis) and 
several mutants (22, 69). LctM dehydration involves initial phosphorylation of the 
hydroxyl-bearing amino acids in the presence of ATP and Mg2+, followed by phosphate 
elimination (Figure 1.4) (70). In addition, LctM is distributive with respect to the 
dehydration reaction, releasing the intermediates after each dehydration (71). Similarly, 
NisB and NisC are alternating enzymes (50). Sequence alignment of the N-terminal 
domain of LctM and site-directed mutagenesis experiments on the conserved N-
terminal residues of LctM provided some insights into the reaction mechanism of 
dehydration (Figure 1.7). A general base, such as Asp242 or Asp259, has been 
proposed to deprotonate the Ser/Thr residues targeted for dehydration generating a 
transient alkoxide group that could attack the γ-phosphate of ATP producing the 
phosphorylated peptide and ADP. Then, another base, possibly Arg299 or Asp259, 
could deprotonate the α-carbon of pSer/pThr to generate an enolate, which 
subsequently eliminates the phosphate group, possibly assisted by a general acid, such 
as Lys159, and/or Mg2+ (69). Additional mutagenesis studies on the precursor peptide 
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suggested that the secondary structure of the leader peptide is important for peptide 
processing (72). 
 
Figure 1.6. Representative examples of non-ribosomal peptide biosynthetic gene clusters 
identified by genome mining for LanB proteins.  
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Figure 1.7. Proposed general mechanism of dehydration of Ser/Thr by LctM (69). 
 
LanL-like lanthionine synthetases contain a central Ser/Thr kinase domain and 
an N-terminal pSer/pThr lyase domain that catalyze phosphorylation and elimination of 
phosphorylated hydroxyl-containing amino acids, respectively, as demonstrated for 
VenL (45, 49). These two domains have no significant sequence homology with either 
the LanB or the LanM proteins. Based on mutagenesis studies on VenL lacking the C-
terminal cyclase domain, a reaction mechanism for the elimination reaction was 
proposed (Figure 1.8) (49). Lys80 could deprotonate the α-proton of pSer/pThr residues 
to initiate the reaction, while His53 may protonate the phosphate leaving group, leading 
to elimination and formation of the dehydrated amino acids (Figure 1.8) (49). Finally, the 
N-terminal domains of LabKC (a class III biosynthetic protein), which share significant 
homology to the corresponding domains of LanL proteins, were proposed to catalyze 
20 
 
the dehydration of Ser residues in the core peptide by phosphorylation/elimination using 
GTP as cosubstrate rather than ATP (48). Furthermore, a conserved N-terminal 
hydrophobic patch in the precursor peptide and predicted to possess a helical structure 
was recently shown to be important for proper peptide processing (73). 
 
Figure 1.8. Proposed mechanism for β-elimination of the phosphate of pSer/Thr catalyzed by 
the lyase domain of VenL (49). 
 
Cyclization and the LanC-like superfamily 
In lantipeptide biosynthesis, the formation of the thioether bonds is catalyzed by 
enzymes from the LanC-like domain superfamily (PF05147), a highly divergent group of 
peptide-modifying enzymes in bacterial and eukaryotic cells (Figure 1.9). Although 
spontaneous nucleophilic addition of thiol groups into dehydrated amino acids is well 
known and relatively fast, enzymatic control over the chemoselectivity and/or 
processivity is required for formation of the correct ring topologies. The LanC cyclases 
are single domain proteins of about 400 residues long, whereas LanM, LanL, and 
RamC-like modification enzymes are larger proteins (900-1000 aa) that bear the C-
terminal cyclization domain (LanC-like) as well as the N-terminal domains involved in 
dehydrations as discussed above (Figure 1.4). The LanC-like domain is characterized 
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by seven conserved motifs that are present in all the lanthionine-forming enzymes. In 
addition, Cys and His residues (Cys284, Cys330, and His331 in NisC or Cys781, 
Cys836, and His837 in LctM) that function as zinc ligands and that are important for 
catalysis (Figure 1.10) (74-76) are conserved in the LanC, LanM, and LanL proteins, 
although the His residue is sometimes replaced by a Cys (Figure 1.9, diamonds). In 
contrast, these metal ligands are absent from the RamC-like/LabKC proteins and the 
mechanism of cyclization may be different (46). In addition to the metal ligands, the 
coordination sphere is completed by a water molecule believed to be displaced by the 
Cys residues in the substrate (Figure 1.10).  
The enzymatic activity of several members of the LanC-like superfamily, 
including proteins from all the lantipeptide classes, has been reconstituted in vitro and 
the catalytic mechanism has been investigated (22, 45, 48, 74-77). The thiol groups in 
the lantipeptide core peptides are likely activated by the metal that lowers their pKa 
allowing the nucleophilic addition onto the β-carbon of the dehydro amino acids. The 
enolate intermediate thus generated could be protonated by an active site base (Figure 
1.10). A conserved His (His212 in NisC or His725 in LctM) was suggested to be the 
base that deprotonates the thiol of the substrate or the acid that protonates the enolate 
intermediate (75). The mechanism controlling the regioselectivity of cyclization remains 
unclear. However, the crystal structure of NisC evidenced that the active site consists of 
a shallow groove that accommodates the formation of rings of different sizes and that 
the zinc is located on top of an α,α-barrel that resembles the β-subunit of farnesyl 
transferase (74). Interestingly, the directionality of ring formation is not always uniform. 
The LanC cyclases from class I lantipeptides incorporate lanthionine rings solely in the 
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N-to-C terminal direction, whereas for some LanM enzymes some of the lanthionine 
rings in the final structure (such as in mersacidin (78) and cinnamycin (79)) result from 
cyclization in the opposite direction (5). Like the dehydratases, LanC-like proteins, 
including NisC, LctM, and ProcM (in prochlorosins biosynthesis (80)), have low 
substrate specificity, modifying nonlantibiotic peptides and cysteine derivatives (55, 81). 
 
Proteolysis and transport 
After ring formation, and frequently additional posttranslational modifications, the 
leader peptide is removed and the peptide is secreted. However, the order of these 
steps is not conserved. In some cases, the mature bioactive compound is generated 
inside the cytoplasm followed by secretion, as in Pep5 or lactocin S biosynthesis (82, 
83). In other cases, leader removal and peptide secretion are coupled and are 
performed by membrane proteins, such as in lacticin 481 or nukacin ISK-1 biosynthesis 
(23, 84). Finally, the leader peptide can be removed after secretion as in nisin A or 
epidermin biosynthesis (85, 86). 
ATP-binding cassette (ABC) transporters designated as LanT are commonly 
encoded in lantipeptide gene clusters and are involved in the secretion of fully modified 
precursor peptides or mature lantipeptides, as demonstrated for NisT, CylT, and LasT 
(in nisin A, cytolysin, and lactocin S biosynthesis, respectively (82, 87, 88)). These 
proteins contain an intracellular domain with a highly conserved ATP binding motif, 
indicating that ATP hydrolysis is utilized as a source of energy for secretion. 
Furthermore, LanTs contain a membrane-spanning domain that usually possesses six 
transmembrane helices. 
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Figure 1.9. Cladograph of the LanC-like domains from different lanthionine-forming enzymes.  
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Figure 1.9. Continuation. Cladograph of the LanC-like domains from different lanthionine-
forming enzymes. Four distinctive clades corresponding to different classes of LanC-like 
families are shown. LanC (blue), LanM (green), and the group of RamC & LanL (red) proteins 
are involved in lantipeptide biosynthesis in bacteria. The clade designated as LanCL is mostly 
composed of eukaryotic lanthionine synthetases and is shown compressed. Branches with 
diamonds correspond to proteins in which the conserved His residue (His331 in NisC) is 
replaced by Cys. The evolutionary history was inferred using the Neighbor-Joining method (13) 
and considering only the C-terminal LanC-like domain from LanM, RamC-like, and LanL 
proteins. The tree was adapted from the National Center for Bioinformatic Information (NCBI) 
curated domain hierarchy for the LanC-like domain superfamily (89) and modified by using 
CDTree3.1 (90) and MEGA5 (91). 
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Figure 1.10. Active site of NisC (A) and proposed mechanism for the cyclization reaction (B). 
Reproduced in part with permission from (75). 
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One group of LanT proteins, frequently found in class II lantipeptide biosynthesis, 
contains an extra N-terminal, intracellular, cysteine-type protease domain of about 150 
residues. A similar domain architecture is also found in several other ABC transporter, 
maturation, and secretion proteins (AMS) (92). The protease domain cleaves the leader 
peptide after a highly conserved double-glycine motif with consensus sequence 
(I/L/V)(S/T)X2E(L/M)X2(I/L/V)XG(G/A/S), where X can be any amino acid (92). The in 
vitro enzymatic activity, mechanism, and substrate specificity of the protease domain of 
LctT (23) and NukT (84) (in lacticin 481 and nukacin ISK-1 biosynthesis) have been 
investigated. The conserved Cys12 residue in LctT seems to be essential for catalysis, 
while His90 could play a role in the regiospecificity of amide bond hydrolysis (23). In 
addition, the GA motif C‐terminal to the cleavage site, Glu−8, and the secondary 
structure of LctA  are all important for substrate processing (23). In the case of NukT, 
the peptidase activity depends on ATP hydrolysis, suggesting that the N-terminal 
protease domain and the C-terminal ATP-binding domain may function cooperatively 
maybe through conformational changes (84). 
For most class I lantipeptides, and also for some class II members, removal of 
the leader region is performed by a subtilisin-like protease commonly designated as 
LanP. These proteins vary greatly in size ranging from about 250 to 680 amino acids, 
due to the presence or absence of preprosequences, which direct the enzyme to the 
sec-dependent secretory pathway. In some cases, an additional C-terminal extension, 
consisting of a spacer of about 100 residues and a C-terminal transmembrane 
sequence with the cell wall anchor consensus motif (LPXTG), is also found (85). The 
most conserved regions of these serine proteases are around the active site and 
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include the catalytic triad residues (Asp, His, and Ser) as well as the oxyanion-hole 
residue (Asn). The substrate-scope of this family of proteases will be discussed in more 
detail in chapter 4.  
 
1.4. GENOME MINING FOR LANTIPEPTIDES 
The ever-increasing amount of DNA sequence data and the knowledge about the 
biosynthetic routes to lantipeptides, described above, have lead to the discovery of 
novel gene clusters encoding previously unknown peptides. Upon identification of the 
clusters, prediction of the chemical structures of the mature lantipeptides based on the 
genomic context of the precursor genes, in combination with several chemical and 
biological strategies, has aided bioassay-independent discovery and isolation of novel 
lantipeptides. In the first such example, a bioinformatic analysis of the genome of 
Bacillus halodurans C-125 revealed the presence of two genes encoding for precursor 
peptides clustered with two additional open reading frames (ORF) encoding for LanM-
type synthetases. Analysis of cell-free supernatants by mass spectrometry (MS), in vitro 
reconstitution of the LanM enzymes, antimicrobial assays, and mutagenesis 
experiments, allowed the identification and structural characterization of the two-
component lantibiotic haloduracin (Figure 1.11) (77, 93, 94).  
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Figure 1.11. Lantipeptides recently discovered by genome mining using the notation described 
in Figure 1.1. The two-component lantibiotics haloduracin from B. halodurans C-125 and 
lichenicidin from B. licheniformis ATCC14580, DSM13, and VK21 were discovered after 
genome mining for LanM lanthionine synthetases. Venezuelin, a lantipeptide predicted from the 
genome sequence of S. venezuelae ATCC10712, was produced in vitro after reconstitution of a 
novel LanL lanthionine synthetase. Prochlorosin 2.11 is one of 29 lantipeptides produced by 
Prochlorococcus MIT9313. BsaA2 was discovered after genome sequence analysis of several 
S. aureus strains. Reproduced in part with permission from (95). 
 
Using similar bioinformatic approaches or PCR amplification of conserved DNA 
sequences, several lanM-containing biosynthetic gene clusters were discovered 
subsequently, including the cluster encoding for lichenicidin in the genome of Bacillus 
licheniformis ATCC14580 (or DSM13) and VK21 (77, 96-98). In follow-up studies, this 
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two-component lantibiotic was detected in bacterial cultures by antimicrobial assays and 
MS analysis (Figure 1.11) (96-98). In a similar study, several variants of the lantibiotic 
epidermin, designated Bsa, and produced by MRSA strains were identified (Figure 
1.11), suggesting that these bacteriocins may confer a competitive ecological 
advantage on community acquired infections (99).  
A new route to lantipeptides was discovered by analysis of the draft genome 
sequence of S. venezuelae ATCC10712 revealing a lantibiotic-like gene cluster with an 
ORF encoding for a novel class of putative lanthionine synthetases (LanL), as described 
above (45). In vitro reconstitution of the enzyme activity with the predicted precursor 
peptide resulted in the production of venezuelin, the first class IV lantipeptide (Figure 
1.11). LanL homologs were also identified in other species of Actinobacteria and 
Firmicutes (45). Another recent genome database analysis revealed that several strains 
of marine Prochlorococcus and Synechococcus contain multiple ORFs encoding a wide 
diversity of lantipeptide precursor peptides but only a single gene encoding a LanM-like 
synthetase (80). The precursor peptides have highly homologous leader peptides but 
display great diversity in the core peptide. The enzymatic activity of the predicted LanM 
from Prochlorococcus MIT9313 was reconstituted in vitro and 17 selected precursor 
peptides (out of the 29 encoded in the genome) were converted to the corresponding 
lantipeptides (prochlorosins), providing an example of natural combinatorial 
biosynthesis. Analysis of the spent media of Prochlorococcus MIT9313 by MS showed 
in vivo production of at least three of these compounds (Figure 1.11), confirming that 
lantipeptide production is not restricted to Gram-positive or soil bacteria as long 
believed (80). A search of sequences in the Global Oceanic Survey uncovered more 
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than 150 prochlorosin precursor genes from many different locations suggesting that 
prochlorosin production is widespread. Interestingly, several LanA peptides with long 
leader sequences (as in prochlorosins biosynthesis) were identified in bacterial 
genomes and classified in two families (NHLP and N11P) based on homology to 
regions of the alpha subnunit of nitrile hydratase and the cyanobacterial Nif11 nitrogen-
fixing protein families (100). Importantly, some of the ORFs encoding for the precursor 
peptides are distant to the genomic regions encoding for LanM proteins and their 
identification would be challenging by using only BLAST searches for lanthionine 
synthetases. More recently, comparative analysis and BLAST searches of 58 
cyanobacterial genomes, by using cyanobacterial LanM sequences as a query, led to 
the identification of sixteen gene clusters encoding for 61 lantipeptide precursor 
peptides, among other bacteriocin precursors, including several members of the NHLP 
and N11P families (101).  
In two additional studies, PSI-BLAST searches of the NCBI database for LanB, 
LanC, and LanM homologs uncovered 49 class I and 61 class II lantipeptide gene 
clusters, including examples in phyla (Chloroflexi, Bacteroidetes, and Proteobacteria) 
not previously identified as lantipeptide producers (51, 96). Similarly, a computerized 
discovery strategy using the genome-mining software BAGEL2 revealed approximately 
150 putative lantibiotic gene clusters based on conserved biosynthetic, transport, and 
immunity machinery (102). By using BAGEL, the biosynthetic gene cluster of 
pneumococcin A1 and A2 was identified in the genome sequence of S. pneumoniae R6 
(103). Interestingly, when the predicted pneumococcin core peptides (belonging to class 
II lantipeptides) were modified in vivo using the nisin A synthetase machinery (a class I 
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system), lanthionine containing-peptides with antimicrobial activity were produced (103). 
Thus, genome sequencing has contributed to the discovery of novel lantibiotics and 
provided a better understanding of their biosynthetic and regulatory mechanisms, which 
may facilitate production and generation of more potent or stable variants. 
 
1.5. BIOENGINEERING OF LANTIBIOTICS 
An alternative approach to access novel/improved lantibiotics involves the 
derivatization of known peptides. Since lantibiotics are gene-encoded as precursor 
peptides, they possess a key advantage over classical antibiotics, as they are more 
amenable to engineering strategies and their antimicrobial activity and stability can be 
potentially enhanced. Mutant precursor peptides can be modified in vitro or in vivo using 
the lantibiotic-associated enzymes to generate new molecules. The simplest systems 
involve in vivo expression of mutant LanA precursor peptides in a variant of the original 
producer strain, either in cis by replacing the original LanA gene or in trans by 
complementing a copy of the mutant gene (104). Indeed, coupling these strategies with 
random and site-directed mutagenesis have allowed the generation of large libraries of 
bioengineered peptides and the identification of enhanced forms of the lantibiotics nisin 
A (105), mersacidin (106), and nukacin ISK-1 (107). For instance, the mutants nisin A 
M21V (renamed nisin V) or K22T were shown to display enhanced antimicrobial activity 
against medically significant pathogens, including MRSA, VRE, Clostridium difficile, S. 
agalactiae, and Listeria monocytogenes (105, 108). However, this approach is limited to 
mutant peptides that are compatible with the native biosynthetic, transport, and 
immunity machineries. 
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An alternative strategy relies on the in vitro reconstitution of biosynthetic 
enzymes. This approach is not affected by reduced or aborted in vivo production of 
novel variants caused by incompatibility with the biosynthetic machinery or self-
destruction of the host. Furthermore, the strategy can be easily coupled with the 
chemical incorporation of non-proteogenic amino acids to generate novel variants not 
easily accessible by using traditional in vivo expression strategies. Using this method, 
two lacticin 481 variants with increased antibacterial activity against a target strain were 
discovered, extending the chemical and structural diversity of lantibiotics (109). Thus, 
the recent advancements in the understanding of lantibiotics regarding biosynthetic 
machinery and mode of action can lead to the design of tailor-made peptides with 
enhanced activity and stability. 
The following chapters focus on the biosynthesis of the antimicrobial compound 
epilancin 15X. In chapter 2, the molecular cloning and sequencing of the biosynthetic 
gene cluster are described. Furthermore, the reconstitution of the enzymatic activities of 
the dehydratase ElxB, the protease ElxP, and the dehydrogenase ElxO involved in 
formation of the N-terminal Lac group is demonstrated, and a biosynthetic route to 
epilancin 15X is proposed. Chapter 3 focuses on the biochemical and structural 
characterization of the dehydrogenase ElxO, displaying relaxed substrate specificity that 
can be used to modify or introduce other chemical functionalities into different peptides. 
Finally, chapter 4 describes the biochemical characterization and bioinformatic analysis 
of the protease ElxP giving some insights into the substrate scope of this family of 
proteins. Additional experiments towards the discovery of novel phosphonate antibiotics 
are described in supplemental chapter A. 
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CHAPTER 2. CHARACTERIZATION OF THE GENE CLUSTER 
AND THE BIOSYNTHETIC PATHWAY OF  
THE LANTIBIOTIC EPILANCIN 15X* 
 
 
2.1. INTRODUCTION 
The lantibiotic epilancin 15X produced by Staphylococcus epidermidis 15X154 is 
a member of the epilancin-group of peptides that have shown potent antimicrobial 
activity against pathogenic bacteria, including methicillin-resistant S. aureus (MRSA) 
and vancomycin-resistant Enterococci (VRE). Like the other members of the family, 
epilancin 15X contains one lanthionine (Lan) and two 3-methyllanthionine (MeLan) 
bridges, one 2,3-didehydroalanine (Dha), three (Z)-2,3-didehydrobutyrine (Dhb) 
residues, and an unusual N-terminal 2-hydroxypropionyl group (lactate, Lac) that might 
be important for antimicrobial activity. Despite the promising biological properties of 
epilancin 15X, as well as other members of the family, its biosynthetic route has not 
been characterized and the stereochemical configuration and role of the N-terminal 
modification in the biological activity have not been determined.  
The gene clusters and biosynthetic pathways of some other staphylococcal 
lantibiotics, such as Pep5, epidermin, and epicidin 280, have been previously 
characterized (1-3). Furthermore, an N-terminal Lac is also present in epicidin 280 and 
a putative oxidoreductase designated EciO was speculated to be involved in its 
biosynthesis, but this hypothesis has not been confirmed experimentally (2). 
Understanding how the N-terminal Lac group is introduced into epilancin 15X and other 
                                                            
* Reproduced in part with permission from: “Velásquez, J. E., Zhang, X., and van der Donk, W. A. (2011) 
Biosynthesis of the antimicrobial peptide epilancin 15X and its N-terminal lactate, Chem. Biol. 18, 857-867.” Copyright 
© 2011 Elsevier Ltd.  
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lantibiotics may facilitate the elucidation of its biological role and the design of novel 
peptides with enhanced antimicrobial properties. This chapter focuses on the 
characterization of the biosynthetic gene cluster of epilancin 15X, obtained after the 
construction of a genome library of S. epidermidis 15X154 and sequencing of fosmids 
encoding for lantibiotic protein homologs. Additionally, an NADP(H)-dependent short-
chain alcohol dehydrogenase/reductase (SDR) designated as ElxO is demonstrated to 
catalyze the conversion of an N-terminal pyruvyl (Pyr) group in a epilancin 15X 
precursor to Lac. The expression, purification, and in vitro reconstitution of the 
enzymatic activity of a peptidase designated ElxP that is involved in leader peptide 
cleavage is also reported, to the best of my knowledge the first such example for a 
member of the serine-type lantibiotic proteases. Finally, the in vivo reconstitution of the 
enzymatic activity of a Ser/Thr dehydratase designated ElxB is described, 
demonstrating its role in biosynthesis. The proposed biosynthetic route of epilancin 15X 
constitutes the first example for a member of the epilancin-group of lantibiotics and 
opens the door for engineering of novel peptides with biological activity against 
pathogenic bacteria. 
 
2.2. EXPERIMENTAL METHODS 
Materials, organisms, media, and growth conditions 
Chemical reagents and media components used in this study were purchased 
from Sigma-Aldrich or Thermo Fisher Scientific, unless otherwise specified, and were 
used without further purification. The strains and plasmids are listed in Table 2.1 and 
the primers are shown in Table 2.2. S. epidermidis 15X154 and S. carnosus TM300 
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were grown on Luria – Bertani (LB) or Mueller Hinton (Oxoid) solid agar or liquid broth 
at 37 °C. Escherichia coli strains were routinely grown in LB solid agar or broth 
supplemented with antibiotics at 37 °C. Strain E. coli WM4489 (4, 5), used as the host 
for genomic library construction, was supplemented with maltose (10 mM) before phage 
transfection, while strains containing fosmid pJK050 (4, 5) or its derivatives were 
supplemented with rhamnose (10 mM) preceding fosmid isolation. For agar diffusion 
bioactivity assays, 25 mL of agar medium inoculated with culture (1/100 dilution) was 
poured into a sterile plate. Aliquots of antibacterial compounds were placed into wells 
made on the solidified agar and the plates were incubated at 37 or 30 °C overnight. The 
bioactivity of the sample was confirmed if a clear growth inhibition zone surrounding the 
well was formed.  
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Table 2.1. Microorganisms and plasmids used in this study 
Strain or plasmid Relevant characteristics Source or reference 
Escherichia coli   
    BL21(DE) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
Novagen 
    DH5α pir/80dlacZM15 Δ(lacZYA-argF)U169 recA1 
hsdR17 deoR thi-1 supE44 gyrA96 relA1 
(6) 
    Rosetta2(DE3) F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) pRARE2 
Novagen 
    T7 Express fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 
R(mcr-73::miniTn10--TetS)2 [dcm] R(zgb-
210::Tn10--TetS) endA1 Δ(mcrC-mrr)114::IS10 
New England 
Biolabs 
    WM4489 E. coli DH10B derivative: mcrA (mrr hsdRMS 
mcrBC) 80(lacM15) lacX74 endA1 recA1 
deoR (ara-leu)7697 araD139 galU galK nupG 
rpsL attB::pAE12(PrhaB::trfA33 oriR6K-
cat::frt5) 
(5) 
 
Staphylococcus 
  
     epidermidis 15X154 Epilancin 15X producer strain (7) 
     carnosus TM300 Epilancin 15X sensitive strain G. Bierbaum,  
U. of Bonn 
 
Plasmids 
  
     pACYCDuet-1 CmR E. coli T7 based vector  for coexpression 
vector of two target genes 
Novagen 
     pACYC.ElxC elxC cloned in pACYCDuet-1 vector This study 
     pACYC.NisBC nisB and nisC cloned in  pACYCDuet-1 N. Bindman, 
van der Donk 
laboratory 
     pACYC.NisC nisC cloned in  pACYCDuet-1 (8) 
     pAE5 Source of mini-Mu transposon (5) 
     pCDF.NisB nisB cloned in pCDFDuet-1 N. Bindman, 
van der Donk 
laboratory 
     pET28b KanR E. coli T7 based histidine-tag fusion 
expression vector 
Novagen 
    pET.His6-ElxA elxA cloned in pET28b vector This study 
    pET.His6-ElxO elxO cloned in pET28b vector This study 
    pET.His6-MBP-ElxP elxP cloned in pET28b vector This study 
    pJK050 oriV, oriS, copy-control cosvector, CmR (5) 
    pRSFDuet-1 KanR E. coli T7 based histidine-tag fusion vector 
for coexpression of two target genes 
Novagen 
     pRSF.His6-ElxAB elxA and elxB cloned in pRSFDuet-1 vector This study 
     pRSF.His6-NisElxA.NisB Chimeric nisA(leader)-elxA(core) gene and nisB 
cloned in pRSFDuet-1 vector 
(8) 
     pRSF.His6-NisAB nisA and nisB cloned in pRSFDuet-1 vector This study 
aATCC, American Type Culture Collection, Manassas, VA.  
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Table 2.2. Primers used in this study 
Name Sequence 
elxA.BamHI.F 5'- GCG AGC CAG GAT CCG ATG AAA AAA GAA TTA TTT GAT TTA 
AAT CTT AAT AAA G -3' 
elxA.EcoRI.R 5'- GGC GCG CCG AAT TCT TAT TTT TTA CCA GTA AAG TG -3' 
elxA.NdeI.F 5'- GGC GCG CCC ATA TGA AAA AAG AAT TAT TTG ATT TAA ATC TTA 
AT -3' 
elxA.NotI.R 5'- GCA TTA TGC GGC CGC TTA TTT TTT ACC AGT AAA GTG ACA 
TCC ACA AGT TAG -3' 
elxA-F1 5'-ATG AAT AAC GAA TTA TT(C/T) (A/G)AT TTG GAT C-3' 
elxA-R2 5'-CTT TGT AGA GGA TTT ACA CTA ACT TG-3' 
elxB.Bglll.F 5'- GAA GGA GAT ATA CAT ATG GCA GAT CTC ATG AAC ATC TTC 
AAA AAA T -3' 
elxB.XhoI.R 5'- CGG TTT CTT TAC CAG ACT CGA GTT AGT TGA TTT TTT TGT AG -
3' 
elxBgapF 5'- GTT ATT TCT TGA ATT ATT CTG CTA CAG AGC -3' 
elxC.NdeI.F 5'- GGA TAT ACA TAT GGA AAA TAG TAT CCA AAA ATC CTT ATC ATA 
CCT TTC AG -3' 
elxC.XhoI.R 5'- ACC AGA CTC GAG TTA CGC AAA ACA AAA CAA TTT ATA CC -3' 
elxC-596F 5'-AT(C/T) TAG G(A/T)T A(T/C)G C(A/T/G)C ATG G(A/T)A T-3' 
elxC-781R 5'- CC(A/G) TA(A/G) CAC CAA (C/G)C(A/G) T(C/T)T CT-3' 
elxCgapR 5'- AAC CCA TAA CAC CAG TAA ATA ATG AAG TAG -3' 
elxO.NheI.F 5'- GGT TGG TTG CTA GCA TGA AAA AAA ATG TTC TTA TTA CAG -3' 
elxO.XhoI.R 5'- AAG TCG ACC TCG AGT TAT TGG GAT AAA TAT CCT C -3' 
elxP.28MBP.F 5'- GAA CCT GTA CTT CCA ATC CGG ATC CAT GGA TAA TTT TCT 
TAG TTG GCC TAA TAA A -3' 
elxP.28MBP.R 5'- GGT GGT GGT GGT GGT GCT CGA GTT AAA TAT GTT CAT TAG 
TAA TAA TCT CCT TTG TG -3' 
nis-elxA.R-1E.F 5'- GAA AGA TTC AGG TGC ATC ACC AGA GTC AGC TAG TAT TGT 
TAA AAC AAC T -3' 
nis-elxA.R-1E.R 5'- CTT AAG CAT TAT GCG GCC GCA AGC TTT TAT TTT TTA CCA GTA 
AAG TGA C -3' 
seqaetf 5'- TCG CCT TCT TGA CGA GTT CT -3' 
seqaetr 5'- TAG GAA CTT CGG GAT CCG TT- 3' 
 
S. epidermidis 15X154 genomic DNA isolation 
An aliquot of S. epidermidis 15X154 culture was pelleted by centrifugation and 
cells were washed with TE25S buffer (25 mM Tris-HCl, 25 mM EDTA, 0.3 M sucrose, 
pH 8). Cells were then lysed with 2 mg/mL of lysozyme (Sigma) and 50 g/mL of 
lysostaphin (Sigma) in TE25S buffer at 37 °C for 60 min. The washed protoplasted cells 
49 
 
were incubated with proteinase K (0.15 mg/mL, Sigma) in TE25S buffer at 50 °C for 30 
min. Sodium dodecyl sulfate (SDS) was added to 0.5% (w/v) final concentration and 
gently mixed for 10 min at room temperature. The cell lysate was mixed with an equal 
volume of saturated buffer of phenol, chloroform, and isoamyl alcohol (25:24:1). After 
centrifugation, the aqueous layer was removed and mixed gently with an equal volume 
of a mixture of chloroform and isoamyl alcohol (24:1). The top layer was removed again 
and 0.1 volumes of 5 M NaCl and 0.7 volumes of isopropanol were added to precipitate 
the DNA. The DNA was washed three times with 70% ethanol and once with 100% 
ethanol, air-dried, and resuspended in TE buffer (pH 8.0). See Notebook III, page 05. 
 
Genomic library construction, screening, and DNA sequencing 
 Genomic DNA was partially digested with Sau3A1 (New England Biolabs) in the 
presence of RNAse A (Sigma) using serial dilutions of the enzyme. The DNA solutions 
were analyzed by field inversion gel electrophoresis on a 1% agarose/TBE gel and the 
fraction containing ~20-60 kb DNA fragments was treated with shrimp alkaline 
phosphatase (Roche Diagnostics). Cosmid pJK050 was digested with NheI (New 
England Biolabs), treated with shrimp alkaline phosphatase (Roche Diagnostics), and 
purified by sequential extraction with phenol:chloroform:isoamyl alcohol (25:24:1) and 
precipitation with ammonium sulfate and ethanol. The cosmid was further treated with 
BamHI (Invitrogen). Digested pJK050 and genomic DNA were ligated with T4 DNA 
ligase (New England Biolabs) and cosmid constructs were packaged into lambda phage 
with a MaxPlax Lambda Packaging Extract Kit (Epicentre) according to the 
manufacturer’s protocol, followed by transfection of E. coli WM4489. Library clones 
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were screened by PCR for the elxA gene using forward primer elxA-F1 and reverse 
primer elxA-R2 (Table 2.2), or for the elxC gene with forward primer elxC-596F and 
reverse primer elxC-781R, Taq polymerase (Invitrogen), and 1× PCR premix A 
(Epicentre).  
Plasmid pAE5 was digested with BglII and the 1084 bp fragment to be used as a 
transposon was gel purified. For each positive fosmid, the fragment and the positive 
fosmid were mixed and treated with MuA transposase (Finnzymes) and the dialyzed 
DNA was used to transform E. coli WM4489. Sets of 192 clones were sequenced from 
the ends of the transposon insert using primers seqaetf and seqaetr at the Keck Center 
for Comparative and Functional Genomics at the University of Illinois at Urbana-
Champaign. Using S. epidermidis 15X154 as template, the specific primers elxBgapF 
and elxCgapR were used to amplify and sequence a DNA fragment of 1.2 kb, closing 
the sequence gap between the fosmids. See also Notebook III, page 25. 
 
Construction of plasmids pET.His6-ElxO, pET.His6-ElxA, and pET.His6-MBP-ElxP 
The gene elxO was amplified by PCR from S. epidermidis 15X154 genomic DNA 
using a forward primer containing an NheI restriction site (elxO.NheI.F) and a reverse 
primer containing a XhoI site (elxO.XhoI.R). The PCR product and the vector pET28b 
(Novagen) were digested with restriction endonucleases NheI and XhoI (Invitrogen) and 
ligated using T4 DNA ligase (New England Biolabs) to produce the plasmid pET.His6-
ElxO. See also Notebook III, page 60. 
The gene elxA was amplified by PCR from S. epidermidis 15X154 genomic DNA 
using a forward primer containing an NdeI restriction site (elxA.NdeI.F) and a reverse 
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primer containing a EcoRI site (elxA.EcoRI.R). The PCR product and the vector pET28b 
(Novagen) were digested with restriction endonucleases NdeI and EcoRI (Invitrogen) 
and ligated using T4 DNA ligase (New England Biolabs) to produce the plasmid 
pET.His6-ElxA. See also Notebook III, page 71. 
The gene elxP was amplified by PCR from S. epidermidis 15X154 genomic DNA 
using a forward primer (elxP.28MBP.F) and a reverse primer (elxP.28MBP.R). The PCR 
product contained annealing regions to a modified pET28b vector (Novagen) that 
encodes for a fusion of pelB to hexahistidine tagged MBP. The purified PCR product 
was used as a primer to amplify the vector using Phusion® Hot Start DNA polymerase 
(New England Biolabs), followed by treatment with DpnI (New England Biolabs) before 
transformation of E. coli DH5α cells to generate the plasmid pET.His6-MBP-ElxP that 
encodes for ElxP fused at its N-terminus to a TEV protease cleavage site, an MBP tag, 
a hexahistidine tag, and a pelB signal peptide. The correct sequences of the inserts 
were confirmed by sequencing at the Keck Center at the University of Illinois at Urbana-
Champaign. See also Notebook VII, page 05. 
 
Overproduction and purification of His6-ElxO 
Electrocompetent E. coli Rosetta2(DE3) cells were transformed with pET.His6-
ElxO and a single colony was grown in LB medium supplemented with antibiotics. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 
mM when OD600 = 0.7 and the culture was shaken for additional 16 h at 18 °C. The cells 
were harvested by centrifugation and the pellet was resuspended in lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 5 mM imidazole, pH 7.5) and stored at −80 °C until used. 
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The cell pellet was thawed, lysozyme was added to a final concentration of 1 
mg/mL, and the suspension was passed through a French-press after incubation for 30 
min at 4 °C. The protein was purified by immobilized metal ion affinity chromatography 
(IMAC) using an ÄKTApurifier (Amersham Biosciences, GE Healthcare) equipped with a 
HisTrap HP 5 mL column prepacked with Ni SepharoseTM (GE Healthcare). A gradient 
of 0-100% buffer B (20 mM Na2HPO4, 500 mM NaCl, 500 mM imidazole, pH 7.4) in 
buffer A (20 mM Na2HPO4, 500 mM NaCl, 20 mM imidazole, pH 7.4) over 20 column 
volumes (CV) was used to elute the proteins. The fractions containing His6-ElxO were 
concentrated using an Amicon Ultracel 10k filter (Millipore). Imidazole was removed by 
using a PD-10 desalting column (GE Healthcare) and the protein was eluted and stored 
in buffer (50 mM Tris-HCl, 300 mM NaCl, 20% glycerol, pH 7.5). The native molecular 
weight of His6-ElxO was determined by size exclusion chromatography using an 
ÄKTApurifier equipped with a Superdex 200 HR 10/30 GL column (GE Healthcare) and 
utilizing cytrochrome c (12.4 kDa), carbonic anydrase (29 kDa), bovine serum albumin 
(66 kDa), alcohol dehydrogenase (150 kDa), β-amylase (200 kDa), and blue dextran 
(2000 kDa) as standards (MWGF200, Sigma). See also Notebook V, page 82. 
 
Overexpression and purification of His6-ElxA 
 Electrocompetent E. coli Rosetta2(DE3) cells were transformed with pET.His6-
ElxA and a single colony was inoculated in 5 mL of LB medium containing 50 µg/mL 
kanamycin and 12.5 µg/mL chloramphenicol and grown for 12 h with shaking. An aliquot 
of 1 mL was used to inoculate 100 mL of LB medium containing the same antibiotics 
followed by overnight incubation at 37 °C. Finally, an aliquot of 20 mL of the overnight 
53 
 
culture was used to inoculate 2 L cultures. The cells were grown at 37 °C until OD600 = 
1.0. IPTG was added to a final concentration of 1.0 mM and the cultures were shaken 
for 16 h at 18 °C. The cells were harvested by centrifugation and resuspended in lysis 
buffer (20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH 7.5). After 
sonication and centrifugation, the pellets were resuspended in denaturing buffer (6 M 
guanidine hydrochloride, 20 mM NaH2PO4, 0.5 mM imidazole, 500 mM NaCl, pH 7.5) 
and sonicated and centrifuged again. The supernatants were loaded onto a HisTrap HP 
5 mL column prepacked with Ni SepharoseTM (GE Healthcare) and washed with buffer 
(4 M guanidine hydrochloride, 20 mM NaH2PO4, 30 mM imidazole, 300 mM NaCl, pH 
7.5). The peptides were then eluted with elution buffer (20 mM Tris-HCl, 100 mM NaCl, 
1 M imidazole, 4 M guanidine hydrochloride, pH 7.5). Finally, the peptides were purified 
by C4 semi preparative reverse phase high performance liquid chromatography (HPLC) 
using an Agilent 1200 instrument equipped with a Delta-Pak C4 column (25 mm i.d. x 
100 mm L, Waters) and a variable wavelength detector set at 220 nm. The mobile 
phase was 0.1% trifluoroacetic acid (TFA) in water (A) and 0.086% TFA in 80% 
acetonitrile / 20% water (B). A gradient of 2-100% B in A over 60 min and a flow rate of 
8 mL/min were used. The masses of the purified peptides were determined by matrix-
assisted laser desorption/ionization – time-of-flight mass spectrometry (MALDI-TOF 
MS) on a Voyager DE-STR Biospectrometry Workstation using α-cyano-4-
hydroxycinnamic acid as matrix at the Mass Spectrometry Laboratory of the University 
of Illinois at Urbana Champaign. See also Notebook V, page 19. 
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Overexpression and purification of His6-MBP-ElxP 
Electrocompetent E. coli Rosetta2(DE3) cells were transformed with pET.His6-
MBP-ElxP and a single colony was resuspended in 100 µL of LB and plated on an LB 
agar plate containing 50 µg/mL kanamycin and 12.5 µg/mL chloramphenicol and grown 
overnight at 37 °C. The colonies were scraped-off and resuspended in 2 mL of LB 
medium and used to inoculate a 2 L culture. The culture was incubated at 37 °C with 
shaking until OD600 = 1.0. IPTG was added to a final concentration of 0.1 mM and the 
culture was shaken for an additional 16 h at 18 °C. The cells were harvested by 
centrifugation and the cell pellet was resuspended in 20 mL of lysis buffer (50 mM 
Na2HPO4, 500 mM NaCl, 20 mM imidazole, 5 mg/mL lysozyme, pH 7.5). After 
incubation at 4 °C for 45 min, the cells were lysed using French-press. The suspension 
was centrifuged for 45 min at 16,000 × g and 4 °C and the supernatant was filtered 
through a 0.45 µm syringe-tip filter (Millipore). The protein was purified by IMAC using 
an ÄKTApurifier (Amersham Biosciences, GE Healthcare) equipped with a HisTrap HP 
5 mL column prepacked with Ni SepharoseTM (GE Healthcare). After loading and 
washing the column with 15 CV of buffer A (20 mM Na2HPO4, 500 mM NaCl, 20 mM 
imidazole, pH 7.4), a gradient of 0-100% buffer B (20 mM Na2HPO4, 500 mM NaCl, 500 
mM imidazole, pH 7.4) in buffer A over 20 CV was used to elute the protein. The 
fractions containing His6-MBP-ElxP, as confirmed by SDS-PAGE analysis, were 
concentrated using an Amicon Ultracel 50k filter (Millipore). Imidazole was removed by 
using a PD-10 desalting column (GE Healthcare) and the protein was eluted from the 
column using an elution buffer containing glycerol (50 mM HEPES, 300 mM NaCl, 20% 
glycerol, pH 7.5). Aliquots were frozen in liquid N2 and stored at −80 °C. An aliquot 
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containing His6-MBP-ElxP was incubated with TEV protease (0.1 mg TEV/mg protein) in 
the presence of TCEP (1 mM) at 4 °C overnight. The suspension was incubated with Ni-
NTA agarose beads (Qiagen) for 30 min with shaking at 4 °C to remove the 
hexahistidine tagged MBP-containing peptides. The supernatant was recovered and 
aliquots were frozen in liquid N2 and stored at −80 °C. See also Notebook VIII, page 19. 
 
Synthesis of substrate analogues and products 
The peptides Pyr-AAIVK, D-Lac-AAIKV, L-Lac-AAIVK, ASIVK, Pyr-AAIVKBBIKA, 
and AAIVKBBIKA were synthesized by Fmoc-based solid phase peptide synthesis 
(SPPS) using a PS3 peptide synthesizer (Protein Technologies). Fmoc groups were 
removed during the deprotection steps with 20% piperidine in dimethylformamide 
(DMF). Coupling of the amino acids was performed using DMF as solvent and 2-(6-
chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) 
and 0.4 M N-methylmorpholine (NMM) as activating reagents. Coupling reactions of 
pyruvic acid or L/D-lactic acid were performed using hydroxybenzotriazole (HOBt) and 
diisopropylcarbodiimide (DIC) as activating reagents. Coupling of unprotected Ser in 
ASIVK was performed using 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one 
(DEPBT) and N,N'-diisopropylethylamine (DIPEA) as activating reagents. ADhaIVK was 
produced after solid phase dehydration of Ser with large excess of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and CuCl as described elsewhere (9). D-Lac-
ADhaIKV and L-Lac-ADhaIVK were produced after coupling of L- or D-lactic acid to 
ADhaIVK as described above. Peptides were cleaved from the resins using a mixture of 
TFA/water/phenol (90:5:5) or TFA/triisopropylsilane (95:5) in the case of D/L-Lac-
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ADhaIKV. The cleavage solutions were evaporated using a rotary evaporator and the 
peptides were precipitated from the solution with cold diethyl ether. The peptide was 
purified by C18 semi preparative reverse phase HPLC using an Agilent 1200 instrument 
equipped with an Eclipse XDB-C18 column (9.4 mm i.d. x 250 mm L, Agilent). A 
gradient of 2-30% B (acetonitrile) in A (0.1% formic acid) in 30 min was used. The 
masses of the purified peptides were determined by electrospray ionization – mass 
spectrometry (ESI-MS) using a Waters ZMD quadrupole instrument at the Mass 
Spectrometry Laboratory of the University of Illinois at Urbana-Champaign. See also 
Notebook VI, page 41. 
 
His6-ElxO and ElxP activity assays 
His6-ElxO (10 µM) and the peptide Pyr-AAIVK (1 mM) generated by Fmoc-based 
SPPS were incubated with NADPH (1 mM) in assay buffer (100 mM HEPES, 500 mM 
NaCl, pH 7.5) at room temperature for 6 h. Reaction progress was monitored by UV-vis 
spectrophotometry, measuring the disappearance of the NADPH peak at 340 nm. 
Formation of reduced peptide was confirmed by liquid chromatography mass 
spectrometry (LC-MS) using an Agilent 1200 instrument equipped with a single 
quadrupole multimode ESI/APCI ion source mass spectrometry detector (Agilent) and a 
Synergi Fusion-RP column (4.6 mm i.d. × 150 mm L, Phenomenex). See also Notebook 
V, page 93. 
ElxP or His6-MBP-ElxP (5 µM) and purified His6-ElxA (10) (50 µM) were 
incubated in the presence of assay buffer (50 mM HEPES, pH 7.5) at room temperature 
for 2–3 h. A control sample lacking enzyme was incubated under identical conditions. 
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Cleavage of the peptide in the reaction sample was confirmed by MALDI-TOF MS on a 
Voyager DE-STR Biospectrometry Workstation as described above. See also Notebook 
VIII, page 21. 
 
Production and purification of epilancin 15X 
A medium composed of Lab-Lemco meat extract (10%, Oxoid), malt extract (3%, 
BD), ammonium chloride (20 mM), Ca(OH)2 (0.4%), and NaCl (2%) was inoculated with 
an overnight pre-culture of S. epidermidis 15X154 in LB broth (1/100 dilution). Cells 
were incubated at 37 °C with shaking for 12 h and harvested by centrifugation. The 
supernatant was filtered through a 0.22 m pore size filter and heated at 80 °C for 1 h to 
deactivate proteases. Solid (NH4)2SO4 was added to the culture supernatant to reach 
80% saturation at 4 °C and stirred for 4 h followed by centrifugation. The pellet was 
resuspended in water and loaded onto a Vydac® C4 reverse phase solid phase 
extraction column (SPE) (214SPE1000, Discovery Sciences). The column was washed 
with 25% acetonitrile in ammonium acetate buffer (20 mM, pH 5.0) to remove impurities 
and the peptide was eluted with 0.1% TFA  in 80% methanol / 20% water. The 
lantibiotic was further purified by HPLC using an Agilent 1200 instrument equipped with 
a Vydac® 214TP54 C4 reverse phase column (4.6 mm i.d. × 250 mm L, Discovery 
Sciences). A gradient of 50-60% B (0.1% TFA in methanol) in A (0.1% TFA in water) 
over 50 min was used. The fractions corresponding to the major peak were collected 
and analyzed by MALDI-TOF MS on a Voyager DE-STR Biospectrometry Workstation 
as described above. See also Notebook VI, page 68. 
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Determination of stereochemical configuration of N-terminal Lac 
After incubation of Pyr-AAIVK (1 mM) with ElxO (10 µM) and NADPH (1 mM) in 
reaction buffer (100 mM HEPES, 500 mM NaCl, pH 7.5), the reaction mixture and the 
synthetic peptides D-Lac-AAIKV and L-Lac-AAIVK were analyzed individually or 
combined by HPLC using an Agilent 1200 instrument equipped with a Synergi Fusion-
RP column (4.6 mm i.d. × 150 mm L, Phenomenex). A gradient of 0-70% B (methanol) 
in A (0.1% formic acid in water) over 30 min was used and absorbance at 210 nm was 
monitored. See also Notebook VI, page 51. 
Epilancin 15X (30 µM) was incubated with Trypsin (5 µM, Sigma) in buffer (50 
mM HEPES, pH 7.5) at room temperature for 3 h. The resulting proteolyzed peptide and 
the synthetic peptides D-Lac-ADhaIKV and L-Lac-ADhaIVK were analyzed individually 
or combined by LC-MS using a Waters SYNAPTTM mass spectrometry system equipped 
with an ACQUITY UPLC®, an ESI ion source, a quadrupole time-of-flight detector 
(Waters) scanning a range 570 - 573 Da, and an ACQUITY Bridged Ethyl Hybrid (BEH) 
C18 column (2.1 mm i.d. × 50 mm L, 1.7 µm, Waters). A gradient of 9-12% B (0.1% 
formic acid in acetonitrile) in A (0.1% formic acid in water) over 15 min was used. See 
also Notebook VIII, page 43. 
 
Cloning and coexpression of elxA, elxB, and elxC 
The gene elxA was amplified by PCR from S. epidermidis 15X154 genomic DNA 
using a forward primer containing a BamHI restriction site (elxA.BamHI.F) and a reverse 
primer containing a NotI site (elxA.NotI.R). The PCR product and the vector pRSFDuet-
1 (Novagen) were digested with restriction endonucleases BamHI and NotI (New 
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England Biolabs) and ligated using T4 DNA ligase (New England Biolabs) to produce 
the plasmid pRSF.His6-ElxA encoding ElxA fused at its N-terminus to a His6-tag. A 
sequence-optimized synthetic elxB gene (Geneart) was amplified by PCR using a 
forward primer containing an BglII restriction site (elxB.Bglll.F) and a reverse primer 
containing an XhoI restriction site (elxB.XhoI.R). The PCR product and the vector 
pRSF.His6-ElxA were digested with restriction endonucleases BglII and XhoI 
(Invitrogen) and ligated using T4 DNA ligase (New England Biolabs) to produce the 
plasmid pRSF.His6-ElxAB encoding for ElxA fused at its N-terminus to a hexahistidine 
tag and for ElxB. See also Notebook VIII, page 23. 
The gene elxC was amplified by PCR from S. epidermidis 15X154 genomic DNA 
using a forward primer containing an NdeI restriction site (elxC.NdeI.F) and a reverse 
primer containing a XhoI site (elxC.XhoI.R). The PCR product and the vector 
pACYCDuet-1 (Novagen) were digested with restriction endonucleases NdeI and XhoI 
(Invitrogen) and ligated using T4 DNA ligase (New England Biolabs) to produce the 
plasmid pACYC.ElxC encoding for ElxC. 
Electrocompetent E. coli BL21(DE3) cells were transformed with pRSF.His6-
ElxAB or cotransformed with pRSF.His6-ElxAB and pACYC.ElxC. Single colonies were 
inoculated in 5 mL of LB medium containing the appropriate antibiotics (50 µg/mL 
kanamycin or 12.5 µg/mL chloramphenicol) and grown for 12 h with shaking. Aliquots of 
2 mL were used to inoculate 200 mL of LB medium containing the same antibiotics 
followed by shaken at 37 °C until OD600 = 0.7. IPTG was added to a final concentration 
of 0.5 mM and the cultures were shaken for 16 h at 18 °C. The cells were harvested by 
centrifugation and resuspended in lysis buffer (20 mM NaH2PO4, 500 mM NaCl, 20 mM 
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imidazole, 2 mg/mL lysozyme, pH 7.4). After sonication and centrifugation, the 
supernatants were loaded onto HisTrap HP 5 mL columns prepacked with Ni 
SepharoseTM (GE Healthcare) and washed with buffer (20 mM NaH2PO4, 500 mM NaCl, 
20 mM imidazole, pH 7.4). The peptides were then eluted with elution buffer (20 mM 
NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.4) and loaded onto Vydac® C4 
reverse phase SPE columns (214SPE1000, Discovery Sciences). The columns were 
washed with 0.1% TFA in 5% methanol / 95% water to remove impurities and the 
peptides were eluted with 0.1% TFA in 80% methanol / 20% water and 0.1% TFA in 
80% acetonitrile / 20% water. After lyophilization, the peptides were resuspended in 
buffer (50 mM HEPES, pH 7.5) and incubated with His6-MBP-ElxP at room temperature 
overnight to cleave the leader peptide. Ni-NTA agarose beads (Qiagen) were added 
and the supernatant was recovered and analyzed by MALDI-TOF MS on a Voyager DE-
STR Biospectrometry Workstation as described above. See also Notebook VIII, page 
25. 
 
Cloning of nisA(leader)-elxA(core) and coexpression with nisB and nisC 
The fragment of the gene elxA encoding for the core peptide was amplified by 
PCR from S. epidermidis 15X154 genomic DNA using a forward (nis-elxA.R-1E.F) and 
a reverse (nis-elxA.R-1E.R) primer and iProofTM high-fidelity DNA polymerase (Bio-
Rad). A mutation for cleavage with GluC at the N-terminus of the encoded core peptide 
was also introduced in the forward primer. The PCR product contained annealing 
regions to the pRSF.His6-NisAB plasmid (8), which encodes for hexahistidine tagged 
NisA and for untagged NisB, allowing replacement of the nisA core region for elxA by 
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PCR amplification of the entire plasmid. After treatment with DpnI (New England 
Biolabs) and transformation of E. coli DH5α cells, the plasmid pRSF.His6-NisElxA.NisB 
was generated. This plasmid encodes for the hexahistidine tagged chimera 
NisA(leader)-ElxA(core) R-1E precursor peptide and for NisB. See also Notebook IX, 
page 05. 
Chemically competent E. coli T7 Express or electrocompetent BL21(DE3) cells 
were transformed with pRSF.His6-NisElxA.NisB, or cotransformed with pRSF.His6-
NisElxA.NisB and pACYC.NisC (8), pACYC.NisBC, or pCDF.NisB in different 
combinations. Single colonies were inoculated in 5 mL of LB medium containing the 
appropriated antibiotics (50 µg/mL kanamycin, 12.5 µg/mL chloramphenicol, or 25 
µg/mL streptomycin) and grown for 12 h at 37 °C with shaking. Aliquots of 2.5 mL were 
used to inoculate 250 mL of LB medium containing the same antibiotics followed by 
incubation at 37 °C until OD600 = 0.6. IPTG was added to a final concentration of 0.5 
mM and the cultures were shaken for 16 h at 18 °C. The cells were harvested by 
centrifugation and resuspended in lysis buffer (20 mM NaH2PO4, 500 mM NaCl, 20 mM 
imidazole, 2 mg/mL lysozyme, pH 7.4). After sonication and centrifugation, the 
supernatants were loaded onto HisTrap HP 5 mL columns prepacked with Ni 
SepharoseTM (GE Healthcare) and washed with buffer (20 mM NaH2PO4, 500 mM NaCl, 
20 mM imidazole, pH 7.4). The peptides were then eluted with elution buffer (20 mM 
NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.4) and loaded  onto Vydac® C4 
reverse phase SPE columns (214SPE1000, Discovery Sciences). The columns were 
washed with 0.1% TFA in 5% methanol / 95% water to remove impurities and the 
peptides were eluted with 0.1% TFA in 80% methanol / 20% water and 0.1% TFA in 
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80% acetonitrile / 20% water. After lyophilization, the peptides were resuspended in 
buffer (50 mM HEPES, pH 7.5) and incubated with the endopeptidase GluC (2 ng/µL, 
New England Biolabs) at room temperature overnight to cleave the leader peptide. The 
products were analyzed by MALDI-TOF MS using a Bruker Daltonics UltrafleXtreme 
MALDI TOF/TOF mass spectrometer at the Mass Spectrometry Laboratory of the 
University of Illinois at Urbana-Champaign. See also Notebook IX, page 06. 
 
2.3. RESULTS 
Cloning and sequencing of the epilancin 15X biosynthetic gene cluster 
To identify and sequence the epilancin 15X biosynthetic gene cluster, a fosmid 
library of S. epidermidis 15X154 genomic DNA was constructed in E. coli. The fosmid 
library was screened by PCR using degenerate primers to amplify a fragment of elxA 
(the gene encoding the precursor peptide) and elxC (the gene encoding a lanthionine 
cyclase). The primers for elxA were designed based on the amino acid sequence of 
epilancin 15X by Dr. Xingang Zhang, a previous postdoctoral researcher at the van der 
Donk laboratory, while primers for elxC were designed based on the conserved amino 
acid sequences in the cyclase enzymes. Two positive clones containing non-
overlapping DNA fragments were isolated and the fosmids were sequenced using 
transposon insertions. Specific primers annealing with regions of S. epidermidis 15X154 
genomic DNA were then used to amplify by PCR a bridging 1.2 kb DNA fragment that 
was sequenced to obtain the biosynthetic gene cluster (Figure 2.1). The open reading 
frames (ORFs) were analyzed with the Basic Local Alignment Search Tool (BLAST) 
(11) and six ORFs encoding putative proteins with high sequence identity to enzymes 
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involved in the production and transport of lantibiotics were identified: elxA, elxB, elxC, 
elxP, elxT, and elxO (Table 2.3 and Figure 2.1). Additionally, three genes with no 
homology to characterized lantibiotic genes and presumably involved in immunity were 
identified and designated as elxI1, elxI2, and elxI3. With the exception of elxO, the role 
of the other genes in epilancin 15X biosynthesis can be predicted based on homology to 
previously characterized lantibiotic genes. The gene encoding the precursor peptide, 
elxA, encodes a serine residue at the first position of the core peptide, which 
corresponds to lactate in epilancin 15X. Thus, Ser1 must be posttranslationally modified 
by an undetermined enzyme.  
 
 
Figure 2.1. Epilancin 15X biosynthetic gene cluster. 
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Table 2.3. Open reading frames analysis of the epilancin 15X gene cluster using BLASTp at the 
NCBI website.  
Predicted 
ORF 
Number 
of AA1 Protein homology
2 Identity3 Expect4
elxA 55 ElkA, epilancin K7 precursor peptide, S. 
epidermidis K17, (AAA79236) ( 55 aa) 
38/55 
(69%) 
7e-15 
elxB 986 PepB, Pep5 dehydratase, S. epidermidis 5, 
(CAA90025) (967 aa) 
327/994 
(32%) 
7e-104 
elxC 402 PepC, Pep5 cyclase, S. epidermidis 5, 
(CAA90026) (398 aa) 
142/379 
(37%) 
8e-56 
elxO 248 EciO, oxidoreductase, S. epidermidis BN280, 
(CAA74346) (247 aa) 
(126/248) 
50% 
8e-64 
elxP 297 EciP, epicidin 280 protease, S. epidermidis 5, 
(CAA74349) ( 300 aa) 
123/286 
(43%) 
3e-48 
elxT 573 PepT, Pep5 ABC transporter, S. epidermidis 5, 
(CAA90021) (571 aa) 
354/571 
(61%) 
0.0 
elxI1 72 Hypothetical protein SE2390, S. epidermidis 
ATCC12228, (NP_765945) (76 aa) 
43/65 
(66%) 
7e-18 
elxI2 241 CAAX amino protease, S. epidermidis 
M23864:W1, (ZP_04817536) (248 aa) 
70/178 
(39%) 
8e-24 
elxI3 71 Hypothetical protein, S. aureus subsp. aureus 
USA300_TCH959, (ZP_04865952)  (75 aa) 
43/71 
(60%) 
6e-17 
orf1 177 Recombinase, S. aureus subsp. aureus TCH70, 
(ACZ58811)  (182 aa) 
154/176 
(87%) 
4e-85 
orfA 261 Membrane spanning protein, S. hominis SK119, 
(ZP_04060547) (257 aa) 
249/257 
(96%) 
1e-110 
1AA: amino acid. 2Results are from a BLASTp search of the GenBank protein database 
on January 2010. 3Identities in the aligned region. 4Expectation value. 
 
Cloning and overexpression of elxO 
To study the role of ElxO, the corresponding gene was cloned into a pET28b 
vector to generate pET.His6-ElxO that encodes an N-terminal hexahistidine fusion 
protein (His6-ElxO). His6-ElxO was heterologously produced in E. coli Rosetta2(DE3) 
cells and the enzyme was purified by immobilized metal ion affinity chromatography 
(IMAC) with Ni2+, resulting in 60 to 90 mg of purified protein per liter of cell culture. The 
enzyme migrated as a protein of approximately 30 kDa by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis, close to the predicted 
monomeric molecular weight of His6-ElxO (29.7 kDa). Native molecular weight analysis 
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using gel filtration chromatography suggests that His6-ElxO exists as a dimer (59 kDa, 
observed). 
 
In vitro reconstitution of the enzymatic activity of His6-ElxO and determination of 
the stereochemistry of the reaction 
On the basis of its amino acid sequence, ElxO is a member of the short-chain 
dehydrogenase/reductase (SDR) superfamily that catalyzes the interconversion of 
alcohols to aldehydes or ketones using NAD(P)(H) as a cofactor. Dehydroepilancin 15X, 
a peptide containing an N-terminal Pyr group, could therefore be the substrate for ElxO. 
Since dehydroepilancin 15X was not available, the small peptide AAIVK was 
synthesized by Fmoc-based SPPS followed by coupling of pyruvic acid to produce the 
ketone containing substrate Pyr-AAIVK. This peptide resembles the N-terminal portion 
of dehydroepilancin 15X, with Dha at position 3 replaced with Ala for simplicity. 
Incubation of Pyr-AAIVK with ElxO resulted in a decrease in absorbance at 340 nm over 
time with NADPH but not NADH. The reaction sample was also analyzed by LC-MS and 
a new peak with slightly shorter retention time and with a mass of 572.4 Da, 
corresponding to Lac-AAIVK, was observed (Figure 2.2). 
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Figure 2.2. Enzymatic assay of His6-ElxO with Pyr-AAIVK. Single ion chromatograms at m/z = 
573.4, corresponding to the expected [M+H]+ ion for Lac-AAIVK, of the peptide incubated with 
(blue) or without (red) His6-ElxO are shown. The peak at 16 min observed in the reaction 
sample but not in the control sample confirms the enzymatic reduction of the peptide. The peak 
at 17 min in the control sample corresponds to higher molecular weight isotopes of the substrate 
(monoisotopic m/z = 571.4). 
 
To determine the stereochemical configuration of the N-terminal Lac, the two 
possible reaction products (D-Lac-AAIVK and L-Lac-AAIVK) were synthesized by Fmoc-
based SPPS using D- or L-lactic acid during the last coupling step. The enzymatic 
product of Pyr-AAIVK, after incubation with His6-ElxO and NADPH, was combined with 
D-Lac-AAIVK or L-Lac-AAIVK and analyzed by HPLC (Figure 2.3). The enzymatic 
product of His6-ElxO co-eluted with D-Lac-AAIVK, but not with L-Lac-AAIVK, 
demonstrating that ElxO catalyzes the formation of an N-terminal D-lactate ((R)-2-
hydroxypropionate). 
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Figure 2.3. Determination of the stereochemical configuration of the enzymatically synthesized 
N-terminal lactate (Lac). The two possible diastereoisomers of Lac-AAIKV have different 
retention times when analyzed by reverse-phase HPLC. A) A mixture of chemically synthesized 
D-Lac-AAIVK and L-Lac-AAIVK separated by HPLC. B) The reaction product of Pyr-AAIVK after 
incubation with His6-ElxO and NADPH analyzed under the same conditions as A). C) A mixture 
of the enzymatic reaction product of Pyr-AAIVK and D-Lac-AAIVK produced a single peak. D) 
The enzymatic product of Pyr-AAIVK combined with L-Lac-AAIVK produced two well separated 
peaks. 
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Production of epilancin 15X and stereochemical characterization of its N-terminal 
Lac group 
The production of lanthionine-containing polypeptide antibiotics by staphylococci 
is highly dependent on the composition of the media (12, 13). Media containing Lab-
Lemco meat extract, malt extract, ammonia, Ca(OH)2, and NaCl have been shown to 
support the production of Pep5, gallidermin, and epidermin, whereas small 
concentrations of phosphate and glucose can repress bacteriocin production (12, 13). 
To identify the optimal conditions for the production of epilancin 15X, a set of cultures, in 
which the concentrations of meat extract, NaCl, and NH4Cl were systematically varied, 
were grown and epilancin production was compared with the original conditions (7). 
Analysis of culture supernatants for bioactivity using an agar diffusion assay with 
Staphylococcus carnosus TM300 as indicator strain (Figure 2.4) demonstrated that a 
medium containing 10% Lab-Lemco meat extract, 2% NaCl, 20 mM NH4Cl, 3% malt 
extract, and 0.4% Ca(OH)2 produced the highest concentration of epilancin 15X under 
the conditions tested. Purification yielded about 3.0 mg of bacteriocin per liter of culture, 
compared with a yield of 0.5 mg per liter reported previously (7). The identity of 
epilancin 15X was determined by MALDI-TOF MS, confirming the presence of only the 
lantibiotic and one possible oxidation product or hydrated dehydroepilancin 15X (Figure 
2.4). 
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Figure 2.4. Production of epilancin 15X. A) S. epidermidis 15X was grown in media containing 
different concentrations of meat extract, NaCl, and NH4Cl. The supernatants were concentrated 
(5×) and tested against S. carnosus TM300 for bioactivity. A medium containing 10% meat 
extract, 2% NaCl, 20 mM NH4Cl, 3% malt extract, and 0.4% Ca(OH)2 produced the higher 
concentration of epilancin 15X (sample 4). No significant production was observed when 
Mueller Hinton broth II or nutrient broth were used (samples 9 and 10, respectively). Ampicillin: 
sample 11 (positive control). B) MALDI-TOF MS spectrum of epilancin 15X after HPLC 
purification. The peaks at m/z = 3176 corresponds to the [M+H]+ ion of epilancin 15X (expected 
average mass 3175 Da). The peak at m/z = 3192 may correspond to an oxidation product of 
epilancin 15X or hydrated epilancin 15X.  
   
 To determine the stereochemical configuration of the N-terminal Lac in epilancin 
15X, a sample of purified lantibiotic was treated with trypsin generating Lac-ADhaIVK, 
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among other peptide fragments. The resulting peptide mixture and synthetic samples of 
D-Lac-ADhaIVK and L-Lac-ADhaIVK, produced by SPPS, were analyzed by LC-MS 
(Figure 2.5). The N-terminal proteolytic fragment of epilancin 15X co-eluted with D-Lac-
ADhaIVK, confirming the stereochemical configuration of the N-terminal Lac. 
 
Figure 2.5. Determination of the stereochemical configuration of the N-terminal lactate (Lac) in 
epilancin 15X. The peptides were detected using a quadrupole time-of-flight MS detector 
scanning the range 570 - 573 Da. A) A mixture of chemically synthesized D-Lac-ADhaIVK and L-
Lac-ADhaIVK separated by UPLC. B) The reaction product of epilancin 15X after digestion with 
trypsin analyzed under the same conditions as A). C) A mixture of the enzymatic digestion 
product of epilancin 15X and D-Lac-AAIVK produced a single peak. D) The enzymatic digestion 
product of epilancin 15X combined with L-Lac-AAIVK produced two well-separated peaks.  
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Cloning and overexpression of elxP 
The gene elxP was cloned initially into a pET28b vector to generate an N-
terminal hexahistidine fusion of ElxP (His6-ElxP). However, attempts to overexpress the 
protein in E. coli were unsuccessful, since the rate of growth of the host was greatly 
reduced after induction with IPTG, suggesting that ElxP is toxic to the heterologous 
host. To overcome toxicity problems and improve solubility, elxP was cloned into 
pET.His6-MBP-ElxP that encodes for a fusion protein containing an N-terminal pelB 
signal, followed by a hexahistidine tag for purification, and a maltose binding protein 
(MBP) tag for solubility, separated from ElxP by a Tobacco Etch Virus (TEV) protease 
cleavage site (Figure 2.6). Heterologous expression trials in E. coli Rosetta2(DE3) by 
using the plating method (14) afforded successful production of His6-MBP-ElxP. The 
enzyme was purified by IMAC with Ni2+, resulting in about 9 mg of purified protein per 
liter of cell culture. After treatment of His6-MBP-ElxP with TEV protease and SDS-PAGE 
analysis, protein bands at about 34 kDa and 45 kDa, corresponding to ElxP (predicted 
mass 34.3 kDa) and His6-MBP (predicted mass of 45.5 kDa), respectively, were 
observed.  
 
Figure 2.6. Scheme of ElxP fused to a TEV protease cleavage site, a MBP tag, a hexahistidine 
tag, and a pelB signal peptide encoded by pET.His6-MBP-ElxP. 
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In vitro reconstitution of the enzymatic activity of ElxP 
Based on its amino acid sequence, ElxP is a serine protease that may cleave the 
leader peptide from the fully cyclized precursor peptide. Since modified ElxA was not 
available, linear His6-ElxA was tested as substrate. The peptide was obtained by 
expression from a pET28b vector in E. coli Rosetta2(DE3) cells, followed by purification 
by IMAC with Ni2+ and subsequent HPLC. Linear His6-ElxA was incubated with ElxP or 
His6-MBP-ElxP at pH 7.5 and the reaction products were analyzed by MALDI-TOF MS, 
confirming the formation of two proteolytic products in both cases (Figure 2.7). The peak 
at m/z = 4862 corresponds to the N-terminal hexahistidine tagged leader peptide 
(residues −1 to −43) resulting from amide bond hydrolysis at the predicted Gln−1/ Ser1 
cleavage site, whereas the peak at m/z = 3313 corresponds to the C-terminal 
unmodified core peptide.  
 
Figure 2.7. MALDI-TOF MS analysis of the products after digestion of His6-ElxA by His6-MBP-
ElxP. Similar results were obtained when ElxP was used. A) Analysis of His6-ElxA (calculated 
average mass = 8162 Da) after incubation without enzyme in reaction buffer. B) Analysis of 
peptide mixture after incubation with enzyme under the same conditions. Peaks corresponding 
to the leader peptide (calculated average mass = 4864 Da) and to the core peptide (calculated 
average mass = 3316 Da) were observed. 
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Cloning and coexpression of elxA, elxB, and elxC in a heterologous host 
Based on bioinformatic analysis (Table 1), ElxB likely catalyzes the dehydration 
of the Ser and Thr residues in the precursor peptide ElxA, while ElxC catalyzes the 
regioselective addition of the thiol groups from the Cys residues into the dehydrated 
amino acids, generating the Lan/MeLan rings. To confirm the role of ElxB in epilancin 
15X biosynthesis, the genes elxA and a synthetic codon optimized version of elxB were 
cloned into a pRSFDuet-1 vector, as a biscistronic construct as previously described for 
nisin (8). The generated plasmid pRSF.His6-ElxAB encodes for an N-terminal 
hexahistidine fusion of ElxA (His6-ElxA) allowing rapid purification and for untagged 
ElxB (Figure 2.8A). Additionally, Ms. Isabel Neacato, a graduate student at the van der 
Donk laboratory, designed and prepared a pACYCDuet-1 derivative plasmid encoding 
for ElxC (Figure 2.8A). Upon coexpression of elxA and elxB in E. coli BL21(DE3), 
followed by peptide purification and cleavage of the leader region with His6-MBP-ElxP, a 
mixture of peptides potentially containing up to three out of eight expected dehydrations 
was observed by MALDI-TOF MS (Figure 2.8B). Coexpression of the same genes and 
elxC, followed by a similar treatment, allowed the production of peptides with up to five 
dehydrations (Figure 2.8C). Attempts to obtain fully dehydrated peptide or to 
reconstitute the enzymatic activity of ElxB in vitro were not successful. 
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Figure 2.8. Coexpression of elxA, elxB, and elxC. The genes elxA, elxB, and elxC were cloned 
into compatible vectors for coexpression in E. coli (A). The MALDI-TOF MS spectra of the 
mixtures of peptides obtained after coexpression of elxA and elxB (B), or elxA, elxB, and elxC 
(C) in E. coli BL21(DE3) and cleavage of leader peptide with His6-MBP-ElxP are shown. Peaks 
likely corresponding to the unmodified core peptide (calculated average m/z = 3317) or to 
oxidized single dehydrated peptide (calculated average m/z = 3315) and to 1× to 5× dehydrated 
peptides (calculated average m/z = 3299, 3281, 3263, 3245, and 3227) were observed. The 
peaks at m/z = 3347 and 3363 might correspond to oxidation products. 
 
Cloning and coexpression of the chimera nisA(leader)-elxA(core), nisB, and nisC 
in a heterologous host 
The nisin biosynthetic machinery has been successfully used to modify peptides 
other than nisin that are fused to the leader region of NisA using a Lactococcus lactis 
expression system (15-19). To evaluate if a similar strategy can be used to produce 
epilancin 15X, using the recently developed nisin A production system with E. coli as 
heterologous host (8), a chimeric gene encoding for the NisA leader peptide fused to 
the ElxA core peptide was cloned into a pRSFDuet-1 derivative plasmid that also 
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encodes for NisB (8), generating pRSF.His6-NisElxA.NisB (Figure 2.9A). Furthermore, 
an N-terminal hexahistidine tag was encoded at the N-terminus of the chimeric NisA-
ElxA peptide for rapid purification and an artificial GluC protease cleavage site was 
introduced between the leader and the core region to allow in vitro cleavage of the 
leader sequence after peptide purification. Upon coexpression of nisA-elxA and nisB in 
E. coli T7 express, a mixture of peptides, potentially containing up to six out of eight 
expected dehydrations, was observed by MALDI-TOF MS (Figure 2.9B). Additional 
assays cotransforming pRSF.His6-NisElxA.NisB with the plasmids pACYC.NisC 
(encoding for NisC, Figures 2.9A and C), pACYC.NisBC (encoding for NisB and NisC, 
Figures 2.9A and D), or pACYC.NisBC and pCDF.NisB (containing an additional copy of 
nisB, Figures 2.9A and E), followed by coexpression in E. coli T7 express, were also 
performed generating peptides with up to seven dehydrations. Interestingly, an increase 
in the extent of dehydration was observed with the introduction of multiple copies of 
nisB based on the relative intensity of the peaks in the MALDI-TOF MS spectra. Thus, 
the nisin A biosynthetic machinery can be used to modify peptides different than NisA in 
vivo using E. coli as a host. Further optimization is required to produce fully dehydrated 
ElxA and dehydroepilancin 15X. 
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Figure 2.9. Coexpression of nisA(leader)-elxA(core), nisB, and nisC.  
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Figure 2.9. Continuation. A chimeric gene encoding for the NisA leader peptide fused to ElxA 
core sequence was cloned together with nisB to generate a biscistronic construct (A). The 
genes nisB and nisC were also cloned individually or together into compatible vectors for 
coexpression in E. coli (A). The MALDI-TOF MS spectra of the mixtures of peptides obtained 
after coexpression of nisA-elxA and nisB (B); nisA-elxA, nisB, and nisC (C); nisA-elxA, nisB (two 
copies), and nisC (D); and nisA-elxA, nisB (three copies), and nisC (E) in E. coli T7 express and 
cleavage of leader peptide with GluC are shown. Peaks corresponding to 3× to 7× dehydrated 
peptides (calculated monoisotopic m/z = 3293.8, 3275.8, 3257.8, 3239.8, and 3221.8) were 
observed. The observed masses correspond to the peptides with addition of methanol to N-
terminal Pyr (M+MeOH) or double oxidized peptides (M+2O). Additional peaks might 
correspond to different oxidation products. A copy of nisC and multiple copies of nisB seem to 
favor dehydration. 
 
2.4. DISCUSSION 
As discussed in chapter 1, lantibiotics are produced from ribosomally synthesized 
linear precursor peptides that consist of an N-terminal leader region and a C-terminal 
core peptide. The mature lantibiotic is generated from the core peptide after several 
posttranslational modifications. The reactions involved in the formation of the 
characteristic Lan/MeLan rings formation have been investigated (20-22), but only a few 
enzymes introducing other posttranslational modifications have been studied (23, 24). 
This chapter focuses on the mechanism of formation of N-terminal lactate groups and 
on the enzymatic cleavage of the leader peptide. 
The epilancin 15X gene cluster contains five genes involved in biosynthesis 
(elxABCOP), one gene involved in the export of the mature peptide (elxT), and three 
genes potentially involved in immunity (elxI1, elxI2, and elxI3) (Table 1 and Figure 2). 
The cluster organization resembles that of the lantibiotics Pep5 (3) and epicidin 280 (2) 
produced by different strains of S. epidermidis, suggesting that these clusters have 
evolved from a common ancestor. The predicted peptide ElxA has high amino acid 
sequence similarity to the epilancin K7 precursor peptide ElkA (25) (Figure 2.10). ElxA 
contains an N-terminal leader sequence of 24 amino acids and a C-terminal core 
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peptide region comprised of 31 amino acids, as predicted from the chemical structure of 
epilancin 15X. The leader region also contains the conserved motif F-(D/N)-L-(D/E/N) 
and a Pro at position −2 that are characteristic of class I lantibiotics (Figure 2.10) (26). 
 
 
Figure 2.10. Sequence alignment of ElxA with related lantibiotic precursor peptides. ElxA: 
epilancin 15X precursor peptide, ElkA: epilancin K7 precursor peptide, EpiA: epidermin 
precursor peptide, EciA: epicidin 280 precursor peptide, PepA: Pep5 precursor peptide, NisA: 
nisin A precursor peptide. 
 
Downstream of elxA, an ORF designated as elxP was identified. The encoded 
protein ElxP possesses high amino acid sequence similarity to EciP, the protease 
involved in the biosynthesis of epicidin 280 (2), and to other subtilisin-like serine 
proteases. Importantly, the residues of the predicted catalytic triad and oxyanion hole 
(Asp27, His62, Ser240, and Asn154) are conserved in ElxP. The lack of an N-terminal 
sec-signal sequence, a pro- sequence, and a C-terminal cell wall anchor sequence 
(LPXTG) suggests that ElxP is localized inside the cytoplasm, possibly as part of a 
membrane-bound biosynthetic complex. Thus, ElxP likely removes the leader peptide 
before the mature peptide is transported outside the cell, in contrast to other serine-type 
lantibiotic proteases, such as NisP or EpiP, that are located extracellularly and remove 
the leader region once the peptide has been secreted (see chapter 4) (27, 28). 
In a previous attempt to study lantibiotic proteases, an E. coli host carrying a 
plasmid encoding for NisP was able to express the protease at low concentrations 
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based on SDS-PAGE analysis using 35S-Met (27). Although NisP was not purified, the 
E. coli cell extracts cleaved the nisin A cyclized precursor peptide, producing a 
biologically active compound (27). Additional in vivo studies indicated that NisP is able 
to cleave the leader region only from fully processed precursor peptide, but not from 
uncyclized dehydrated or unmodified NisA (29). Similar results were obtained from in 
vivo studies of the lantibiotic Pep5 (3). In contrast, culture supernatants of S. carnosus 
TM300 expressing EpiP processed unmodified EpiA to the expected proteolytic 
products (28). In the present study, ElxP was successfully expressed in E. coli and its 
enzymatic activity was reconstituted in vitro after enzyme purification (Figure 2.7). The 
protease was able to process unmodified His6-ElxA, indicating that neither the 
Lan/MeLan ring nor the dehydrated residues, including Dha at position 1, are strictly 
required for enzyme recognition and proteolytic processing. 
Downstream of elxP, an ORF designated as elxB encodes a protein with 
homology to PepB, the enzyme that catalyzes the dehydration of Ser or Thr residues in 
the Pep5 precursor peptide (3). Analysis of ElxB with SignalP 3.0 using neuronal 
networks trained with Gram-positive bacteria (30) suggests that this protein may contain 
an N-terminal cell membrane anchor signal (Figure 2.11). The activity of ElxB homologs 
of class I lantibiotics has never been reconstituted in vitro (31) and the cofactors or 
metals involved in catalysis are currently unknown. In this work, I was also unable to 
reconstitute ElxB activity in vitro. However, coexpression of His6-ElxA and ElxB with or 
without ElxC in E. coli produced a partially dehydrated peptide (Figure 2.8) confirming 
the role of the protein in the biosynthesis of epilancin 15X. Closer inspection of the ElxB 
sequence indicates that it contains an almost conserved Walker A motif (GXXXXGKT/S: 
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GLLENWKT) and a conserved Walker B motif (hhhhD: IIFPD, where h stands for 
hydrophobic residue) (Figure 2.12). In addition, the three potential binding sites 
characteristic of GTP binding proteins are also present (DXXG: DFLG, NKXG: 
NTID/NDID/NLND/NRND, SAX: SAT) (32) suggesting that GTP or another nucleotide 
may be required for dehydration by LanB proteins, similar to class II-IV lanthionine 
synthetases (20, 22, 33, 34). The ORF elxC encodes a protein with high amino acid 
sequence similarity to PepC, the cyclase responsible for Lan and MeLan ring formation 
in Pep5 (3). Additionally, ElxC contains the conserved residues comprising a zinc ion 
binding site (Cys269, Cys318, and His319) and the residues involved in acid-base 
catalysis (His205 and Asp142) that are characteristic of this family of proteins (21, 35). 
 
Figure 2.11. Analysis of ElxB with SignalP 3.0. High values of the S-score indicate that the 
corresponding amino acid is part of a signal peptide (30). 
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Figure 2.12. Potential binding motifs and protein domain analysis of ElxB. Lantibiotic 
dehydratase - N terminus (pfam04737, pink) and C terminus (pfam04738, blue) domains and an 
N-terminal signal peptide (red) are present in ElxB. Potential Walker A and B motifs (yellow) and 
GTP binding sites (green) are almost perfectly conserved. h, stands for hydrophilic residue. 
 
Based on the experimental results and on bioinformatic analysis, the first steps of 
epilancin 15X biosynthesis can be postulated (Figure 2.13). The precursor peptide ElxA 
is modified by the dehydratase ElxB and the cyclase ElxC to produce the crosslinked 
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peptide. Then, the leader peptide is removed by the protease ElxP producing an N-
terminal enamine (dehydroalanine, Dha) present in equilibrium with the corresponding 
imine that can be hydrolyzed to produce dehydroepilancin 15X. Although enamine 
hydrolysis is fast (36), enzymatic assistance (e.g. by ElxP) cannot be ruled out at 
present. The reduction of the N-terminal ketone to the respective alcohol will complete 
the synthesis of mature epilancin 15X. 
The ORF elxO encodes a protein with homology to EciO, an oxidoreductase 
hypothesized to be involved in the reduction of pyruvate to lactate in the biosynthesis of 
epicidin 280 (2). ElxO contains a predicted N-terminal NAD(P)(H) binding site 
(GXXGXG: GGFKGIGK) and the catalytic triad residues (Ser139, Tyr152, and Lys156) 
of the short-chain dehydrogenase/reductase (SDR) protein superfamily (Figure 2.14) 
(37, 38). The absence of the ‘proximal Asp residue’ (Ser33 in ElxO) and the presence of 
the ‘proximal basic residues’ (Lys12 and Arg34), responsible for cofactor specificity, 
correctly predicted that ElxO is an NADPH-dependent enzyme and that it belongs to the 
cP3 subfamily (38, 39). The stereochemical course of the reaction established here 
allows assignment of the configuration of the N-terminal lactate group of epilancin 15X 
as (R). Because His6-ElxO was able to reduce a hexamer peptide, the thioether rings or 
other structural motifs in dehydroepilancin 15X are not essential for enzyme recognition.  
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Figure 2.13. Proposed biosynthetic steps involved in the production of epilancin 15X (A) and its 
N-terminal D-lactate group (B). 
 
The N-terminal Lac is not a common modification in lantibiotics. Indeed, besides 
epilancin 15X, only three other lantibiotics, epilancin K7 (25, 40), SWLP1 (41), and 
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epicidin 280 (2), have been reported to contain this modification. Interestingly, genome 
mining for LanC homologs allowed the identification of a lantipeptide gene cluster 
containing an open reading frame encoding for a putative SDR protein in the genome of 
Streptomyces griseoflavus Tu4000 (SgriT_010100000930) (42). Although the predicted 
lantipeptide has not been isolated and the function of the protein is unknown, this 
finding suggests that N-terminal Lac groups may not be restricted to staphylococcal 
lantibiotics. 
The ORF elxT encodes a putative protein with homology to PepT (3). The C-
terminal domain of ElxT contains an ATP-binding site characterized by the conserved 
Walker A motif (GXXXXGKT/S: GPSGAGKT) or P-loop, the Walker B motif (hhhhD: 
ILLLD), and the C motif or "signature" motif (LSGGQ) specific to ABC transporters 
(Figure 2.15). Additionally, analysis of ElxT with TMHMM 2.0 (30) indicates that its N-
terminal portion contains six transmembrane helices (Figure 2.15). Thus, ElxT is likely 
involved in lantibiotic secretion. 
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Figure 2.14. Sequence alignment of ElxO and several other short-chain dehydrogenase 
reductase proteins. The highly conserved residues Asn111, Ser139, Tyr152, and Lys156, the 
GXXGXG motif, and the proximal Asp residue (Asp42 in 7α-hydroxysteroid dehydrogenase, 
which is substituted by Ser33 in ElxO) and the ‘proximal basic residues’ (Arg34 in ElxO) are in 
bold. EciO: epicidin 280 oxidoreductase, MLCR: Mouse lung carbonyl reductase, DHPR: 
Dihydropteridine reductase, 7α-HSD: 7α-hydroxysteroid dehydrogenase, 3α,20β-HSD: 3α,20β- 
hydroxysteroid dehydrogenase. 
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Figure 2.15. Domain analysis of ElxT. The N-terminal transmembrane domains predicted with 
TMHMM 2.0 (30) are highlighted in blue, the Walker A and B motifs in yellow and the C-motif 
characteristic of ABC transporters in green. 
 
Epilancin 15X has potent activity against staphylococci, including strains of S. 
epidermidis (43), suggesting that the producer strain must have an effective self-
resistance mechanism. Such immunity is particularly important for epilancin 15X 
because it is activated by leader peptide removal within the cytoplasm unlike most 
lantibiotics for which leader peptide cleavage occurs after or concomitant with secretion. 
Downstream of elxC, three ORFs elxI1, elxI2, and elxI3 were identified. The genes elxI1 
and elxI3 potentially encode for 72 aa and 71 aa paralog peptides (47% identity) with no 
sequence homology to previously characterized proteins. Analysis by TMHMM 2.0 (30) 
indicates that ElxI1 and ElxI3 contain two highly hydrophobic α-helical domains followed 
by strongly hydrophilic C-terminal segments (Figure 2.16). Thus, although ElxI1 and 
ElxI3 contain no signal peptides, these small proteins may be localized at the 
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cytoplasmic membrane. A similar pattern of helical domains followed by a hydrophilic 
region is found in small proteins encoded by the gene clusters of the closely related 
lantibiotics Pep5 (44) and epicidin 280 (2), the structurally unrelated lactosin S (45), the 
nonlantibiotic bacteriocin divergicin A (46), and the circular bacteriocins AS-48, acidocin 
B, butyrivibriocin AR10, and circularin A (47). In the case of Pep5, the protein was 
designated PepI and was shown to be a determinant for self-immunity of the producer 
strain (48). Interestingly, in all of the lantibiotics mentioned above, intracellular 
peptidases remove the leader peptide and the mature bacteriocin is produced inside the 
cell (see chapter 4). PepI has been suggested to bind to a (currently unknown) target 
molecule, avoiding docking of the lantibiotic Pep5 onto the target (44). Despite the 
absence of significant sequence homology between PepI and ElxI1/3, the topological 
similarity suggests that these peptides may protect the host organism in a similar 
fashion (Figure 2.16).  
Interestingly, epilancin 15X and Pep5 are two of the most highly charged 
lantibiotics with a net positive charge of +7.1 and +8.0 at pH 7.4, respectively 
(compared, for instance, to a charge of +3.2 for nisin), suggesting that their targets 
might be negatively charged. The hydrophilic and positively charged tail of ElxI1/3 may 
protect this target by electrostatic repulsion of epilancin 15X. In another scenario, 
mature epilancin 15X may recognize the highly hydrophobic, membrane-like helical 
domains of ElxI1/3 to form a complex that protects the host against the lethal bioactivity. 
The entire complex, instead of the mature lantibiotic alone, may be recognized and 
secreted by ElxT. This potential role for ElxI1/3 is equivalent to that of substrate-binding 
proteins commonly found in ABC transporter systems (49). 
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Figure 2.16. Domain analysis of PepI (A) and ElxI1 (B). Both proteins are predicted to contain 
two highly hydrophobic α-helical domains followed by strongly hydrophilic C-terminal segments. 
The helical regions were predicted using TMHMM 2.0 (30). 
  
Finally, the putative immunity protein ElxI2 has high sequence similarity to Abi 
proteins, membrane-bound metalloproteases that are involved in self-immunity to 
plantaricin EF and JK, sakacin 23K, or streptolysin S (50, 51). ElxI2 is predicted to 
contain seven transmembrane domains, including the final four α-helices that form the 
Abi domain (Figure 2.17). Three highly conserved motifs (EEXXXR: EEILYR , FXXXH: 
FSLIH, and His226) likely constitute the active site of the protease (52). Thus, ElxI2 may 
protect the host against the bacteriocin by direct degradation of the peptide as in the 
case of the extracellular metalloprotease gelatinase in Enterococcus faecalis (53). An 
ortholog neighborhood analysis revealed that several putative ElxI2 orthologs exist in 
other staphylococci that are sensitive to epilancin 15X. The encoding ORFs are 
surrounded by genes likely involved in carbohydrate-phosphotransferase systems 
(PTS) responsible for the concomitant import and phosphorylation of carbohydrates. 
The mannose-PTS has previously been shown to serve as target receptor for several 
class IIa and IIc bacteriocins, including pediocin PA-1, enterocin P, sakacin P, and 
lactococcin A (54, 55). Thus, epilancin 15X might also interact with a PTS membrane 
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protein triggering pore formation and ElxI2 could be a resistant copy of the target 
instead of a bacteriocin peptidase. Experimental investigation of these hypotheses may 
help to elucidate the mode of action of epilancin 15X and the self-protection 
mechanism. 
 
Figure 2.17. Domain analysis of ElxI2. The transmembrane domains are highlighted in blue and 
the conserved Abi motifs in green. 
 
Whether elxI1, elxI2, and elxI3 are part of the cluster and are involved in the 
immunity mechanism is at present not certain. Closer analysis of the non-coding 
sequences upstream of elxC, elxI1, and elxI2 suggests the presence of only one 
relevant inverted repeat between elxC and elxI1, partially overlapping elxC, and with a 
calculated free energy of -10.2 kcal/mol. This repeat may work as a weak rho-
independent transcriptional terminator that allows partial read-through, indicating that 
elxC and elxI1-3 may be part of a single operon and the same gene cluster. 
Downstream of elxI3, a non-coding region of 329 bp is followed by the ORF orfA in a 
different operon that encodes a putative ABC transporter with no sequence homology to 
any known lantibiotic proteins, but with significant homology to transporters from 
staphylococci. Thus, OrfA is not likely to be related to epilancin 15X biosynthesis. 
Flanking the putative epilancin 15X gene cluster on the other side, an ORF designated 
orf1 was identified. Orf1 is a putative recombinase, not likely to be involved in epilancin 
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15X biosynthesis, transport, or immunity. Thus, the epilancin 15X cluster likely spans a 
9.2 kb region in the S. epidermidis 15X154 genome and includes the genes from elxO 
to elxI3 (Figure 2.1). 
Previously, the nisin biosynthetic machinery was successfully used to produce 
linear, dehydrated, or cyclized peptides fused to the leader region of NisA using a L. 
lactis expression system (15-17). Furthermore, production of fully modified 
nisinA(leader)/subtilin(core) or vice versa, with either nisin A or subtilin modification 
machineries was also demonstrated (18, 56). In the present study, a chimeric peptide 
containing the nisin A leader peptide and the epilancin 15X core peptide was 
dehydrated several fold when coexpressed with NisB, demonstrating that peptides 
different to NisA can be modified using the nisin tailoring enzymes in E. coli as 
heterologous host. Moreover, inclusion of multiple copies of nisB or simultaneous 
expression of NisC seem to favor the dehydration efficiency, in contrast with previous 
results in the L. lactis system (16).  
The recently discovered lantibiotic epilancin 15X produced by S. epidermidis 
15X154 has potent antimicrobial activity against drug-resistant strains of S. aureus. 
Epilancin 15X is structurally simple compared with other lantibiotics and yet is very 
active. The compound contains an unusual N-terminal D-lactate group that could be 
essential for biological activity. In this investigation, the gene cluster for epilancin 15X 
and the biosynthetic route of Lac were determined. Furthermore, the enzymatic activity 
of the dehydratase, protease, and oxidoreductase involved in the biosynthesis were 
demonstrated in vitro or in vivo, opening the door for engineering studies as well as for 
elucidation of the epilancin 15X mode of action.   
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CHAPTER 3. BIOCHEMICAL AND STRUCTURAL 
CHARACTERIZATION OF A LANTIBIOTIC 
DEHYDROGENASE*  
 
 
3.1. INTRODUCTION 
Lantipeptides are characterized by the presence of the thioether-cross-linked 
amino acids lanthionine and methyllanthionine and commonly by the dehydrated amino 
acids dehydroalanine (Dha) and dehydrobutyrine (Dhb) (Figure 1.1) (1). In addition to 
these usual modifications, lantipeptides may contain several other unnatural amino 
acids (Figure 1.1), such as the lysinoalanine and hydroxy-aspartate residues in 
cinnamycin (2); S-aminovinyl-D-cysteine, hydroxyproline, and chlorinated tryptophan in 
microbisporicin (3); and D-alanine and N-terminal pyruvyl (Pyr) in lactocin S (4). These 
less common residues can facilitate the interaction with the cellular target or protect the 
peptides from proteolytic degradation (5). The recently discovered lantibiotic epilancin 
15X produced by Staphylococcus epidermidis 15X154 is remarkably potent against 
antibiotic-resistant strains of S. aureus and Enterococcus faecalis and contains an 
unusual N-terminal D-lactate (Lac) group (5, 6). As described in chapter 2, the Lac 
group is produced by dehydration of the N-terminal Ser residue in the core peptide by 
the lantibiotic dehydratase ElxB, followed by cleavage of the leader peptide by the 
protease ElxP, and spontaneous or enzymatic hydrolysis of the resulting N-terminal Dha 
residue to generate a Pyr group. The resulting ketone-containing peptide, designated 
dehydroepilancin 15X, is finally reduced to the alcohol by a short chain 
                                                 
* Reproduced in part with permission from: “Velásquez, J. E., Zhang, X., and van der Donk, W. A. (2011) 
Biosynthesis of the antimicrobial peptide epilancin 15X and its N-terminal lactate, Chem. Biol. 18, 857-867.” Copyright 
© 2011 Elsevier Ltd. 
98 
 
dehydrogenase/reductase (SDR) designated ElxO, generating the mature Lac-
containing lantibiotic (Figure 2.13) (5). 
Despite the large diversity of topologies and unusual amino acids in the 
structures of lantipeptides (1), only a few posttranslational modification enzymes have 
been reconstituted and characterized in vitro, including the lanthionine synthetases 
LanM (7-15), LanL (16), and RamC-like (or LabKC) (17), and the cyclase (LanC) (18-
20) involved in (methyl)lanthionine ring formation. Chapter 2 describes the in vitro 
reconstitution of the enzymatic activity of the lantibiotic dehydrogenase ElxO (5), an 
enzyme that may alter the biological activity and the stability of epilancin 15X. In this 
chapter, additional studies regarding the structural and biochemical characterization of 
ElxO are presented, demonstrating that the protein is highly tolerant with respect to the 
structure of its substrates. Indeed, ElxO was used to modify lactocin S, a lantibiotic that 
is structurally unrelated to epilancin 15X and that contains an N-terminal Pyr, obtaining 
the Lac-containing analog peptide. Additionally, the reverse reaction catalyzed by ElxO 
was used to convert epilancin 15X to dehydroepilancin 15X, which was further modified 
to a fluorescent analog of the lantibiotic. Finally, the role of the N-terminal Lac group in 
the protection of epilancin 15X against degradation by aminopeptidases is also 
demonstrated (5), suggesting that the introduction of this modification at the N-terminus 
of different lantibiotics may be advantageous. Thus, ElxO could be used as a tool to 
generate peptides that are more stable against proteolytic degradation, possess 
improved biological activity, or contain additional functional groups.  
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3.2. EXPERIMENTAL METHODS 
Materials, organisms, media, and growth conditions 
Chemical reagents and media components used in this study were purchased 
from Sigma-Aldrich or Thermo Fisher Scientific, unless otherwise specified, and were 
used without further purification. All microorganisms and primer sequences are 
summarized in Tables 3.1 and 3.2, respectively. Escherichia coli strains were routinely 
grown in LB solid agar or broth supplemented appropriately at 37 °C. Kanamycin (50 
µg/mL) and chloramphenicol (12.5 µg/mL) were used to select for plasmid propagation. 
The strains Lactobacillus sake L45 and Pediococcus acidilactici Pac1.0 were grown in 
de Man-Rogosa-Sharpe (MRS) solid agar or broth (Difco), a medium that favors the 
growth of Lactobacilli (21). The strains Lactococcus lactis subsp. lactis CNRZ481 and L. 
lactis subsp. cremoris HP were grown in Elliker broth medium without gelatin and 
supplemented with sodium β-glycerophosphate (15 g/L) as buffering agent (EG’P 
medium) or in M17 medium (Difco) containing 0.5% glucose (GM17 medium), 
respectively.  
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Table 3.1. Microorganisms and plasmids used in this study 
 
 
 
  
Strain or plasmid Relevant characteristics Source or reference
Escherichia coli   
     DH5α pir/80dlacZM15 Δ(lacZYA-argF)U169 
recA1 hsdR17 deoR thi-1 supE44 gyrA96 
relA1
(22)
     Rosetta2(DE) F– ompT gal dcm lon hsdSB(rB- mB-) 
λ(DE3 [lacI lacUV5-T7 gene 1 ind1 
sam7 nin5]) pRARE2 
Novagen
 
Lactococcus 
  
     lactis  subsp. lactis CNRZ 481 Lacticin 481 producer strain (23)
     lactis  subsp. cremoris HP 
ATCC12602 
Lacticin 481 sensitive strain ATCCa
 
 Lactobacillus sake L45 
Lactocin S producer strain (24)
 Pediococcus  acidilactici Pac1.0 Lactocin S sensitive strain (24)
 
Plasmids 
  
     pET28b KanR E. coli T7 based histidine-tag fusion 
expression vector
Novagen
    pET.His6-ElxO elxO cloned into pET28b vector (5)
    pET.His6-ElxO(S139A) Mutant  pET.His6-ElxO encoding for  His6-
ElxO S139A
This study
    pET.His6-ElxO(Y152F) Mutant  pET.His6-ElxO encoding for  His6-
ElxO Y152F
This study
    pET.His6-ElxO(K156A) Mutant  pET.His6-ElxO encoding for  His6-
ElxO K156A
This study
    pET.His6-ElxO(K156M) Mutant  pET.His6-ElxO encoding for  His6-
ElxO K152A
This study
aATCC, American Type Culture Collection, Manassas, VA. 
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Table 3.2. Primers used in this study 
Name Sequence 
ElxO.S139A.FP 5'- GGA AAT CCG CTT AAT CCT GTA ATA GCA GAA ATA TTT ACT ATT 
GCT CC -3' 
ElxO.S139.RP 5'- GGA GCA ATA GTA AAT ATT TCT GCT ATT ACA GGA TTA AGC 
GGA TTT CC -3'
ElxO.Y152F.FP 5'- GCG GAT TTC CTT ACT CTA TAT TAT TCG GTA GCA CAA AAC ATG 
CTG -3' 
ElxO.Y152F.RP 5'- CAG CAT GTT TTG TGC TAC CGA ATA ATA TAG AGT AAG GAA ATC 
CGC -3' 
ElxO.K156A.FP 5'- CCT TTA GTT AAA CCA ATA ACA GCA TGT GCT GTG CTA CCG TAT 
AAT ATA GAG TAA GG -3'
ElxO.K156A.RP 5'- CCT TAC TCT ATA TTA TAC GGT AGC ACA GCA CAT GCT GTT ATT 
GGT TTA ACT AAA GG -3'
ElxO.K156M.FP 5'- CCT TTA GTT AAA CCA ATA ACA GCA TGC ATT GTG CTA CCG TAT 
AAT ATA GAG TAA GG -3'
ElxO.K156M.RP 5'- CCT TAC TCT ATA TTA TAC GGT AGC ACA ATG CAT GCT GTT ATT 
GGT TTA ACT AAA GG -3'
 
 
Synthesis of substrate analogues 
Peptides were synthesized on a 0.1 mmol or 0.15 mmol scale by Fmoc-based 
SPPS using a PS3 peptide synthesizer (Protein Technologies) or an Apex SC-396 
Peptide Synthesizer (Advanced Chemtech). Fmoc groups were removed during the 
deprotection steps with 20% piperidine in N,N-dimethylformamide (DMF) for 3 × 3 min. 
Coupling of the amino acids was performed for 1-1.5 h with 0.5 or 0.75 mmol (five 
equiv) of each Fmoc-AA (ChemImpex) and using DMF as solvent and 2-(6-chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) with 0.4 M 
N-methylmorpholine (NMM) or hydroxybenzotriazole (HOBt) with 
diisopropylcarbodiimide (DIC) as activating reagents. Coupling reactions of pyruvic acid 
or α-ketobutyric acid were performed twice for 1-1.5 h using five equiv of acid in the 
presence of HOBt and DIC. After completion of synthesis, peptidyl-resins were washed 
with DMF and ethanol, and dried in vacuo. Peptides were cleaved from the resins using 
a mixture of TFA/water/phenol (90:5:5) for 2 h. For Pyr-MAIVK a cleavage cocktail 
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containing TFA/water/phenol/thioanisole/mercaptoethanol (82.5:5:5:5:2.5) was used, 
and for Pyr-YAIVK, Pyr-TAIVK, Pyr-RAIVK, and Obu-RAIVK a cleavage mixture of 
TFA/water/phenol/thioanisole (85:5:5:5) was used. The cleavage solutions were 
evaporated using a rotary evaporator to remove TFA and the peptides were precipitated 
from the solution with cold diethyl ether. The precipitated materials were resuspended in 
0.1% TFA in acetonitrile/water (50:50) and lyophilized to dryness. The synthesis of Glx-
AAIVK, where Glx stands for glyoxylic acid, was performed by oxidation of SAAIVK (5 
mM) with sodium periodate (10 mM) in sodium phosphate buffer (40 mM, pH 7.5) for 5 
min, followed by quenching with sodium sulfite (40 mM) (25). The peptides were purified 
by semi preparative reverse phase high performance liquid chromatography (HPLC) 
using an Agilent 1200 instrument equipped with an Eclipse XDB-C18 column (9.4 mm x 
250 mm, Agilent) or a Synergi Fusion-RP column (9.4 mm × 150 mm, Phenomenex) 
and a variable wavelength detector set at 220 nm. The mobile phase was 0.1% formic 
acid in water (A) and acetonitrile (B). A gradient of 2-30% B in A and a flow rate of 4 
mL/min were used. The masses of the purified peptides were determined by 
electrospray ionization mass spectrometry (ESI-MS) using a Waters ZMD quadrupole 
instrument at the Mass Spectrometry Laboratory of the University of Illinois at Urbana-
Champaign. See also Notebook VI, page 41. 
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Construction of plasmids pET.His6-ElxO(S139A), pET.His6-ElxO(Y152F), pET.His6-
ElxO(K156A), and pET.His6-ElxO(K156M) and expression and purification of 
proteins 
To generate pET.His6-ElxO(S139A), pET.His6-ElxO(Y152F), pET.His6-
ElxO(K156A), and pET.His6-ElxO(K156M), the entire pET.His6-ElxO (5) was amplified 
by PCR using PfuTurbo hotstart DNA polymerase (Stratagene) or iProofTM  high-fidelity 
DNA polymerase (BioRad) and the appropriate mutagenesis primers (Table 3.2) 
followed by treatment with DpnI (New England Biolabs) and transformation of E. coli 
DH5α cells. The correct sequence of the insert was confirmed by sequencing at the W. 
M. Keck Center for Comparative and Functional Genomics at the University of Illinois at 
Urbana-Champaign. The proteins were expressed in E. coli Rosetta2(DE3) cells and 
purified using a HisTrap HP column (GE Healthcare) as described in chapter 2 for His6-
ElxO (5), followed by further purification by size exclusion chromatography using an 
ÄKTApurifier equipped with a HiLoad 16/60 Superdex 200 column (GE Healthcare) and 
a flow of 1.5 mL/min of running buffer (50 mM HEPES, 300 mM NaCl, 10% glycerol, pH 
7.4). See also Notebook VI, page 81. 
 
Wild-type and mutant His6-ElxO activity assays 
Wild-type or mutant His6-ElxO (2 or 10 µM) and purified peptide (0.1 to 5 mM) 
were incubated with NADPH (2.5 mM) in assay buffer (100 mM HEPES, 500 mM NaCl, 
pH 7.5) at 25 °C. The reaction was initiated by addition of the enzyme and the progress 
was monitored by UV spectrophotometry, measuring the disappearance of NADPH at 
340 nm by using a molar extinction coefficient for NADPH of 6.22 mM-1 cm-1. Formation 
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of reduced peptides was confirmed by liquid chromatography coupled to mass 
spectrometry (LC-MS) using an Agilent 1200 instrument equipped with a single 
quadruple multimode ESI/APCI ion source mass spectrometry detector and a Synergi 
Fusion-RP column (4.6 mm × 150 mm, Phenomenex). The mobile phase was 0.1% 
formic acid in water (A) and methanol (B). A gradient of 0-70% B in A over 30 min and a 
flow rate of 0.5 mL/min were used. See also Notebook VII, page 14. 
 
Production of dihydrolactocin S and bioactivity assays 
Synthetic lactocin S (50 µM), obtained from Prof. J. Vederas (University of 
Alberta) (26), was incubated with His6-ElxO (50 µM) and NADPH (10 mM) in assay 
buffer (100 mM HEPES, 500 mM NaCl, pH 7.5) at room temperature for 12 h. The 
formation of reduced peptide was confirmed by LC-MS using a Waters SYNAPTTM 
mass spectrometry system equipped with an ACQUITY UPLC®, an ESI ion source, a 
quadrupole time-of-flight detector, and an ACQUITY Bridged Ethyl Hybrid (BEH) C8 
column (2.1 mm × 50 mm, 1.7 µm, Waters). A gradient of 3-97% B (0.1% formic acid in 
methanol) in A (0.1% formic acid in water) over 12 min was used. 
Agar diffusion bioactivity assays were performed using MRS agar media (Difco) 
(21). For each assay, aliquots of agar medium inoculated with overnight cultures of 
indicator strain (1/100 dilution) were poured into sterile plates. Aliquots of 20 L of 
sample were placed into wells made on the solidified agar and the plates were 
incubated at 37 °C overnight. For determination of critical concentration, the diameter of 
the inhibition zones were determined and fitted to the equation ܦ ൌ ܽ ൅ ܾ ൈ ܮ݊ሺܥሻ, 
where D is the diameter of the inhibition zone, C is the concentration of bacteriocin, and 
105 
 
a and b are constant parameters (27-29). For MIC determinations, serial dilutions of 
peptides were prepared in MRS broth. Then, aliquots of 50 µL of peptide solutions were 
dissolved in 150 µL of a 1 to 50 dilution of an overnight culture of indicator strain in fresh 
MRS broth and placed on 96-well plates. The plates were incubated at 37 °C overnight 
and the wells with no bacterial growth (OD600 < 0.3 AU) were determined. See also 
Notebook VII, page 41. 
 
Production of dehydroepilancin 15X and fluorescently labeled epilancin 15X 
Epilancin 15X (30 µM) purified from the producer strain as described in chapter 2 
(5) was incubated with His6-ElxO (30 µM) and NADP+ (80 mM) in assay buffer (575 mM 
boric acid, 500 mM NaCl, pH 9.5) at room temperature for 12 h. Control samples lacking 
enzyme, cofactor, or both were incubated under identical conditions. Formation of 
oxidized peptide was confirmed by LC-MS analysis using a Waters SYNAPTTM mass 
spectrometry system as described above. Additionally, reaction and control samples 
containing (dehydro)epilancin 15X were reacted with phenylene-1,2-diamine (40 mM) in 
assay buffer (4.0 M sodium acetate, pH 4.8) at 37 °C for 48 h as described elsewhere 
(30). The reaction products were analyzed by matrix-assisted laser desorption/ionization 
– time-of-flight mass spectrometry (MALDI-TOF MS) on a Voyager DE-STR 
Biospectrometry Workstation using α-cyano-4-hydroxycinnamic acid as matrix at the 
Mass Spectrometry Laboratory of the University of Illinois at Urbana Champaign. See 
also Notebook VII, page 48. 
For lantibiotic labeling, epilancin 15X (30 µM) was incubated with His6-ElxO (30 
µM), NADP+ (70 mM), and cascade blue hydrazine trisodium salt (10 mM, Invitrogen) in 
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the presence of aniline (50 mM) and in assay buffer (100 mM HEPES, 500 mM NaCl, 
pH 7.5) at room temperature for 72 h (31). The formation of the hydrazone was 
confirmed by LC-MS using a Waters SYNAPTTM mass spectrometry system as above. 
See also Notebook VII, page 53. 
 
Production and purification of lacticin 481 
Production of lacticin 481 was performed as suggested before (23, 32). In brief, 
L. lactis subsp. lactis CNRZ481 was grown for 9 h in EG’P media (Elliker broth medium 
without gelatin and supplemented with sodium β-glycerophosphate), maintaining the 
culture pH at 5.5 by adding aliquots of 3 M ammonium hydroxide. In previous studies, 
the purification of lacticin 481 and other lantibiotics has been accomplished using a 
complex combination of chromatographic techniques and/or organic solvent extractions 
with low recovery yields and high amounts of oxidized products that are difficult to 
separate (32-35). To purify lacticin 481, the culture supernatant was heat-treated to 
deactivate proteases and the lantibiotic was concentrated with an ammonium sulfate 
precipitation step saturating the solution at 60% and 4 °C. After resuspension of the 
pellet in a Sorensen buffer (NaH2PO4 176 mM, Na2HPO4 24 mM, pH 6.0), lacticin 481 
was further purified by solid phase extraction (SPE) using Vydac C4 reverse phase 
columns (214SPE1000, Discovery Sciences) and 20 mM ammonium acetate and 
acetonitrile as eluting solvents. The bacteriocin was eluted with 32% acetonitrile, while 
most of the impurities were eluted at lower concentrations of organic solvent. The 
fraction containing lacticin 481 was concentrated by lyophilization and further purified by 
HPLC using an Agilent 1200 instrument equipped with a Vydac® 214TP54 C4 reverse 
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phase column (4.6 mm i.d. × 250 mm L, Discovery Sciences). A gradient of 30-40% B 
(acetonitrile) in A (20 mM, ammonium acetate, pH 5.5) over 30 min was used. A yield of 
1.1 mg of lacticin 481 per liter of culture was obtained, compared with a yield of 0.24 mg 
per liter reported previously (32). The identity of lacticin 481 was confirmed by MALDI-
TOF MS. See also Notebook II, page 64. 
 
Incubation of peptides with Aeromonas proteolytica aminopeptidase 
After incubation of epilancin 15X and NADP+ with (or without) His6-ElxO,  aliquots 
of the peptide solutions were incubated with A. proteolytica aminopeptidase (10 U/mL, 
Sigma-Aldrich) in assay buffer (40 mM Tris-HCl, pH 8.0) at room temperature for 24 h. 
Samples containing purified lacticin 481 with or without protease were incubated under 
the same conditions for 12 h. The reaction products were analyzed by MALDI-TOF MS. 
The lacticin 481 containing samples were tested by agar diffusion bioactivity assays 
using M17 agar medium supplemented with 0.5% glucose and L. lactis subsp. cremoris 
HP as indicator strain. See also Notebook VII, page 78. 
A solution containing Lac-AAIVKBBIKA, generated enzymatically with His6-ElxO 
as described above, and control samples containing Pyr-AAIVKBBIKA or AAIVKBBIKA 
were also incubated with the peptidase under the conditions described above for 6 h. 
The peptides were then purified by SPE using Discovery® DSC-18 columns (1 mL, 50 
mg, Supelco, Bellefonte, PA) and 0.1% formic acid in water or 0.1% formic acid in 60% 
acetonitrile as washing and eluting solvents, respectively. The reaction products were 
finally analyzed by ESI-MS using a Waters ZMD quadrupole instrument at the Mass 
Spectrometry Laboratory of the University of Illinois at Urbana-Champaign. 
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3.3. RESULTS AND DISCUSSION 
The data presented in chapter 2 showed that His6-ElxO catalyzes the conversion 
of the synthetic peptide Pyr-AAIVK, that resembles the N-terminal region of 
dehydroepilancin 15X, to D-Lac-AAIVK, demonstrating that the (methyl)lanthionine rings 
and full length ElxA peptide are not strictly required for substrate recognition by ElxO 
(5). Thus, ElxO could be potentially used to introduce N-terminal alcohols to other 
peptides or proteins that contain N-terminal Pyr or 2-oxobutyryl (Obu) groups, thereby 
enhancing their biological activity or chemical stability. The purpose of this study was to 
evaluate the substrate requirements of ElxO, to characterize its reaction mechanism, 
and to explore the application of the enzyme for the modification of peptides and other 
lantibiotics. A combination of site-directed mutagenesis, crystallographic, and kinetic 
studies using several synthetic substrates was conducted. 
 
Synthesis of substrate analogs and substrate specificity analysis of ElxO 
To explore the substrate specificity of the enzyme, a series of small potential 
substrates was synthesized by Fmoc-based solid phase peptide synthesis (SPPS) 
followed by coupling of pyruvic acid using hydroxybenzotriazole (HOBt) and 
diisopropylcarbodiimide (DIC) as activating reagents to produce the Pyr-containing 
peptides. Single residues of the originally tested substrate, Pyr-AAIVK, were replaced 
systematically with Ala, and Ala2 was changed to a wide variety of amino acids, 
including polar, nonpolar, acidic, and basic residues obtaining a diverse set of 
alternative substrates (Table 3.3).  
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Table 3.3. Substrates tested with His6-ElxO. The closest substrate analog Pyr-AAIVK is shown 
in entry 1 and residues different from Pyr-AAIVK in the subsequent entries are highlighted in 
red.  
 
 
Entry Substrate kcat/KM (M-1· s-1) 
Relative 
kcat/KM 
  1  23456 
1 Pyr-AAIVK 2.43 ± 0.06 1.00 
2 Pyr-AAIV_ 1.13 ± 0.00 0.47 
3 Pyr-AAI__ 0.06 ± 0.00 0.02 
4 Pyr-AA___ < 0.03 < 0.01 
5 Pyr-A____ < 0.03 < 0.01 
6 Pyr-AAIVKBBIKAAKKa 14.17 ± 0.36 5.83 
7 Pyr-AAIVA 1.33 ± 0.01  0.55 
8 Pyr-AAIAK 1.59 ± 0.02  0.65 
9 Pyr-AAAVK 0.29 ± 0.01  0.12 
10 Pyr-RAIVK 5.50 ± 0.05  2.26 
11 Pyr-KAIVK 4.22 ± 0.04 1.74 
12 Pyr-DAIVK 0.29 ± 0.02  0.12 
13 Pyr-NAIVK 7.60 ± 0.04 3.13 
14 Pyr-PAIVK 0.13 ± 0.01 0.05 
15 Pyr-MAIVK 15.54 ± 0.11 6.40 
16 Obu-AAIVK 0.92 ± 0.03 0.38 
17 Obu-RAIVK 1.51 ± 0.02 0.62 
18 Glx-AAIVK < 0.03 < 0.01 
Other substrates confirmed by LC-MS: 
19 Non-polar Pyr-GAIVK Pyr-IAIVK Pyr-VAIVK Pyr-FAIVK 
20 Polar Pyr-TAIVK Pyr-YAIVK 
21 Basic Pyr-HAIVK 
22 Pyr-containing analogs Pyr-ASIVK 
23 Obu-containing analogs Obu-AAAVK Obu-AAIAK 
24 Lantibiotic analogs 
Pyr-AAVLK Pyr-LGPAIK 
Pyr-APVLA Obu-AGPAIR 
Pyr-BPVLAAVAVAKKKa 
Note: a: B stands for L-2-aminobutyric acid. 
 
If Thr instead of Ser were located at the position 1 of the epilancin 15X core 
peptide (Figure 2.13), an N-terminal Obu group, instead of a Pyr group, would be 
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generated upon dehydration and hydrolysis of the N-terminal Dhb residue as in the 
lantipeptides Pep5 (36, 37), lacticin 3147 A2 (38), lichenicidin (39-41), and prochlorosin 
1.7 (14). Being able to reduce enzymatically the Obu moiety to the corresponding 
alcohol would provide a means for generating a number of potentially useful analogs as 
the more reactive carbonyl group is removed. To explore the specificity of ElxO for the 
N-terminal ketone group, a series of analogs containing the N-terminal Obu group was 
also generated by coupling 2-oxobutanoic acid (α-ketobutyric acid) to the N-terminus of 
the synthetic peptides. To release the peptides from the solid supports, the peptidyl-
resins were treated with TFA cleavage cocktails not containing triisopropylsilane (TIS) 
since presence of this reagent resulted in the chemical reduction of the ketone-
containing peptides, as suggested before (42). Finally, the peptides were purified by 
revere phase high performance liquid chromatography (HPLC) and the identities of the 
compounds were confirmed by electrospray ionization mass spectrometry (ESI-MS). 
Purified peptides at different concentrations were incubated with or without His6-
ElxO in the presence of NADPH and the changes in absorbance at 340 nm over time 
were monitored by UV spectrophotometry establishing the reaction rates. Attempts to 
determine the steady state kinetic parameters kcat and KM using a subset of peptides 
were not successful, since it was not possible to saturate the enzyme with the 
substrates before reaching the solubility limits of the peptides (Figure 3.1). However, the 
catalytic efficiencies (kcat/KM) for some of the substrates were determined after 
measuring the reaction rates at different peptide concentrations (Table 3.3). For all 
tested substrates, the kcat/KM constants were small, presumably because the peptides 
are lacking structural features compared to the expected physiological substrate, such 
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as the thioether rings or additional amino acids that may provide essential binding 
interactions with the enzyme. Alternatively, ElxO could be part of a biosynthetic complex 
in the native producer and the interaction with other proteins might be required to 
enhance the catalytic efficiency. Aliquots of the peptide solutions, incubated with 
NADPH and with or without enzyme, were also analyzed by LC-MS to confirm that the 
reduced peptides are only formed in the presence of enzyme. 
 
 
 
Figure 3.1. Dependence of the reaction rate on Pyr-AAIVK (A), Pyr-MAIVK (B), Pyr-RAIVK (C), 
and Pyr-NAIVK (D) concentrations by His6-ElxO and using NADPH as co-substrate. Saturation 
of the enzyme with the peptide substrates was not achieved even at high peptide concentrations 
(5 mM) as exemplified with the trials with Pyr-AAIVK and Pyr-RAIVK. 
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The smaller peptides Pyr-AAIV and Pyr-AAI (entries 2 and 3), but not Pyr-AA and 
Pyr-A (entries 4 and 5), were reduced by His6-ElxO in the presence of NADPH based on 
the spectrophotometric analysis, although with considerably lower reaction rates 
compared with Pyr-AAIVK. In contrast, the peptide Pyr-AAIVKBBIKAAKK, where B 
stands for L-2-aminobutyric acid, was converted at a higher rate (Table 3.3, entry 6), 
suggesting that the length of the peptide is important for substrate recognition. The Ala 
scanning analysis performed along the sequence of Pyr-AAIVK (Table 3.3, entries 7-9) 
indicated that the enzyme was able to reduce all the peptides tested; however, kcat/KM 
was lower for Pyr-AAAVK (Table 3.3, entry 9). Additionally, peptides containing amino 
acids with different polarity properties, such as nonpolar (Pro, Met, Gly, Ile, Val, Phe; 
Table 3.3, entries 14, 15, and 19), polar (Asn, Thr, Tyr; Table 3.3, entries 13 and 20), 
acidic (Asp; Table 3.3, entry 12), or basic (Arg, Lys, His; Table 3.3, entries 10, 11, and 
21) residues at position 2 were transformed to the reduced products. These results 
suggest that no substrate residue is absolutely required for enzymatic activity and that 
the minimal length of the peptide to be accepted as substrate is four residues. 
Interestingly, Pyr-RAIVK, Pyr-KAIVK, Pyr-NAIVK, and Pyr-MAIVK are better substrates 
than Pyr-AAIVK (Table 3.3, entries 10, 11, 13, 15 vs. 1), while Pyr-DAIVK and Pyr-
PAIVK are converted considerably less efficiently (Table 3.3, entries 12 and 14), 
suggesting that negatively charged residues next to the Pyr group are not well tolerated 
and that the conformation of the peptide is important for catalysis or substrate 
recognition.  
Obu-AAIVK and Obu-RAIVK were also accepted as substrates leading to the 
formation of an N-terminal 2-hydroxybutyryl group (Hob), although at lower rates (Table 
113 
 
3.3, entries 16 and 17). Similarly, the peptides Obu-AAAVK and Obu-AAIAK were 
substrates for the enzyme (Table 3.3, entry 23). However, when Pyr was substituted for 
a glyoxylyl (Glx) group, such as in the peptide Glx-AAIVK (Table 3.3, entry 18), no 
significant formation of the reduced peptide was observed based on LC-MS analysis.  
In addition to epilancin 15X, two other known lantibiotics, epilancin K7 and 
epicidin 280, contain an N-terminal Lac moiety. To explore the potential of using His6-
ElxO for the synthesis of other lantibiotics, peptides mimicking the N-terminal portion of 
dehydroepilancin K7 (Pyr-AAVLK) and dehydroepicidin 280 (Pyr-LGPAIK) were 
synthesized and tested as substrates (Table 3.3, entry 24). His6-ElxO reduced both 
peptides, even though their sequences are quite different from the N-terminus of 
epilancin 15X. Several other lantibiotics, e.g. lactocin S and Pep5, contain N-terminal 
Pyr and Obu groups produced after dehydration of Ser or Thr at the N-terminus of the 
core peptide, followed by spontaneous or enzymatic enamine hydrolysis upon leader 
peptide removal (Figure 2.13). These lantibiotics might be modified to produce the 
corresponding unnatural dihydropeptides, provided they are substrates for His6-ElxO. 
To test this possibility, peptides resembling the N-terminus of lactocin S (Pyr-APVLA 
and Pyr-BPVLAAVAVAKKK) and Pep5 (Obu-AGPAIR) were incubated with His6-ElxO in 
the presence of NADPH (Table 3.3, entry 24). The peptides were reduced as confirmed 
by LC-MS analysis. These observations suggest that ElxO is quite promiscuous and 
may be used to synthesize a variety of peptides that contain N-terminal 2-
hydroxypropionyl (lactate, Lac) or 2-hydroxybutyryl (Hob) groups. 
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Production of dihydrolactocin S 
 Lactocin S is a 37-residue lantibiotic produced by L. sake L45 that contains an N-
terminal Pyr and that inhibits the growth of species from the genera Lactobacillus, 
Pediococcus, and Leuconostoc (Figure 3.2A) (24). To evaluate if lactocin S is a 
substrate for ElxO, a synthetic sample of the lantibiotic, obtained from Prof. J. Vederas 
laboratory, was incubated with NADPH in the presence of His6-ElxO and the reduction 
of the peptide was monitored by high-resolution LC-MS (Figure 3.2B), confirming the 
formation of dihydrolactocin S.  
 
Figure 3.2. Schematic structure of lactocin S and formation of dihydrolactocin S. The lantibiotic 
lactocin S (A) that contains an N-terminal Pyr group was converted to dihydrolactocin S as 
evidenced by LC-MS analysis (B). B, left: MS analysis of lactocin S (calculated monoisotopic 
m/z = 3762.89) incubated with NADPH in the absence of His6-ElxO. The peak at m/z = 3794.93 
corresponds to oxidized lactocin S (M+O). B, right: MS analysis of dihydrolactocin S (calculated 
monoisotopic m/z = 3764.89) generated after incubation of lactocin S with both NADPH and 
His6-ElxO. The peaks at m/z = 3786.88 and 3808.84 correspond to the sodium and disodium 
adducts of dihydrolactocin S.  
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Samples containing the reduced peptide and control samples containing 
unmodified lactocin S were tested by single concentration (Figure 3.3A) and serial 
dilution (Figure 3.3B) agar diffusion bioactivity assays using either P. acidilactici Pac1.0 
as indicator strain or the lactocin S producer strain. As expected, all the peptides were 
active against P. acidilactici Pac1.0 but not against L. sake L45 suggesting that the N-
terminal Pyr is not involved in self-immunity. From the serial dilution assay (Figure 
3.3B), the sizes of the inhibition zones were determined and the critical concentrations, 
i.e. the concentrations at which no inhibition zones are observed (28), were calculated 
(Figure 3.3C). Interestingly, the sample containing dihydrolactocin S produced slightly 
larger inhibition zones and smaller critical concentrations than control samples 
containing the unreduced peptide (Figure 3.3E), suggesting that the Pyr group of 
lactocin S is not essential for bioactivity and that Lac may favor the biological activity. 
Similar results were obtained upon determination of apparent minimal inhibitory 
concentrations (MIC) by a serial dilution bioactivity assay in liquid media (Figure 3.3D 
and E).  
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Figure 3.3. Antimicrobial activity assays with lactocin S and its reduced analog. Single 
concentration (A) and serial dilution (B) agar diffusion bioactivity assays of enzymatically 
synthesized dihydrolactocin S (sample 1, blue) and control samples lacking enzyme (sample 2, 
red), cofactor (sample 3, green), or both (sample 4, purple) and incubated under identical 
conditions are shown. Sample 5 was a control assay lacking lactocin S. The sizes of the 
inhibition zones of the serial dilution agar diffusion bioactivity assays (B) were determined and 
fitted to a linear model to establish the critical concentration (inhibition zone diameter, D = 0) (C) 
(28). Apparent minimal inhibitory concentrations (MIC) were also determined by a serial dilution 
bioactivity assay in liquid media (D). The MIC values were established based on the smallest 
concentration of antibiotic that caused OD600 to be less than 0.3 AU. A table summarizing the 
results is also presented (E).  
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Preparation of dehydroepilancin 15X and fluorescently labeled epilancin 15X 
In addition to formation of alcohols in peptides other than epilancin 15X, as 
shown above for lactocin S, ElxO could be potentially used to catalyze the reverse 
reaction and oxidize existing alcohol moieties. The resulting ketone groups may then be 
conjugated with orthogonal functional groups such as hydrazines or aminooxy 
containing compounds to generate potentially useful lantibiotic analogs. Indeed, when 
epilancin 15X was incubated with His6-ElxO, in the presence of an excess of NADP+ 
and at high pH, a new peptide with a difference in mass of −2 Da and corresponding to 
dehydroepilancin 15X was observed by LC-MS (Figure 3.4A). Additionally, when the 
dehydrated peptide was incubated with phenylen-1,2-diamine (30), the N-terminal Pyr 
group was removed as determined by MALDI-TOF MS analysis (Figure 3.4B), 
confirming the formation of the oxidized peptide. Furthermore, when the 
dehydrogenation reaction was performed in the presence of cascade blue labeled 
hydrazine and aniline (43), the corresponding fluorophore-containing peptide was 
produced (Figure 3.5). Such labeled peptide could be highly valuable, for example, for 
studies of mode of action. Similarly, ElxO could be used to modify other Lac-containing 
lantibiotics such as epilancin K7 or epicidin 280 due to its relaxed substrate specificity. 
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Figure 3.4. Production of dehydroepilancin 15X. A) LC-MS analysis of epilancin 15X after 
incubation with (blue) or without (red) His6-ElxO in the presence of NADP+. A new peak 
corresponding to dehydroepilancin 15X (calculated monoisotopic m/z = 3171.68) was observed 
only in the sample containing enzyme. B) MALDI-TOF MS analysis of samples from A), after 
treatment with phenylene-1,2-diamine. In addition to unreacted epilancin 15X (calculated 
average m/z = 3176), a new compound corresponding to epilancin(2-31) was observed 
(calculated average m/z = 3106).  
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Figure 3.5. Chemo-enzymatic labeling of epilancin 15X with cascade blue. A) Scheme of the 
labeling reaction of epilancin 15X with cascade blue in the presence of His6-ElxO. B) After the 
labeling reaction, the predicted product was observed by LC-MS analysis (calculated 
monoisotopic m/z = 3683.65). The peaks at m/z = 3189.63 and 3699.57 correspond to oxidation 
products (M+O) of epilancin 15X and the labeled peptide, respectively. 
 
X-ray crystal structure of ElxO  
At present, very little is known about the structural biology of lantibiotic 
biosynthetic enzymes, as structures are available only for LanC (18), LanD (44, 45), and 
LanP (46) enzymes. To obtain some insights into the substrate scope of ElxO and to 
characterize structurally this lantibiotic dehydrogenase, Ms. Nega Garg, a joint graduate 
student between the Nair and the van der Donk laboratories, and Professor Satish Nair 
determined the x-ray crystal structure of the complex of ElxO with NADPH at 1.8 Å 
resolution (Figure 3.6). Attempts to obtain a co-crystal structure with bound peptide 
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(Pyr-AAIVK, Pyr-DAIVK, Pyr-VAIVK, Obu-AAIVK, or Obu-RAIVK) were unsuccessful, 
presumably because of the expected high KM values for these substrates.  
 
Figure 3.6. X-ray crystal structure of ElxO bound to NADPH. ElxO displays the characteristic 
Rossman fold of dinucleotide-binding proteins (A). A hydrophobic pocket surrounding the 
catalytic side may accommodate the pyruvyl-containing substrate (B). The three highly 
conserved catalytic triad residues (Ser139, Tyr152, and Lys156) (C) and an extended 
hydrophobic patch covering both monomers and in the opposite side of the protein (D) are 
shown. The hydrophobicity surface structures are shown in colors from blue (hydrophilic) to red 
(hydrophobic) based on the Kyte and Doolittle scale (47). 
 
The crystallographic data revealed that ElxO displays a single domain 
architecture and the characteristic Rossman fold (48) common to dinucleotide-binding 
proteins (Figure 3.6A). The core of the enzyme is formed by seven strands creating a 
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twisted parallel β-sheet flanked by three α-helices from each side and a small one-turn 
α-helix on the top at the beginning of the active site loop (Figure 3.6A). The region 
between Glu188 and Ile204 was not observed in the electron density map and it is 
expected to fold in an additional helix on the top edge of the β-sheet forming a 
protective lid over the active site that may undergo an ‘open to close’ conformational 
change upon substrate-binding (49, 50). The structural characterization confirmed that 
the protein exists as a dimer in solution as suggested by size exclusion chromatography 
(5), with the C-terminal β-strand and an α-helix in each monomer at the edge of the 
interface.  
The structural analysis also revealed that three highly conserved residues 
(Ser139, Tyr152, and Lys156) located in the active site of the protein (Figure 3.6C) 
likely play a catalytic role as suggested by amino acid sequence alignment with other 
proteins from the short-chain dehydrogenase/reductase (SDR) family (5, 49, 51). 
Furthermore, the highly conserved Asn111 presumably involved in a proton relay 
system that connects bulk solvent to Tyr152 was also identified (49, 52). In addition to 
these residues, other motifs that define classical SDR proteins are apparent. The 
backbone nitrogen atoms of Gly13, Ile14, and Gly15 and the ε-amino group of Lys12 in 
the conserved TGX3GXG motif may stabilize the pyrophosphate moiety by hydrogen 
bonding interactions with the phosphate oxygens. Furthermore, the adenine group of 
the cofactor fits into a hydrophobic pocket bounded by Leu58, Val60, Ile70, Ala87, and 
Ile89 and is isolated from the external solvent by Arg34. A hydrophobic floor in the 
nicotinamide ring-binding pocket is defined by residues Ile14, Pro182, Ile223, and 
Val219. Lys156 forms hydrogen bonds to both 2’ and 3’ hydroxyl groups of the 
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nicotinamide ribose, positioning the cofactor, and possibly also lowering the pKa of the 
catalytic base Tyr152 through an electrostatic influence (50, 52). Overall, NADP(H) 
binds in an extended conformation with the adenine and nicotinamide rings oriented 
roughly perpendicular to the planes of the respective ribose groups, resulting in an anti 
conformation for the adenine ring and a syn conformation for the nicotinamide group 
and suggesting a B-face 4-pro-S hydride transfer reaction. 
Although a co-crystal structure with a pyruvyl-containing substrate is not 
available, the structural analysis revealed a hydrophobic pocket surrounding the 
catalytic site and bounded at the sides by branched aliphatic residues (Ile14, Ile184, 
Ile185, Ile207, Val219, and Ile223) (Figure 3.6B). This cavity may provide dominant 
interactions with the substrate. Indeed, when the charged residue Asp was located at 
position 2 of the substrate (Table 3.3, entry 12), the peptide was processed 
considerably less efficiently than the substrates containing the non-polar Met, the 
isosteric Asn, or even basic residues with long side chains such as Arg or Lys at the 
same position (Table 3.3, entries 10, 11, 13, and 15). Furthermore, when Ile at position 
4 was substituted for Ala (Table 3.3, entry 9) the catalytic efficiency was also reduced. 
Thus, peptides containing long side chains at positions 2 or 4, and likely at position 3, 
may have better affinities for the enzyme due to hydrophobic interactions at the active 
site.  
Interestingly, an extended hydrophobic patch with several branched aliphatic 
amino acids (Ile, Val, or Leu), exposed to the solvent, and covering both monomers was 
identified in the opposite face of the protein (Figure 3.6D). This region could anchor the 
enzyme by hydrophobic interactions with membrane lipids, or more specifically with 
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membrane proteins such as the ABC transporter ElxT or the putative immunity protein 
ElxI2. Thus, ElxO could be part of a complex of proteins involved in biosynthesis, 
activation, and secretion of epilancin 15X. Alternatively, this patch might interact with 
the hydrophobic B and C rings of dehydroepilancin 15X (Figure 1.2) providing additional 
binding energy and justifying the low catalytic efficiencies with the short peptides.  
SDR proteins usually act on small substrates, like steroids, prostaglandins, 
sugars, and small xenobiotics or aliphatic alcohols (50, 52). Importantly, although more 
than 200 structures have been deposited in the Protein Data Bank and several 
members have been biochemically characterized (52), no SDR enzyme acting on larger 
substrates, such as lantibiotics, has been characterized so far to the best of my 
knowledge. Interestingly, ElxO structure still resembles the single domain structures of 
the enzymes recognizing small molecules and additional domains are not required to 
interact with the long cyclized peptide. 
 
ElxO catalytic mechanism 
To determine the importance of Tyr152, Ser139, and Lys156 for catalysis, the 
single mutant proteins His6-ElxO Y152F, S139A, K156A, and K156M were prepared 
and purified. Enzymatic assays with wild-type and mutant proteins were performed 
using Pyr-AAIVK as substrate and the consumption of NADPH over time was 
determined by UV spectrophotometry (Figure 3.7). Single mutations of Tyr152 to Phe, 
Ser139 to Ala, or Lys156 to Ala or Met resulted in a considerable reduction of reaction 
rate (kcat/KM < 0.03 M-1·s-1), supporting the role of these residues in catalysis and in 
agreement with similar results for other SDR proteins (50). Based on these findings, the 
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structural characterization of ElxO, and previous studies on SDR enzymes (49, 50, 52), 
an ordered ‘bi-bi’ catalytic mechanism, with NADP(H) binding first and leaving last, can 
be proposed for ElxO (Figure 3.8). Initially, the hydroxyl group of protonated Tyr152 and 
possibly the hydroxyl group of Ser139 are hydrogen bonded to the N-terminal carbonyl 
oxygen of dehydroepilancin 15X, promoting nucleophilic attack. Then, the 4-pro-S 
hydride anion is transferred from C-4 of the nicotinamide ring to the Si-face of the 
carbonyl. The resulting positive charge on the oxidized nicotinamide ring and the 
adjacent ε-amino group of Lys156 may lower the Tyr152 hydroxyl pKa, allowing proton 
transfer to the formed alkoxide in the substrate, generating the (R)-Lac moiety of 
epilancin 15X and NADP+ (5). 
 
Figure 3.7. Consumption of NADPH (2.5 mM) over time upon reduction of Pyr-AAIVK (5.0 mM) 
by wild-type His6-ElxO (black) or the mutants Y152F (blue), S139A (red), K156A (green), or 
K156M (orange) compared with a control sample lacking peptide (purple). 
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Figure 3.8. Proposed reaction mechanism for NADPH-dependent reduction of dehydroepilancin 
15X catalyzed by ElxO. 
 
Role of Lac in proteolytic stability 
N-Terminal modification is fairly common in lantibiotics and includes 
(methyl)lanthionines, disulfides, pyruvate and lactate groups, 2-oxobutyrate groups, and 
acylations. The importance of these modifications is largely unknown, but the N-terminal 
disulfide in Halα (one of the two peptides in haloduracin) was shown not to be important 
for antimicrobial activity, but to protect the peptide from exoproteases (15, 53). In 
addition, the N-terminal lanthionine in lacticin 3147 A1 is not strictly required for 
antimicrobial activity (54), but may protect lacticin 3147 A1 from proteolysis. A similar 
role can be proposed for the N-terminal Lac group in epilancin 15X. To test this 
hypothesis, samples of dehydroepilancin 15X, enzymatically generated as described 
above, and epilancin 15X were incubated with a commercially available aminopeptidase 
from A. proteolytica. Interestingly, only the lantibiotics but not proteolyzed peptides were 
observed by MS, suggesting that both lactate and pyruvate groups protect the 
lantibiotics against degradation by the aminopeptidase (Figure 3.9). Although, the N-
terminal pyruvate in dehydroepilancin 15X is sufficient to protect the bacteriocin from N-
terminal proteolytic degradation, the reduction of this group to lactate may have evolved 
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because of the high reactivity of ketones. Without its reduction to an alcohol, the 
pyruvate group in dehydroepilancin 15X may react intramolecularly with the ε-amino 
groups in the side chains of lysine residues or with other external amines affecting its 
mode of action.  
 
 
Figure 3.9. MALDI-TOF MS analysis of dehydroepilancin 15X and epilancin 15X after treatment 
with A. proteolytica aminopeptidase. Dehydroepilancin 15X (A) and epilancin 15X (B) are 
resistant to the protease. The peaks at m/z = 3173 and 1588 or m/z = 3177 and 1589 
correspond to the [M+H]+ and [M+2H]2+ ions of dehydroepilancin 15X (calculated average mass 
3173 Da) and epilancin 15X (calculated average mass 3175 Da), respectively. Peaks at m/z= 
1927, 2322, and 2693 are also present in the control sample containing aminopeptidase but 
lacking lantibiotic (C). 
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To further evaluate the role of the lactate and pyruvate groups in the stability 
against aminopeptidases, the synthetic peptide Pyr-AAIVKBBIKA (where B stands for L-
2-aminobutyric acid) mimicking the N-terminal portion of dehydroepilancin 15X and the 
corresponding peptide without the Pyr group were synthesized by SPPS. The reduced 
peptide containing the N-terminal Lac group was also generated enzymatically after 
incubation of the ketone-containing peptide with His6-ElxO and NADPH. The three 
peptides were incubated with the aminopeptidase from A. proteolytica, followed by 
analysis by ESI-MS (Figure 3.10). Whereas the peptide lacking the lactate or pyruvate 
group was completely degraded, the peptides containing these N-terminal moieties 
were detected intact, confirming that lactate or pyruvate can prevent the proteolytic 
degradation by aminopeptidases. 
In contrast, when lacticin 481 (Figure 3.11A), a lantibiotic lacking N-terminal 
modifications, was incubated with the aminopeptidase under similar conditions, a 
peptide lacking the first seven N-terminal residues was obtained as the main product 
(Figure 3.11B). Thus, the aminopeptidase was able to remove N-terminal unmodified 
amino acids with the exception of the His preceding the first MeLan ring that protects 
the lantibiotic from additional proteolysis. Lacticin 481(2-27) and lacticin 481(3-27) were 
also observed, suggesting that the GG motif at position 2 is processed at a lower rate 
and may partially protect the lantibiotic against the action of aminopeptidases. The 
proteolyzed lacticin 481 and control samples were tested by agar diffusion assays using 
the indicator strain L. lactis subsp. cremoris HP (Figure 3.11C), demonstrating a 
decrease in antibacterial activity of the proteolyzed peptides. These results are 
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consistent with previous reports that have shown that the linear N-terminal portion of 
lacticin 481 is important for bioactivity (55, 56). 
 
 
Figure 3.10. Degradation of peptides by A. proteolytica aminopeptidase. Samples containing 
the peptides Pyr-AAIVKBBIKA (A), Lac-AAIVKBBIKA (B), and AAIVKBBIKA (D) were incubated 
with A. proteolytica aminopeptidase and analyzed by ESI-MS. Only the peptide lacking the Lac 
or Pyr groups was completely degraded by the aminopeptidase (D) compared with a control 
sample lacking enzyme and incubated under identifcal conditions (C). The observed m/z peaks 
correspond to the [M+2H]2+ ions. 
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Figure 3.11. Degradation of lacticin 481 by A. proteolytica aminopeptidase. A) Structure of the 
lantibiotic lacticin 481, using the shorthand notation described in Figure 1.1. B) MALDI-TOF MS 
analysis of lacticin 481 (calculated average m/z = 2902) after incubation with (blue) or without 
(red) A. proteolytica aminopetidase. A new peak corresponding to lacticin 481(8-27) was 
observed (calculated average m/z = 2304). Peaks corresponding to the lantibiotic after removal 
of the first Lys (calculated average m/z = 2774) or LysGly (calculated average m/z = 2717) were 
also observed. C) Agar diffusion bioactivity assay of lacticin 481 after treatment with the 
peptidase (spot 1) and control sample with no peptidase (spot 2) using L. lactis subsp. cremoris 
HP as indicator strain. A control sample containing the peptidase but no lantibiotic was also 
tested (spot 3). The proteolyzed sample has a considerably lower antibacterial activity.  
 
In summary, ElxO is a lantibiotic dehydrogenase that tolerates diverse N-terminal 
ketone-containing peptides as substrates and that can be used to generate novel 
lantibiotics, such as dihydrolactocin S. It can also be used to introduce reactive ketones 
into Lac-containing peptides that can be subsequently modified by reaction with 
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hydrazines or aminooxy groups. The x-ray crystal structure of ElxO and the 
mutagenesis studies suggest that Ser139, Tyr152, and Lys156 play an essential role in 
catalysis and that substrates with long side chains at position 2 are better tolerated. 
Furthermore, the N-terminal Lac group introduced by ElxO into epilancin 15X confers 
stability against proteolytic degradation by aminopeptidases, a feature that may be 
applied for the engineering of novel lantibiotics with enhanced antibacterial activities or 
different spectra of action. 
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CHAPTER 4. STUDIES ON THE SUBSTRATE SCOPE OF THE 
SERINE-TYPE LANTIBIOTIC PROTEASES 
 
 
4.1. INTRODUCTION 
Lantipeptides are ribosomally synthesized as precursor peptides, followed by 
posttranslational modifications that generate the biologically active compounds. The 
precursor molecules consist of a leader region that is not modified and a core peptide 
that comprises the backbone of the final metabolite. Based on the enzymes that 
introduce the thioether cross-links into the core region, lantipeptides can be categorized 
in four classes as discussed in chapter 1. In class I members (exemplified by the well 
studied nisin, Pep5, epidermin, and the recently discovered epilancin 15X), the serine 
and threonine residues in the core peptide are dehydrated by a dehydratase (ElxB in 
epilancin 15X) and the intramolecular additions of the cysteine residues into the 
dehydrated amino acids are catalyzed by a cyclase (ElxC in epilancin 15X) (Figure 4.1). 
In the other three classes, a bifunctional lanthionine synthetase (LanM in class II, 
RamC-like in class III, or LanL in class IV) catalyzes both dehydration and 
(methyl)lanthionine formation (1-3). Subsequent to ring formation, the leader peptide is 
cleaved by a protease releasing the bioactive molecule. 
Two different classes of proteases are known to remove the leader peptide from 
the lantipeptide precursors. In most of the class II lantibiotics, as well as in linear 
bacteriocins and class II microcins (4, 5), proteolysis of the leader peptide is performed 
by a membrane located ATP-binding cassette (ABC) transporter, maturation, and 
secretion protein (AMS), designated as LanT, that contains an N-terminal cysteine-type 
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protease domain (Figure 4.2, purple diamonds). These LanT proteins cleave the leader 
peptide after a highly conserved double-glycine motif with consensus sequence 
(I/L/V)(S/T)X2E(L/M)X2(I/L/V)XG(G/A/S), where X can be any amino acid (4, 5). The in 
vitro enzymatic activity, mechanism, and substrate specificity of some AMS proteins, 
including LctT (6) and NukT (7) (the LanT enzymes that cleave off the leaders from 
lacticin 481  and nukacin ISK-1), among others (8-12), have been investigated. 
 
 
Figure 4.1. Cleavage of the leader peptide by ElxP and formation of the intermediate 
dehydroepilancin 15X in epilancin 15X biosynthesis. The positions in the leader peptide that 
were investigated in the current work are underlined and residues in the same region that are 
likely important for substrate recognition are shown in red (see results and discussion).
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Figure 4.2. Cladograph of LanP proteases.  
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Figure 4.2. Continuation. Cladograph of LanP proteases. The clades are named based on the 
C-terminal residue of the corresponding leader peptides (see discussion and Figure 4.4). The 
tree was constructed using the Neighbor-Joining method (13) and the distances were computed 
using the JTT matrix-based method (14) in units of number of amino acid substitutions per site. 
The optimal tree with the sum of branch length = 14.72311067 is shown. The percentage of 
replicate trees in which the associated proteins clustered together in the bootstrap test are 
shown next to the branches, only for values over 70% (15). Evolutionary analyses were 
conducted in MEGA5 (16). The analysis involved the amino acid sequences from the predicted 
proteases for the biosynthesis of epilancin 15X (ElxP), epilancin K7 (ElkP), Pep5 (PepP), 
epicidin 280 (EciP), lactocin S (LasP), cytolysin L and S (CylA), lichenicidin (LicP), epidermin 
(EpiP), gallidermin (GdmP), Bsa (BsaP), mutacin I (MutP.I), mutacin III/1140 (MutP.III), 
pneumococcin (PneP), nisin Q (NiqP), nisin A (NisP), nisin U (NsuP), and additional members 
identified by genome mining. The AMS proteins LctT and HalT (in lacticin 481 and haloduracin 
biosynthesis) were included as an out-group. The subtilisin AprE is one of the proteases that 
can cleave the leader peptide from subtilin (17). Notation: Circles, class I lantipeptides; 
diamonds, class II lantipeptides; red, intracellular proteases; blue, extracellular proteases; 
green, cell wall-anchored proteases; purple, AMS proteins. 
 
In contrast, for most class I lantipeptides (Figure 4.2, circles), such as epilancin 
15X, and also for some class II members (Figure 4.2, diamonds), removal of the leader 
region is performed by a serine-type protease from the subtilisin group and commonly 
designated as LanP (Figure 4.1). However, the cellular localization and domain 
structure of LanP proteases vary considerably (Figures 4.2 and 4.3). In the biosynthesis 
of epidermin and several other lantipeptides (Figure 4.2, blue and Figure 4.3), the 
peptidases (EpiP in epidermin) contain an N-terminal signal and a pro-peptide 
sequence and are located extracellularly (18, 19). Similarly, the proteases NisP and 
NiqP (Figure 4.2, green and Figure 4.3) involved in nisin A and nisin Q biosynthesis, 
respectively, are also extracellular, but are attached to the cell wall through a C-terminal 
anchor peptide (20). For these two classes of proteases, the inactive and fully modified 
precursor peptide is secreted before leader removal. In contrast, in epilancin 15X 
biosynthesis, the peptidase ElxP is predicted to be located intracellularly (Figure 4.2, 
red and Figure 4.3), possibly as part of a membrane-bound biosynthetic complex, and 
the mature peptide is produced entirely in the cytoplasm (21, 22). 
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Figure 4.3. Sequence alignment of representative proteases from the different classes of LanP 
proteins. The N-terminal signal peptide of NisP and EpiP as well as the C-terminal anchor signal 
in NisP are shown in blue bold letters. The putative NisP and EpiP autocleavage sites after the 
pro-sequences are shown in green bold letters and the starting amino acids in the mature 
proteins are underlined. The central subtilisin-like serine protease domains are shown in black 
bold letters and the residues of the catalytic triad are shown in red bold letters. NisP: protease 
for nisin A, EpiP: protease for epidermin, PepP: protease for Pep5, and ElxP: protease for 
epilancin 15X.   
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Figure 4.3. Continuation. 
 
Despite considerable efforts in the study of lantipeptide biosynthesis, the 
mechanism and substrate specificity of LanP proteases have remained elusive, mainly 
due to the difficulties in the overexpression of these enzymes that are commonly toxic to 
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the heterologous hosts and the reconstitution of their enzymatic activities in vitro under 
cell extract- or culture supernatant-free conditions. In a previous attempt, an Escherichia 
coli host carrying a plasmid encoding for NisP was able to express the protease, albeit 
at low concentrations, based on a SDS-PAGE analysis after selective labeling of 
plasmid-encoded proteins with 35S-Met (20). Although NisP was never purified, the E. 
coli cell extracts were able to cleave the nisin A cyclized precursor peptide, producing a 
biologically active compound (Table 4.1, entry 1) (20). Even though a large variety of 
fully modified NisA with mutations across the core sequence, including the ring A, are 
recognized by NisP (23), several studies have evidenced that mutations across the 
leader region are not as well tolerated (Table 4.1). For instance, when a gene encoding 
for the chimera subtilin(leader)/nisinZ(core) was transformed into a nisin A producer 
strain, only the cyclized peptide with the leader attached was detected, presumably 
because of the alteration at the cleavage site R−1Q (Table 4.1, entry 2) (24). 
Furthermore, mutations at Arg−1 and Ala−4 in nisin Z leader peptide, but not at the 
widely conserved Pro−2 and other amino acids, greatly affected amide bond hydrolysis 
in vivo (Table 4.1, entries 3 to 7) (25). In contrast, a more recent study evidenced that 
NisP-expressing Lactococcus lactis cells cleave the leader from fully modified NisA with 
double mutations at Ala−4 and Pro−2 or from unmodified NisA with the putative proNisP 
autocleavage site, VSLR-QP (Table1, entries 13 to 17) (26). However, a different study 
suggested that NisP is able to cleave the leader region only from fully processed 
precursor peptide, but not from dehydrated or unmodified NisA (Table 4.1, entries 8 to 
12) (27).  
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Regarding other lantibiotic proteases, in vivo studies with Pep5 indicated that its 
protease PepP does not recognize the unmodified precursor peptide, but can process 
the dehydrated peptide, suggesting that dehydration of Thr1 may be important for 
substrate recognition (Table 4.1, entries 18 and 19) (21). In contrast, culture 
supernatants of S. carnosus TM300 expressing EpiP processed unmodified EpiA to the 
expected proteolytic products, but not the mutant peptide R−1Q (Table 4.1, entries 20 
and 21) (19). Thus, the sequence of the amino acids near the cleavage site in the 
leader peptide and the structure of the cyclized core region are likely determinants for 
the recognition of the substrates by LanP proteases, including ElxP. Although these 
results regarding substrate specificity have provided valuable insights into the 
importance of certain leader peptide residues for proteolytic processing by LanP 
proteins, a comprehensive analysis on the importance of leader peptide residues in 
proteolysis is not available.  
The epilancin 15X precursor peptide (ElxA), like other lantibiotic precursors (28, 
29), is expected to fold in an α-helical configuration between residues Lys−7 and 
Asp−12 upon binding to biosynthetic proteins based on computational predictions (GOR 
V (30) and PredictProtein (31)). Disruption of a similar helical region in LctA, the 
precursor peptide of the class II lantibiotic lacticin 481, greatly affects the activity of the 
protease domain of LctT (6). Although LctT is not related to ElxP by sequence (Figure 
4.2), the secondary structure of ElxA may also be important for proteolysis, in addition 
to the primary amino acid sequence as described above. Herein, we report the first in 
vitro analysis of the substrate scope of a serine-type lantibiotic protease. The 
importance of the partially conserved motifs F(D/N)L(D/N) at position −19 and Pro at 
144 
 
position −2, common to class I lantipeptide precursor peptides (Figure 4.4), and the 
leader peptide secondary structure were evaluated. Furthermore, homology modeling of 
ElxP, based on the crystal structures of other subtilisin-like proteases, provided 
additional insights into the substrate scope of the peptidase. Based on these results, 
protein engineering could be used to design peptidases with a desired specificity. 
 
 
Figure 4.4. Leader peptides of selected class I lantibiotics. A) Sequence alignment of the leader 
regions of class I lantibiotic precursor peptides processed by proteases from the Q- and R-
clades (Figure 4.2). The predicted helical regions are shown in bold and underlined. B) 
Sequence logo generated using all the leader peptide sequences from A). The partially 
conserved FDLD motif is highlighted. The logo shows the probability of each amino acid (height 
of the letter) and it is scaled (width of the letter) according to the number of sequences 
considered for a specific position (i.e. narrow letters were generated from a smaller number of 
sequences than wider letters). The alignment was performed using ClustalW (32), the sequence 
logo with WebLogo 3.1 (33), and the helical regions were predicted with GOR V (30). ElxA’: 
Leader peptide of epilancin 15X; ElkA’: Leader peptide of epilancin K7; EciA’: Leader peptide of 
epicidin 280; PepA’: Leader peptide of Pep5; NisA’: Leader peptide of nisin A, nisin F, nisin Z; 
NisQ’: Leader peptide of nisin Q; NsuA’: Leader peptide of nisin U; EpiA’: Leader peptide of 
epidermin; GdmA’: Leader peptide of gallidermin; MutA’: Leader peptide of mutacin I and 
mutacin III/1140; BsaA1’ and BsaA2’: Leader peptide of the Bsa group of lantibiotics. 
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Table 4.1. Cleavage of mutated lantibiotic precursor peptides by LanP proteases. Mutations in the precursor peptide sequences in 
comparison with the wild-type peptides are highlighted in red and the cleavage sites are shown in bold letters. Dha: 2,3-
dehydroalanine, Dhb: 2,3-dehydrobutyrine, Lan: lanthionine. 
 
Entry LanP Precursor Peptide 
Cleavage site 
(Leader-Core) 
Core peptide 
modifications Assay description Cleavage Reference
1 NisP NisA SGASPR-I(Dhb)(Lan) Fully modified In vitro with cell extract Yes (20) 
2 NisP SpaS(leader)-NisZ(core) SKITPQ-I(Dhb)(Lan) Fully modified In vivo No (24) 
3 NisP NisZ SGASPR-I(Dhb)(Lan) Fully modified In vivo Yes (25) 
4 NisP NisZ SGASPQ-I(Dhb)(Lan) Fully modified In vivo No (25) 
5 NisP NisZ SGASGR-I(Dhb)(Lan) Fully modified In vivo Yes (25) 
6 NisP NisZ SGASAR-I(Dhb)(Lan) Fully modified In vivo Yes (25) 
7 NisP NisZ SGDSPR-I(Dhb)(Lan) Fully modified In vivo No (25) 
8 NisP NisA SGASPR-I(Dhb)(Lan) Fully modified In vivo Yes (27) 
9 NisP NisA SGASPR-ITS Unmodified In vivo No (27) 
10 NisP NisA PGASLR-I(Dhb)(Dha) Dehydrated In vivo No (27) 
11 NisP NisA PGASLR-I(Dhb)(Lan)a Dehydrated In vivo Yes (27) 
12 NisP NisA(leader)-Angiotensin (1-7) SGASPR-NR(Dha) Dehydrated In vivo No (27) 
13 NisP NisAb SGASPR-I(Dhb)(Lan) Fully modified In vitro with cell extract Yes (26) 
14 NisP NisAb SGVSLR-I(Dhb)(Lan) Fully modified In vitro with cell extract Yes (26) 
15 NisP NisAb SGVSLR-ITS Unmodified In vitro with cell extract No (26) 
16 NisP NisAb SGVSLR-QP(Lan) Partially modified In vitro with cell extract Yes (26) 
17 NisP NisAb SGVSLR-QPS Unmodified In vitro with cell extract Yes (26) 
18 PepP PepA DELEPQ-(Dhb)AG Fully modified In vivo Yes (21) 
19 PepP PepA DELEPQ-TAG Unmodified In vivo No (21) 
20 EpiP EpiA SGAEPR-IAS Unmodified In vitro with culture supernatant Yes (19) 
21 EpiP EpiA SGAEPQ-IAS Unmodified In vitro with culture supernatant No (19) 
Notes: a: Ring topology was not confirmed. 
b: Culture supernatant containing modified or unmodified NisA was used 
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4.2. EXPERIMENTAL METHODS  
Materials, organisms, media, and growth conditions 
 Chemical reagents and media components used in this study were purchased 
from Sigma-Aldrich or Thermo Fisher Scientific and were used without further 
purification. All E. coli strains were grown at 37 °C in Luria-Bertani (LB) liquid or solid 
media with the addition of the appropriate antibiotics, unless otherwise specified. The 
list of strains and plasmids used in this study are shown in Table 4.2. 
 
Construction of mutant pET.His6-ElxA plasmids and overexpression and 
purification of wild-type and mutant His6-ElxA peptides 
Site directed mutagenesis was used to generate the mutant pET.His6-ElxA 
plasmids (Table 4.2). Briefly, the entire pET.His6-ElxA was amplified by PCR using 
iProofTM high-fidelity DNA polymerase (BioRad) and the appropriate mutagenesis 
primers (Table 4.3), followed by treatment with DpnI (New England Biolabs) before 
transformation of E. coli DH5α cells. The correct sequences of the inserts were 
confirmed by sequencing at the W. M. Keck Center for Comparative and Functional 
Genomics at the University of Illinois at Urbana-Champaign. See also Notebook IX, 
page 03. 
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Table 4.2. Microorganisms and plasmids used in this study 
 
Electrocompetent E. coli Rosetta2(DE3) cells were transformed with pET.His6-
ElxA or mutant plasmids (Table 4.2) and single colonies were inoculated in 5 mL of LB 
medium containing 50 µg/mL kanamycin and 12.5 µg/mL chloramphenicol and grown 
for 12 h with shaking. An aliquot of 3 mL was used to inoculate 300 mL LB medium with 
the appropriate antibiotics and the cells were grown at 37 °C until OD600 = 1.0 AU. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 
Strain or plasmid Relevant characteristics Source or reference 
Strains   
     E. coli DH5α pir/80dlacZM15 Δ(lacZYA-argF)U169 recA1 
hsdR17 deoR thi-1 supE44 gyrA96 relA1 
(34) 
     E. coli Rosetta2(DE3) F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) pRARE2 
Novagen 
 
Plasmids 
  
    pET.His6-MBP-ElxP elxP cloned into pET28b vector (22) 
    pET.His6-ElxA elxA cloned into a pET28b plasmid (a KanR E. coli 
T7 based hexahistidine-tag fusion expression vector) 
(22) 
    pET.His6-ElxA(Q−1A) Mutant pET.His6-ElxA encoding for His6-ElxA Q−1A This study 
    pET.His6-ElxA(Q−1E) Mutant pET.His6-ElxA encoding for His6-ElxA Q−1E This study 
    pET.His6-ElxA(Q−1R) Mutant pET.His6-ElxA encoding for His6-ElxA Q−1R This study 
    pET.His6-ElxA(P−2A) Mutant pET.His6-ElxA encoding for His6-ElxA P−2A This study 
    pET.His6-ElxA(P−2D) Mutant pET.His6-ElxA encoding for His6-ElxA P−2D This study 
    pET.His6-ElxA(P−2K) Mutant pET.His6-ElxA encoding for His6-ElxA P−2K This study 
    pET.His6-ElxA(A−9P) Mutant pET.His6-ElxA encoding for His6-ElxA A−9P This study 
    pET.His6-ElxA(E−10A) Mutant pET.His6-ElxA encoding for His6-ElxA E−10A This study 
    pET.His6-ElxA(E−10P) Mutant pET.His6-ElxA encoding for His6-ElxA E−10P This study 
    pET.His6-ElxA(N−16A) Mutant pET.His6-ElxA encoding for His6-ElxA N−16A This study 
    pET.His6-ElxA(N−16D) Mutant pET.His6-ElxA encoding for His6-ElxA N−16D This study 
    pET.His6-ElxA(L−17A) Mutant pET.His6-ElxA encoding for His6-ElxA L−17A This study 
    pET.His6-ElxA(D−18A) Mutant pET.His6-ElxA encoding for His6-ElxA D−18A This study 
    pET.His6-ElxA(D−18N) Mutant pET.His6-ElxA encoding for His6-ElxA D−18N This study 
    pET.His6-ElxA(F−19A) Mutant pET.His6-ElxA encoding for His6-ElxA F−19A This study 
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mM and the cultures were incubated for 16 h at 18 °C. Attempts to overexpress the 
peptides at 37 °C, as suggested before for other lantibiotic precursor peptides (35), 
were not successful, since His6-ElxA is highly toxic to the host, most likely related to 
peptide glutathionylation by E. coli glutathione S transferases (Dr. Bradly Evans, 
personal communication). After centrifugation, the cell pellets were resuspended in 
denaturing buffer (6 M guanidine hydrochloride, 50 mM NaH2PO4, 20 mM imidazole, 
500 mM NaCl, pH 7.5), followed by incubation at 4 °C with shaking for 1 h, sonication 
and centrifugation. The supernatants were mixed with 5 mL of 50% Ni-NTA 
(nitrilotriacetic acid) slurry (Qiagen) for 60 min. Unbound material was discarded and the 
resin was washed with 15 column volumes (CV) of washing buffer (6 M guanidine 
hydrochloride, 50 mM NaH2PO4, 20 mM imidazole, 500 mM NaCl, pH 7.5). The 
peptides were then eluted with 4 CV of elution buffer (4 M guanidine hydrochloride, 50 
mM NaH2PO4, 500 mM imidazole, 500 mM NaCl, pH 7.5). Finally, the peptides were 
purified by solid phase extraction (SPE) using Varian Bond Elut C18EWP columns 
(Agilent). After loading the peptide-containing solutions, the resin was washed with 
0.1% TFA in 20% acetonitrile / 80% water and the peptides were eluted with 0.1% TFA 
in 80% acetonitrile / 20% water. The masses of the purified peptides were determined 
by matrix-assisted laser desorption/ionization – time-of-flight mass spectrometry 
(MALDI-TOF) on a Voyager DE-STR Biospectrometry Workstation using α-cyano-4-
hydroxycinnamic acid as matrix at the Mass Spectrometry Laboratory of the University 
of Illinois at Urbana Champaign. A sample or His6-NisA was donated by Ms. Nega Garg, 
a current graduate student at the van der Donk lab at the University of Illinois. ElxP was 
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overexpressed and purified following a protocol described in chapter 2 (22). See also 
Notebook IX, page 13. 
 
Cleavage of His6-ElxA substrates by ElxP 
ElxP (2 µM) and wild-type or mutant His6-ElxA peptides (50 µM) were incubated 
in the presence of assay buffer (50 mM HEPES, pH 7.5) at room temperature for 2 h, 
unless otherwise specified. Control samples lacking protease were incubated under the 
same conditions. The reactions were quenched by the addition of 1% TFA to a final 
concentration of 0.5%, and the samples were prepared by C18 Zip-tip (Millipore) before 
analysis by MALDI-TOF MS as described above. See also Notebook IX, page 15. 
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Table 4.3. Primers used in this study 
Name Sequence 
ElxA.Q−1A.FP 5'- GCA CAA AAA AGT GAC CTA AAT CCG GCA TCA GCT AGT ATT GTT AAA ACA AC -3' 
ElxA.Q−1A.RP 5'- GTT GTT TTA ACA ATA CTA GCT GAT GCC GGA TTT AGG TCA CTT TTT TGT GC -3' 
ElxA.Q−1E.FP 5'- CAA AAA AGT GAC CTA AAT CCG GAA TCA GCT AGT ATT GTT AAA A -3' 
ElxA.Q−1E.RP 5'- TTT TAA CAA TAC TAG CTG ATT CCG GAT TTA GGT CAC TTT TTT G -3' 
ElxA.Q−1R.FP 5'- GCA CAA AAA AGT GAC CTA AAT CCG CGA TCA GCT AGT ATT GTT AAA ACA AC -3' 
ElxA.Q−1R.RP 5'- GTT GTT TTA ACA ATA CTA GCT GAT CGC GGA TTT AGG TCA CTT TTT TGT GC -3' 
ElxA.P−2A.FP 5'- GCA CAA AAA AGT GAC CTA AAT GCG CAA TCA GCT AGT ATT GTT AAA ACA AC -3' 
ElxA.P−2A.RP 5'- GTT GTT TTA ACA ATA CTA GCT GAT TGC GCA TTT AGG TCA CTT TTT TGT GC -3' 
ElxA.P−2D.FP 5'- GGC ACA AAA AAG TGA CCT AAA TGA CCA ATC AGC TAG TAT TGT TAA AAC AAC -3' 
ElxA.P−2D.RP 5'- GTT GTT TTA ACA ATA CTA GCT GAT TGG TCA TTT AGG TCA CTT TTT TGT GCC -3' 
ElxA.P−2K.FP 5'- CGA GGC ACA AAA AAG TGA CCT AAA TAA GCA ATC AGC TAG TAT TGT TAA AAC AAC -3' 
ElxA.P−2K .RP 5'- GTT GTT TTA ACA ATA CTA GCT GAT TGC TTA TTT AGG TCA CTT TTT TGT GCC TCG -3' 
ElxA.A−9P.FP 5'- GAT TTA AAT CTT AAT AAA GAT ATC GAG CCA CAA AAA AGT GAC CTA AAT CCG C -3' 
ElxA.A−9P.RP 5'- GCG GAT TTA GGT CAC TTT TTT GTG GCT CGA TAT CTT TAT TAA GAT TTA AAT C -3' 
ElxA.E−10A.FP 5'- GAT TTA AAT CTT AAT AAA GAT ATC GCG GCA CAA AAA AGT GAC CTA AAT CCG -3' 
ElxA.E−10A.RP 5'- CGG ATT TAG GTC ACT TTT TTG TGC CGC GAT ATC TTT ATT AAG ATT TAA ATC -3' 
ElxA.E−10P.FP 5'- GAT TTA AAT CTT AAT AAA GAT ATC CCG GCA CAA AAA AGT GAC CTA AAT CCG -3' 
ElxA.E−10P.RP 5'- CGG ATT TAG GTC ACT TTT TTG TGC CGG GAT ATC TTT ATT AAG ATT TAA ATC -3' 
ElxA.N−16A.FP 5'- GCC ATA TGA AAA AAG AAT TAT TTG ATT TAG CTC TTA ATA AAG ATA TCG AGG CAC -3' 
ElxA.N−16A.RP 5'- GTG CCT CGA TAT CTT TAT TAA GAG CTA AAT CAA ATA ATT CTT TTT TCA TAT GGC -3' 
ElxA.N−16D.FP 5'- GCC ATA TGA AAA AAG AAT TAT TTG ATT TAG ATC TTA ATA AAG ATA TCG AGG CAC -3' 
ElxA.N−16D.RP 5'- GTG CCT CGA TAT CTT TAT TAA GAT CTA AAT CAA ATA ATT CTT TTT TCA TAT GGC -3' 
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Table 4.3. Continuation. 
 
Name Sequence 
ElxA.L−17A.FP 5'- GCC ATA TGA AAA AAG AAT TAT TTG ATG CAA ATC TTA ATA AAG ATA TCG AGG C -3' 
ElxA.L−17A.RP 5'- GCC TCG ATA TCT TTA TTA AGA TTT GCA TCA AAT AAT TCT TTT TTC ATA TGG C -3' 
ElxA.D−18A.FP 5'- CAG CCA TAT GAA AAA AGA ATT ATT TGC TTT AAA TCT TAA TAA AGA TAT CGA GGC -3' 
ElxA.D−18A.RP 5'- GCC TCG ATA TCT TTA TTA AGA TTT AAA GCA AAT AAT TCT TTT TTC ATA TGG CTG -3' 
ElxA.D−18N.FP 5'- GGC AGC CAT ATG AAA AAA GAA TTA TTT AAT TTA AAT CTT AAT AAA GAT ATC GAG GC -3' 
ElxA.D−18N.RP 5'- GCC TCG ATA TCT TTA TTA AGA TTT AAA TTA AAT AAT TCT TTT TTC ATA TGG CTG CC -3' 
ElxA.F−19A.FP 5'- GGC AGC CAT ATG AAA AAA GAA TTA GCT GAT TTA AAT CTT AAT AAA GAT ATC G -3' 
ElxA.F−19A.RP 5'- CGA TAT CTT TAT TAA GAT TTA AAT CAG CTA ATT CTT TTT TCA TAT GGC TGC C -3' 
 
4.3. RESULTS 
Enzymatic activity of ElxP with His6-ElxA mutant peptides  
ElxP is a serine protease that catalyzes the cleavage of the leader peptide from 
fully cyclized precursor peptide ElxA (Figure 4.1) (22). To determine the role of the 
leader peptide sequence and the FDLD and PQ motifs (Figure 4.4) in proteolysis, a 
series of mutant substrates was expressed and purified from E. coli and tested as 
potential substrates under identical conditions (Table 4.4 and Figure 4.5). Since fully 
modified mutant ElxA peptides were not available, linear unmodified peptides were used 
instead, as previous experimental results have evidenced that ElxP is able to process 
linear wild-type His6-ElxA (chapter 2) (22). The reaction products were analyzed by 
MALDI-TOF MS and peaks corresponding to the N-terminal hexahistidine tagged leader 
peptides and to the C-terminal unmodified core peptide (calculated mass 3316 Da) were 
only detected when ElxP processed the substrates. Smaller peaks with a difference in 
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mass of +178 Da with respect to the calculated masses for the precursor and leader 
peptides were also observed. These peaks correspond to the gluconoyl adducts 
generated by modification of the N-terminal α-amino group of the GSS-His-tag during 
peptide expression in E. coli (36). 
 
Table 4.4. MALDI-TOF MS analysis of the cleavage products after incubation of wild-type or 
mutant His6-ElxA peptides with or without ElxP for 2 h under identical conditions. The calculated 
masses are shown in parenthesis. 
 
Entry Peptide Precursor peptide (calcd) 
Leader peptide 
(calcd) 
Core peptide 
(calcd) Result
a 
1 His6-ElxA wt 8161 (8162) 4866 (4864) 3316 (3316) +++ 
2 Q−1A 8107 (8105) 4809 (4807) 3315 (3316) + 
3 Q−1E 8162 (8163) 4864 (4865) 3314 (3316) +++ 
4 Q−1R 8190 (8190) 4890 (4892) 3314 (3316) + 
5 P−2A 8134 (8136) 4839 (4838) 3315 (3316) + 
6 P−2D 8179 (8180) – (4882) – (3316) – 
7 P−2K 8193 (8193) – (4895) – (3316) – 
8 N−16A 8119 (8119) 4819 (4821) 3314 (3316) +++ 
9 N−16D 8161 (8163) 4865 (4865) 3314 (3316) +++ 
10 L−17A 8118 (8120) 4823 (4822) 3315 (3316) +++ 
11 D−18A 8118 (8118) 4818 (4820) 3314 (3316) +++ 
12 D−18N 8159 (8161) 4863 (4863) 3316 (3316) +++ 
13 F−19A 8086 (8086) 4789 (4788) 3315 (3316) ++ 
14 A−9P 8189 (8188) 4889 (4890) 3317 (3316) ++ 
15 E−10A 8105 (8104) 4805 (4806) 3316 (3316) +++ 
16 E−10P 8132 (8130) 4833 (4832) 3317 (3316) ++ 
17 His6-NisA wt 7444 (7444) – (3964) – (3498) – 
Note:  a: The efficiency of the enzymatic activity was determined qualitatively based on the 
intensity of the leader and core peptide ions relative to the precursor peptide ion and it is 
reported in a scale from +++ for highly efficiently processed substrates compared to the 
wild-type to – when no cleavage products were detected.  
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Figure 4.5. MALDI-TOF MS analysis of proteolytic processing of wild-type His6-ElxA (A), His6-
ElxA Q−1A (B), His6-ElxA Q−1E (C), and His6-ElxA Q−1R (D) after incubation with (blue) or 
without (red) ElxP for 2 h. P, L, and C denotate precursor, leader, and core peptide, 
respectively. The single (*) and double (**) asterisks indicate peaks corresponding to double- or 
triple-charged ions, respectively.  
 
Since mutations at the cleavage site of NisA and EpiA were shown to affect 
amide bond hydrolysis by NisP or EpiP (19, 24, 25), Gln−1 in wild-type ElxA was 
mutated to Ala or to charged residues (Glu, Arg) and the resulting peptides were tested 
as potential substrates (Table 4.4, entries 2 to 4 and Figure 4.5). Although all the 
mutants were accepted as substrates by the protease, the peptides Q−1A and Q−1R 
were processed to a much lesser extent than the wild-type or the mutant peptide Q−1E 
when incubated under identical conditions based on the intensity of the peaks in the 
MALDI-TOF MS spectra. Similarly, the highly conserved Pro−2 of ElxA was mutated to 
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Ala, Asp, or Lys (Table 4.4, entries 5 to 7 and Figure 4.6). Interestingly, with the 
substrates P−2D and P−2K a considerably decreased proteolytic activity was observed 
and the cleavage products were only detected after long reaction periods (30 h). 
Similarly, the mutant P−2A did not prevent proteolysis, but did reduce the enzyme 
efficiency, as only small amounts of cleavage products were detected under conditions 
that led to full conversion of His6-ElxA. 
To determine the importance of other conserved residues in the leader 
sequence, the single mutants F−19A, D−18A, D−18N, L−17A, N−16A, and N−16D were 
investigated (Table 4.4, entries 8 to 13 and Figure 4.7). Although we have not obtained 
quantitative kinetic parameters, all the mutant substrates were qualitatively processed 
with very similar efficiencies as wild-type His6-ElxA based on relative intensities of the 
substrate and product ions observed by MALDI-TOF MS. The mutant F−19A was well 
processed, but the cleavage efficiency was reduced to some extent presumably due to 
experimental deviations. 
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Figure 4.6. MALDI-TOF MS analysis of proteolytic processing of His6-ElxA P−2A (A), His6-ElxA  
P−2D (B and C), and His6-ElxA P−2K (D and E) after incubation with (blue) or without (red) ElxP 
for 2 h (A, B and D) or 30 h (C and E). P, L, and C denotate precursor, leader, and core peptide, 
respectively. The single (*) and double (**) asterisks indicate peaks corresponding to double- or 
triple-charged ions, respectively.  
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The leader peptides of several class I lantibiotics, including gallidermin, 
epidermin, Pep5, and nisin, were previously suggested to adopt a helical conformation 
based on circular dichroism experiments (28). These studies were performed dissolving 
synthetic peptides in solutions containing trifluoroethanol that is known to promote 
helicity. However, biosynthetic proteins, including proteases, may also induce and 
recognize similar helical structures as demonstrated for the precursor peptide ComC 
upon binding to the peptidase domain of ComA (9, 10) and as suggested for LctA and 
the corresponding LctT protease domain (6). Secondary structure predicting programs 
anticipate α-helical character for the ElxA leader peptide (GOR V (30), residues −7 to 
−12 and −18 to −21; PredictProtein (31), residues −7 to −11 and −19 to −22), as well as 
for several other class I leader peptides (Figures 4.4 and 4.8). To assess if the predicted 
α-helical structure of ElxA is required for substrate recognition, the helix-breaking 
residue Pro was introduced at positions −9 or −10 (Figure 4.8). Interestingly, the 
mutants A−9P and E−10P did not prohibit the peptidase activity of ElxP, although they 
were processed to a lesser degree than the wild-type and the mutant E−10A under 
identical assay conditions, indicating that the predicted helical conformation is not 
strictly required for substrate-enzyme interaction (Table 4.4, entries 14 to 16, Figure 
4.9).  
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Figure 4.7. MALDI-TOF MS analysis of proteolytic processing of His6-ElxA F−19A (A), His6-
ElxA D−18A (B), His6-ElxA D−18N (C), His6-ElxA L−17A (D), His6-ElxA N−16A (E), and His6-
ElxA N−16D (F) after incubation with (blue) or without (red) ElxP for 2 h. P, L, and C denotate 
precursor, leader, and core peptide, respectively. The asterisk (*) indicates a peak 
corresponding to a double-charged ion.  
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Figure 4.8. Predicted secondary structure of the leader region of ElxA (A) and the mutants 
A−9P (B), E−10A (C), and E−10P (D). The probability of α-helix (blue), β-sheet (red) or random 
coil (green) conformations are shown for every residue. Upon mutation of Ala−9 or Glu−10 to 
Pro, the helical structure at the C-terminus of the leader peptide is predicted to disappear. The 
predictions were performed using GOR V (30). 
 
The leader peptides of NisA and ElxA share some sequence homology, with 7 
out 23 residues being identical. Although these two leader peptides differ in the last 
residue (Gln−1 for ElxA as opposed to Arg−1 for NisA) and in the sequence of the 
FDLD motif (FDLN for ElxA and FNLD for NisA), the peptide His6-ElxA Q−1R was still 
processed by ElxP to some extent and the mutants D−18N and N−16D were processed 
with very similar efficiencies as wild-type ElxA. Thus, it was anticipated that ElxP could 
cleave the linear unmodified NisA peptide. However, after incubation of His6-NisA with 
the peptidase, the predicted cleavage products were not detected by MALDI-TOF MS 
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even after long incubation periods (24 h) (Table 4.4, entry 17 and Figure 4.10), 
suggesting that additional residues in the precursor peptide may be important for 
substrate recognition. 
 
  
Figure 4.9. MALDI-TOF MS analysis of proteolytic processing of His6-ElxA A−9P (A), His6-ElxA 
E−10P (B), and His6-ElxA E−10A (C) after incubation with (blue) or without (red) ElxP for 2 h. P, 
L, and C denotate precursor, leader, and core peptide, respectively. The asterisk (*) indicates a 
peak corresponding to a double-charged ion. 
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Figure 4.10. MALDI-TOF MS analysis of proteolytic processing of His6-NisA after incubation 
with (blue) or without (red) ElxP after 2 h (A) or 24 h (B). P denotates precursor peptide. The 
single asterisk (*) indicates a peak corresponding to a double-charged ion. New peaks at m/z = 
3167 and 4294 appeared after long incubation periods and may correspond to degradation 
products of ElxP. 
 
4.4. DISCUSSION 
Leader peptides seem to assist in several processes during the biosynthesis of 
lantibiotics and other ribosomally synthesized metabolites (4). In some cases, the 
leaders keep the precursor molecules inactive inside the host until secretion and 
proteolysis, as in nisin A biosynthesis (25, 37). However, in epilancin 15X, as well as in 
several other lantibiotics processed by intracellular LanP proteases (Figure 4.2), the 
leader sequence is removed inside the cytoplasm and the mature bioactive peptide is 
produced before secretion. Since the leader peptides usually contain several hydrophilic 
residues, they may also increase the precursor peptide solubility. Indeed, a 
hydrophobicity plot of ElxA evidences that the leader peptide is considerably more 
hydrophilic than the core region (Figure 4.11). Finally, the leaders may also act as a 
scaffold for the modification enzymes, allowing the recognition and binding of the entire 
precursor peptide. For instance, ABC transporters can use the leaders as a recognition 
signal. In fact, the transporter in nisin A biosynthesis, NisT, can secret various 
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engineered nonlantibiotic cargo attached to the leader (27, 38). However, this role of the 
leader peptide is not relevant for the ABC transporter ElxT, since the leader peptide is 
removed before secretion (22). Furthermore, the leaders can guide the interaction of the 
precursor peptide with lanthionine synthetases (LanM) (39-42), as well as with 
dehydratases (LanB) and cyclases (LanC), as demonstrated by the in vivo processing 
of nonlantibiotic therapeutic peptides attached to the nisin A leader peptide (43, 44). 
 
 
Figure 4.11. Hydrophobicity plot of ElxA using the Kyte & Doolittle scale (45). The values were 
calculated using a nine amino acid window for every position. Negative values correspond to 
hydrophilic regions.  
 
For class I lantipeptides, four partially conserved sequences are present in the 
leader peptides: An N-terminal LF(D/N)L(D/N)(I//L/V) or FDLD motif, an Asn at position 
−8, a Ser at position −6, and a Pro at position −2 (Figure 4.4B). In vivo studies with NisB 
demonstrated that the FDLD motif is required for substrate recognition and efficient 
dehydration (25, 26, 46). Indeed, when this motif was replaced by AAAA, the interaction 
of NisA with NisB was abolished and no dehydration of the precursor peptide was 
observed (26, 46). Furthermore, a short NisA leader peptide, containing only the FDLD 
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motif and its N-terminal residues, allows the partial dehydration of the core region by 
NisB (26). A different study suggested that the conserved Ser−6 in NisA, in addition to 
the FDLD motif, is also important for modification of the core peptide (25). Similarly, 
NisC, the cyclase in nisin A biosynthesis, recognizes the leader peptide as suggested 
by in vitro experiments and contains a specific domain that likely interacts with the 
leader (37). A different in vivo study on the biosynthesis of Pep5 suggested that the 
FDLD motif seems to be important for optimal biosynthesis rates, but not strictly 
required for ring formation (47).  
Regarding lantibiotic peptidases, some experimental evidence indicates that the 
C-terminal region of the class I leader peptides is important for substrate recognition 
(Table 4.4). However, this hypothesis has only been investigated through a limited set 
of mutations and a comprehensive analysis of the substrate scope is not available. 
Furthermore, the role of the FDLD motif in proteolysis is currently unknown. The 
sequence conservation of LanP proteins facilitated a phylogenetic analysis and the 
determination of their relatedness (Figure 4.2). The resulting phylogenetic tree 
highlights the existence of three distinct clades of LanP proteases that are not grouped 
based on cellular localization (intracellular, cell-wall anchored, or extracellular) or 
lantibiotic class (class I or class II). Interestingly, the residue N-terminal to the cleavage 
site in the peptidase substrates is conserved within each phylogroup and the clades 
were named based on that amino acid (clade Q, clade D/E, or clade R). Furthermore, 
sequence alignments of leader peptides processed by proteases from the same clade 
evidenced the conservation of some additional residues at the C-terminus of the leaders 
that may act as recognition signals for the proteases (Figure 4.4B). In this work, we 
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obtained some insights into the importance of leader peptide residues for processing of 
the epilancin 15X precursor peptide by the serine-type protease ElxP. This peptidase is 
a member of the Q-clade (Figure 4.2) and the conserved sequence DLXPQ at the C-
terminus of the leader peptide (Figure 4.4A) could be essential for substrate recognition. 
 
Substrate specificity of ElxP 
Because the production of fully modified epilancin 15X precursor peptide has 
proven to be challenging as described in chapter 2 (22), we performed the substrate 
specificity studies on ElxP using linear peptides that were overexpressed and purified 
from E. coli. ElxP was able to cleave the unmodified precursor peptide His6-ElxA and 
several mutants generating the expected proteolytic products (Table 4.4). Mutation of 
Gln−1 to Ala or Arg did not prevent cleavage but did reduce considerably the efficiency, 
as only small amounts of cleavage products were observed under the assay conditions, 
in agreement with previous in vivo results for NisP and EpiP that evidenced that the C-
terminal residue of the leader peptide is important for proteolysis (Table 4.1) (19, 24, 
25). In contrast, the replacement of the non-ionic Gln residue with the isosteric, 
negatively charged Glu residue allowed ElxP to retain good peptidase activity, 
suggesting that the selectivity for this position is based on steric effects more than 
electrostatic interactions. Furthermore, after mutation of Pro−2 to Lys or Asp, no 
significant proteolytic activity was observed and its substitution for Ala considerably 
affected the hydrolysis of the peptide, indicating that this partially conserved residue is 
important for proteolysis, in contradiction with previous in vivo results for NisP (Table 
4.1). However, NisP is located in a different clade of the phylogenetic tree of LanPs 
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(Figure 4.2) and Pro−2 is not as well conserved in the precursor peptides processed by 
this group of proteases (Figure 4.4A). 
Single mutations across the FDLD motif did not dramatically alter proteolytic 
processing by ElxP, suggesting that this region of the leader peptide is only important 
for recognition by the enzymes involved in dehydration and ring formation. Furthermore, 
only a small reduction of activity was observed after disruption of the predicted helical 
region by replacement of Ala−9 or Glu−10 with Pro, indicating that the secondary 
structure of the peptide is not essential. Interestingly, although ElxP cleaved to some 
extent the leader from His6-ElxA Q−1R, His6-NisA completely prohibits proteolysis 
(Figure 4.10). Thus, other residues in addition to the PQ cleavage site, such as Leu−4 
or Asp−5 in the consensus sequence DLXPQ of precursor peptides processed by the 
Q-clade LanP proteases (and that are replaced by Ala−4 and Gly−5 in His6-NisA), may 
be essential for substrate recognition.  
The data discussed in this study was obtained at relatively high substrate 
concentrations (50 µM) and the reported activities might only consider the effect on kcat. 
Thus, some of the peptides might still be poor substrates under physiological conditions 
of low concentration where the effect of the substrate binding affinity for the enzyme on 
the catalytic efficiency (kcat/KM) is more relevant. Future studies in our laboratory will 
focus on the determination of the kinetic parameters kcat and KM for some of the 
substrates. Interestingly, the formation of the (methyl)lanthionine rings and the 
dehydrated amino acids Dha at positions P1’ and P3’ and Dhb at position P7’ and P8’ 
are not required for proteolysis by ElxP, suggesting that the fully modified core region is 
not essential for substrate recognition. However, the N-terminus of dehydroepilancin 
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15X has a linear sequence of eleven residues (Figure 4.1) that might be important for 
substrate recognition and further investigation of the effect of this core region on 
proteolysis is recommended. 
 
LanP proteases in the biosynthesis of class II lantipeptides and genome mining 
for novel lantipeptides 
The LanP serine-type lantipeptide proteases can cleave the leader region from 
precursor peptides in the biosynthesis of not only class I lantibiotics, as commonly 
recognized, but also class II lantipeptides. The LanP-mediated cleavage of class II 
leader peptides occurs either in a single intracellular proteolytic event, as expected in 
the biosynthesis of lactocin S (48) (Figure 4.2), or in a more complex double cleavage 
process, as exemplified by the biosynthesis of cytolysin L and S (49) and probably 
lichenicidin (50, 51). In this case, the N-terminal sequence of the leader peptide 
containing the GG motif (Figure 4.12) is likely removed by the cysteine protease domain 
of a LanT (CylB and LicT for cytolysins and lichenicidin, respectively), concomitant with 
secretion, and followed by removal of the C-terminal amino acids of the leader region by 
a specific LanP peptidase (CylA and LicP for cytolysins and lichenicidin, respectively) 
(49). Interestingly, PneP, a protease likely involved in pneumococcin biosynthesis (52), 
has 49% amino acid identity with NisP (Figure 4.2) and might cleave off the C-terminus 
of the leader region of the precursors PneA1 and PneA2 (Figure 4.12), which have 
homology to the corresponding sequence in NisA (SDGAEPR in PneA1 compared to S–
GASPR in NisA). In another example, a gene encoding for a putative LanP protease 
with 49% sequence similarity to LicP is present in the genome of Bacillus halodurans C-
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125 (BH1491) (50). This protein may be responsible for the removal of the C-terminal 
amino acids of the leader peptide from fully modified HalA2 generating mature and 
biological active Halβ, a process that has remained elusive in the biosynthesis of the 
lantibiotic haloduracin (53). Thus, the double cleavage event in some class II 
lantipeptides further supports the hypothesis that LanP proteases may only recognize 
the C-terminal region of the leader peptide.  
 
 
Figure 4.12. Sequence alignment of the leader regions of selected class I and class II lantibiotic 
precursor peptides. Only leaders encoded by gene clusters containing a lanP gene were 
included. The GG motif recognized by AMS proteins is shown in bold letters and the residues 
known to be important for leader peptide recognition by the protease domain of LanT proteins 
are highlighted in yellow (54). ElxA’: leader peptide of epilancin 15x, NisA’: leader peptide of 
nisin A, PneA1’ and PneA2’: leader peptide of pneumococcin, LicA2’: leader peptide of 
lichenicidin LicA2, CylL’ and CylS’: leader peptides of cytolysin L and S. 
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Figure 4.13. Novel biosynthetic gene clusters encoding for lantipeptides discovered by genome 
mining using the known sequences of LanP proteases. The numbers over the open reading 
frames encoding for putative proteases correspond to the locus tags in genome databases. 
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In recent years, genome mining for lanthionine synthetase homologs has guided 
the discovery of several lantipeptides (55), such as haloduracin (53, 56), lichenicidin 
(50, 51), Bsa (57), venezuelin (2), and prochlorosins (58). Additional diversity could be 
discovered by identifying gene clusters encoding for LanP homologs in genome 
databases. Indeed, ortholog neighborhood analysis at the integrated microbial genome 
website, with known sequences of LanP proteases, allowed the identification of novel 
gene clusters encoding for putative class I and class II lantipeptides (Figure 4.13). In 
particular, three class II biosynthetic clusters from B. tusciae DSM 2912, B. cereus Q1, 
and B. cereus VPC1401 encoding for LanT proteins with N-terminal cysteine protease 
domains, in addition to LanP proteins, were identified, suggesting that the double 
cleavage mechanism of the leader peptide is more widespread than currently 
recognized. However, the reason(s) behind the double proteolytic processing still 
remains unknown. 
Interestingly, no genes encoding peptidases have been reported in the 
lantipeptide gene clusters from Actinobacteria, including the clusters of several class II 
lantibiotics such as cinnamycin (59), actagardine (60), deoxyactagardine (61), and 
michiganin A (62), and the class III and IV lantipeptides (2, 3, 63). Indeed, mining of a 
library of 127 genome sequences of Actinobacteria, composed of published 
Streptomyces spp. sequences and the private Actinobacteria genome database from 
the Institute for Genomic Biology (University of Illinois at Urbana-Champaign) did not 
result in the identification of any lantipeptide gene cluster encoding for a subtilisin-like 
LanP protease (Dr. James Doroghazi, personal communication). Thus, the cleavage of 
the leader in this phylum is likely performed by a different mechanism, not related to 
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LanT or LanP-like proteins. In the case of cinnamycin, proteolysis may be performed by 
the general secretory sec-dependent export machinery (59). However, the conserved 
AXA motif preceding the cleavage site of the type I signal peptidases (64) is absent 
from most of the other leader sequences from Actinobacteria.  
Ortholog neighborhood analysis of class III and IV lanthionine synthetases 
(RamC-like and LanL) unrevealed some lantipeptide gene clusters encoding for 
different classes of peptidases that may cleave off the leader regions from the encoded 
LanA peptides (Figure 4.14). The proteins encoded by the Kribbella flavida and 
Streptococcus pneumoniae gene clusters, which will be designated LanP2, are putative 
intracellular serine peptidases from the prolyl oligopeptidase family. Similar proteins are 
involved in leader peptide removal from amatoxins and phallotoxins, bicyclic octa- and 
heptapeptides, respectively, containing a Trp-Cys crossbridge (tryptathionine) that are 
produced by poisonous mushrooms of the genera Amanita, Galerina, Lepiota, and 
Conocybe (65, 66). The structural fold of members of this peptidase family resembles 
that of carboxypeptidase C, instead of subtilisin as predicted for LanP proteins, 
suggesting that both groups of peptidases have evolved by independent convergent 
evolution (67). Furthermore, the order of the catalytic triad residues (Ser, His, and Asp) 
in the amino acid sequence in both groups of serine peptidases is predicted to be 
different (DHS for LanPs versus SDH for LanP2s) (67). Although members of the prolyl 
oligopeptidase family have different substrate specificity, amino acid sequence 
homology of the identified proteases to previously characterized proteins allows the 
prediction of tentative cleavage sites in the precursor peptides encoded by the 
corresponding gene clusters (Figure 4.14, underlined red letters in LanAs). 
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Figure 4.14. Class III and IV lantipeptides gene clusters potentially encoding for novel classes 
of leader peptide peptidases. For LanP2 proteins (prolyl endopeptidases), the most likely 
residues at the C-terminus of the cleavage site in the precursor peptides are shown in 
underlined red letters. The numbers over the open reading frames encoding for the putative 
peptidases correspond to the locus tags in genome databases. 
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Open reading frames (ORFs) encoding for two additional classes of putative 
peptidases in the neighborhood of lanL/ramC-like genes were identified in the genomes 
of Thermomonospora curvata and Lactobacillus jensenii. However, their involvement in 
lantipeptide biosynthesis is not as clear, since the ORFs are located at the predicted 
boundaries of the clusters. The putative peptidase LanP3 is a transmembrane serine 
protease with a Ser-Lys catalytic diad that may process peptides concomitant with 
secretion, while the protease LanP4 is a predicted intracellular cysteine peptidase. 
Whether the LanP2, LanP3, and LanP4 peptidases are involved in leader peptide 
cleavage during lantipeptide biosynthesis or not is currently uncertain. However, 
heterologous expression of the proteins and in vitro reconstitution of their enzymatic 
activity, as described above, may provide the answer to this question. 
 
Homology modeling of ElxP 
To further understand the substrate specificity of ElxP, homology modeling of the 
protease was performed using as template the recently released X-ray crystal structure 
of BsaP (pdb ID: 3T41) (68), the peptidase involved in the biosynthesis of a group of 
lantibiotics designated Bsa (57). The model was constructed using Phyre2 (Figure 
4.15A) (69). To validate the results, a second model was generated by using the 
“multiple template modeling” tool from the same website and six protein templates  
automatically selected based on heuristics (pdb ID: 2OXA, 1P8J, 1R6V, 3I74, 3QFH, 
and 3T41). This second model was predicted to have more than 90% confidence for 
98% of the amino acid residues. The predicted structures are remarkably similar (Figure 
4.15B), especially near the active site and the substrate-binding region (S4-S1’, based 
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on a notation previously defined for proteases (70)). Therefore, only the model based on 
the BsaP structure will be considered for further discussion (Figure 4.15A). 
ElxP is predicted to have an α/β fold with the active site located between a three-
stranded central parallel β-sheet and two α-helices. The model also supports the role of 
the predicted catalytic triad and oxyanion hole residues previously identified by 
sequence alignment (Asp27, His62, Ser240, and Asn154) (22) (Figure 4.15C). Based 
on the crystal structures of subtilisin BPN’ and thermitase in complex with the inhibitor 
eglin (71, 72) and previous models for NisP (73) and CylA (49), the substrate-binding 
region in ElxP is predicted to be a surface channel or crevice that can accommodate at 
least seven amino acid residues (P5-P2’) (Figure 4.15D). In subtilisin and thermitase, 
the specificity appears to be mainly determined by interactions of the substrate P4 and 
P1 residue side chains with the large S4 and S1 subsites (73, 74). In ElxP, the S1 site is 
predicted to be a large, elongated pocket with residues Ser162 and Ser153 on one side 
and Asp155 at the rim, likely providing H-bonding interactions with the ElxA residue 
Gln−1(P1) (Table 4.5 and Figure 4.16). Importantly, the corresponding residues in a 
mutant subtilisin BPN’ (Glu156 and Asp166), based on sequence alignment, were 
shown to be determinant for the substrate specificity of the enzyme for P1 residues (75). 
Furthermore, when Gln−1 in ElxA was substituted for Ala or Arg, the efficiency of the 
reaction was considerably reduced (Table 4.4 and Figure 4.5), probably due to loss of 
the essential interactions with the predicted ElxP binding residues. In contrast, when 
Gln−1 was substituted for its isosteric P1 homolog Glu, the mutant was processed 
qualitatively with very similar efficiency as the wild-type, suggesting that Glu−1 may still 
interact with Ser162 and Ser153 by H-bonding interactions. As mentioned above, this 
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result may be caused by the high peptide concentrations used in the assay and the 
mutant Q−1E might still be a poor substrate under physiological conditions. The 
corresponding residues in NisP and CylA were previously predicted to be Asp436 and 
Asp408 interacting with Arg−1 in NisA (73) and His275 interacting with Glu−1 in CylLS’ 
and CylLL’ (Figure 4.12) (49), respectively (Table 4.5).  
Sequence alignment allowed the identification of the residues located at the 
predicted S1 subsite in other LanP proteases (Table 4.5). In general, for the proteases 
located in the R-clade of the phylogenetic tree (Figure 4.2), acidic residues (Asp or Glu) 
in the S1 subsite are expected to interact with Arg−1 in the precursor peptides. 
Additionally, for the D/E-clade proteases, basic residues (Lys or His) in the S1 subsite 
usually interact with the Asp−1 or Glu−1 residues of the substrates. Furthermore, the 
residue Ser162 (and Asp155) in ElxP, or their equivalents for other LanP, likely provide 
the dominant interactions with the P1 residue of the substrate and may determine the 
substrate specificity as suggested for subtilisin BPN’ (75). Importantly, determination of 
the location of novel proteases in the phylogenetic tree (Figure 4.2) and the S1 subsite 
residues can provide some insights into the cleavage site of precursor peptides 
identified by in silico methods and the final structure of lantipeptides. For instance, the 
cleavage site of the precursor peptides encoded by the gene clusters identified by 
ortholog neighborhood analysis in the present study (Figure 4.13) can be easily 
predicted using this information (Figures 4.2 and 4.16). Furthermore, for the B. cereus 
VPC1401 gene cluster that encodes two putative LanP proteases, the predicted cellular 
localization of the proteases and the motifs conserved in the leader peptides allowed 
determination of the most likely substrates for every protease (Figure 4.17).  
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Figure 4.15. Model of the epilancin 15X serine-type protease (ElxP). The model was 
constructed based on the structure of BsaP (A and B, blue) and compared with the model 
obtained by multiple template modeling (B, red) using Phyre2 (69). The predicted residues of 
the catalytic triad (C) and the potential substrate binding cleft accommodating residues P5-P2’ 
were identified (D, left: front view; right: side view after 90° rotation). The hydrophobicity surface 
structure is shown in colors from blue (hydrophilic) to red (hydrophobic) based on the Kyte and 
Doolittle scale (45).  
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Table 4.5. Predicted S1 site residues for different lantibiotic serine proteases. The 
enzyme/substrate interaction is probably dominated by S162/D155 in ElxP (shown in red) or the 
equivalent residues in other proteases. 
 
Clade Protease P1 residue S1 residues 
Q 
ElxP Q S162 D155 S122 G123 Y124 S153 
EciP Q L N S G A M 
PepP Q M N S G E M 
D/E CylA E H E G S Y G 
LicP E H K G S Y G 
R 
BsaP R D D G S Y G 
EpiP R D D G N Y G 
GdmP R D D G N Y G 
MutP.I R D D G Q Y G 
MutP.III R D D G Q Y G 
NiqP R D D G Q Y G 
NisP R D D G Q Y G 
NsuP R D E G E Y G 
PneP R D D G Q Y G 
 
 
Figure 4.16. Schematic 2-D representation of the binding cleft of ElxP according to the model in 
Figure 4.15. 
 
The S2 site of ElxP is predicted to be a shallow cleft bounded by Ser28, Thr60, 
Thr91, and the active site residue His62 and can probably accommodate only small 
residues such as Pro−2(P2) in ElxA (Figure 4.16). Indeed, when this amino acid was 
176 
 
mutated for the larger residues Lys or Asp, the cleavage reaction was greatly prohibited 
probably due to steric hindrance (Table 4.4 and Figure 4.6). As in previous models for 
NisP and CylA (49, 73), S3 is not a distinct site and the residue Asn−3(P3) in ElxA might 
point away from ElxP towards the solvent, although Glu96 may provide some interaction 
(Figure 4.16). The S4 site is predicted to be a small pocket bounded by large 
hydrophobic side chains (Tyr97, Phe99, Leu102, Tyr121, and Phe134) and is expected 
to accommodate hydrophobic residues, such as Leu−4(P4) in ElxA (Figure 4.16). 
Finally, a potential S5 site with residues Lys98, Gln126, Asn127, and Asn128 pointing 
towards the solvent may provide crucial interactions with Asp−5(P5) and may explain 
the lack of cleavage activity of ElxP with NisA that contains a Gly residue at this position 
(Figure 4.16). Regarding the binding of the segment C-terminal to the cleavage site, the 
S1’ pocket is predicted to be a less-defined small hydrophobic site bounded by His62, 
Asn236, Phe237, and Ile241 and likely provides weak interactions. Interestingly, a 
hydrophobic patch was identified in a region near the predicted S2’ site (Figure 4.13D). 
This patch might interact with the hydrophobic core peptide (Figure 4.11) further 
providing additional binding energy. Based on the discussed experimental results and 
the simplified structural model, lantipeptide leader peptidases with a desired specificity 
could be designed by protein engineering as reported before for subtilisin BPN’ (75). 
Furthermore, the high fidelity of ElxP suggests that this peptidase and other LanP 
proteins may have interesting potential for application in biotechnology to remove 
expression tags similar to the use of Tobacco Etch Virus (TEV) protease, enterokinase, 
thrombin, and Factor Xa. 
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In summary, the PQ sequence, but not the FDLD motif, in the leader peptide of 
ElxA is critical for substrate recognition by ElxP, as most of the mutants generated at 
these positions were processed at a considerably lesser degree than the wild-type 
peptide. Furthermore, homology modeling of ElxP, phylogenetic analysis of LanP 
proteases, and the lack of NisA cleavage by the peptidase suggest that additional 
residues at the C-terminus of the leader peptide, such as the negatively charged Asp−5 
or the small hydrophilic Leu−4, are involved in substrate recognition. These findings 
also indicate that in class I lantipeptide biosynthesis, different amino acid residues of the 
leader peptide have dissimilar effects on the recognition by the modification enzymes, in 
agreement with previous results on the specificity of LanB dehydratases (25, 26, 46). 
Further investigation, including determination of kinetic parameters and evaluation of 
additional mutants, will contribute to the elucidation of the rules for substrate processing 
by LanP proteases.  
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Figure 4.17. Determination of proteolytic cleavage sites of novel precursor peptides discovered 
by genome mining. The location of the proteases in the phylogenetic tree (Figure 4.2) and the 
S1 site residues corresponding to S162 in ElxP were used to determine the P1 residues (in red 
bold letters) in the predicted precursor peptides. The conserved sequences from class I and II 
lantipeptides are in bold underlined letters. 
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APPENDIX. INVESTIGATIONS ON NOVEL  
PHOSPHONATE NATURAL PRODUCTS 
 
 
A.1. INTRODUCTION 
Over the last several decades, bacterial resistance to known classes of 
antibacterial agents has been rising at an alarming rate, mainly due to the widespread 
overuse of antibiotics (1). Currently, more than 70% of bacteria that give rise to hospital-
acquired infections in the United States are resistant to at least one of the main 
antimicrobial agents (2). Furthermore, the rate of discovery of antibiotics and natural 
products has decreased over the past years, in part because current screening methods 
result in a high rate of rediscovery of previously identified compounds (3). Thus, there is 
an urgent need for new antibacterial drug classes not affected by resistance 
mechanisms already present in pathogenic bacteria and for new approaches to discover 
them in an efficient way. This chapter focuses on the discovery of novel phosphonate 
metabolites and on the study of their biosynthetic pathways.  
Several natural phosphonates with biological activity have been reported. For 
instance, fosfomycin (Figure A.1), an antibiotic produced by some species of 
Pseudomonas and Streptomyces that is effective against a broad spectrum of Gram-
negative and Gram-positive bacteria, has become the first choice for treatment of 
certain types of infections (4). Fosfomycin inactivates UDP-N-acetylglucosamine-3-O-
enolpyruvyltransferase (MurA), an essential enzyme that catalyzes the first step in the 
biosynthesis of the bacterial cell wall. In addition to fosfomycin, several other 
characterized phosphonates have shown biological activity (5). The bioactivity of this 
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class of compounds can be explained by the structural similarity of phosphonic acids 
with natural phosphate esters and carboxylic acids, as well as by the chemical stability 
of the C-P bond, which allows them to act as potent enzyme inhibitors.  
The most abundant and first natural phosphonate to be isolated was 2-
aminoethylphosphonic acid (AEP). Although this compound has been found in many 
species from bacteria to lower plants and animals, the molecule has no apparent 
biological function (6). However, AEP is also found as a head group in membrane 
phosphonolipids or as a side group in polysaccharides and glycoproteins with 
extracellular location. The inert character of phosphonate-containing compounds may 
generate structural components that are resistant to hydrolysis, oxidation, or other 
metabolic processes (6, 7).   
After the discovery of fosfomycin, several other antibiotics have been isolated 
from other species of Streptomyces, Pseudomonas, and Bacillus, among others. The 
compound FR-900098 was isolated from cultures of S. rubellomurinus (8), followed by 
the discovery of its homologs FR-31564 (fosmidomycin) and FR-32863 isolated from S. 
lavendulae, and FR-33289 from S. rubellomurinus subs. indigoferis (Figure A.1) (9). 
These compounds were found to have potent activity against Trypanosoma cruzi and 
various bacterial pathogens. Other isolated natural phosphonates include 
phosphonothrixin produced by Saccharothrix sp. (10) and phosphinothricin tripeptide (or 
bialaphos) isolated from S. hygroscopicus and S. viridochromogenes, both of which are 
being broadly used in agriculture as herbicides (11). Furthermore, plumbemycin from S. 
plumbeus (12), fosfazinomycin from S. lavedofoliae (13), SF-2312 from 
Micromonospora sp. (14), and dehydrophos from S. luridus (15) have also shown 
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antimicrobial activity. Finally, the phosphonates denoted as K-4 (16) and K-26 (17), 
isolated from Actinomadura spiculosospora and Astrosporangium hypotensionis, 
respectively, are potent ACE (angiotensin-converting enzyme) inhibitors that show 
promise in the treatment of high blood pressure (Figure A.1).  
Despite the evident utility of phosphonates, the information about their 
biosynthesis is limited. Currently, the biosynthetic gene clusters of only a few C-P bond-
containing natural products has been reported, including 2-aminoethylphosphonate 
(18), fosfomycin (4), phosphinothricin tripeptide (19, 20), FR-900098 (21), and 
dehydrophos (22). Considering the biological properties of phosphonates and the 
ubiquitous role of their analog phosphate-esters and carboxylic acids in biology, the 
discovery of many other novel phosphonates with inhibitory activity is highly anticipated. 
In addition, knowledge of their biosynthetic pathways could lead to production systems 
with higher yields and to engineered pathways that generate novel antibiotics. 
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Figure A.1. Chemical structures of several representative phosphonate antibiotics. 
 
All the known natural phosphonates, with the possible exception of K-26 and its 
analogs (23), are believed to have a common biosynthetic step, which is the 
rearrangement of phosphoenolpyruvate (PEP) to phosphonopyruvate (PnPy) catalyzed 
by the enzyme PEP mutase (Ppm) (Figure A.2). As a consequence, screening genomic 
DNA for the ppm gene by PCR using degenerate primers can be an efficient strategy to 
identify strains that produce phosphonates and thus, to discover novel bioactive 
compounds. Moreover, the generally observed clustering of secondary metabolite 
genes allows for identification of entire sets of biosynthetic gene clusters. Previously, 
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Prof. William Metcalf and coworkers identified a set of microorganisms that potentially 
produce phosphonate antibiotics using this methodology. The following section 
describes efforts in the construction of genomic DNA libraries and in the identification of 
gene clusters involved in the biosynthesis of novel phosphonates. Based on this 
information, two strains containing gene clusters that potentially encode enzymes for 
the biosynthesis of small molecules were selected for further study. By screening for 
production of phosphonates under different growth conditions and analyzing the 
concentrated culture extracts by 31P NMR spectroscopy, two potentially novel 
phosphonates were identified.  
 
Figure A.2. Rearrangement of phosphoenolpyruvate (PEP) to phosphonopyruvate (PnPy) 
catalyzed by PEP mutase (Ppm). 
 
A.2. EXPERIMENTAL METHODS 
Materials, organisms, media, and general methods 
Chemical reagents and media components used in this study were purchased 
from Sigma-Aldrich, Thermo Fisher Scientific, or Difco, unless otherwise specified, and 
were used without further purification. The strains are listed in Table A.1. Escherichia 
coli and Bacillus subtilis strains were routinely grown in LB solid agar or broth at 37 °C 
or 30 °C, respectively. Streptomyces strains were propagated in malt extract-yeast 
extract-glucose medium (MYG) or ISP medium 2 (ISP2) at 30 °C, unless otherwise 
specified. For agar diffusion bioactivity assays, aliquots of 25 mL of agar medium 
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inoculated with an overnight culture (1/100 dilution) were poured into a sterile plate. 
Aliquots of antibacterial compounds were placed into wells made on the solidified agar 
and the plates were incubated at 37 or 30 °C overnight. The bioactivity of the sample 
was confirmed if a clear growth inhibition zone surrounding the well was formed. 
The construction of the genomic library of strain S. mauvecolor WM6391 and 
sequencing of a ppm-positive fosmid were performed using the protocol described for 
Staphylococcus epidermidis 15X154 in chapter 2. The degenerate forward 
CHIpepmutF1 (5’-CGC CGG CGT CTG CNT NGA RGA YAA-3’) and reverse 
CHIpepmutR2 (5’-GGC GCG CAT CAT GTG RTT NGC VYA-3’) primers that recognize 
conserved regions in the ppm gene were used for library screening. The bioinformatic 
analysis of the gene clusters were performed using several tools, including SMART 
(24), NCBI-CD Search (25), PROSITE Web Server (26), Phyre 3D-PSSM (27), 
NRPSPredictor (28), TMHMM server (29), and SignalP 3.0 (30). The putative 
phosphonate producer WM6391 was further studied by Mr. Joel Cioni, a current 
graduate student in the Metcalf laboratory. 
 
Screening of conditions for production of phosphonates  
Single colonies of the Streptomyces strains WM6372 and WM4235 were 
inoculated in MYG media for 2 to 4 days at 30 °C. For testing of phosphonate 
production in different solid media, aliquots of MYG cultures were spread on agar plates 
and incubated at 30 °C for 5 to 15 days. ISP2, ISP medium 4 (ISP4), Difco nutrient agar 
(DNA), mannitol soya flour medium (MS) (31), supplemented minimal medium (SMMS) 
(32), and minimal medium (MM) with glucose or glycerol (33) were used.  For the 
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extraction of phosphonates, the agar was liquefied by freezing at −20 °C followed by 
thawing at room temperature, and the liquid fractions were decanted. See also 
Notebook IV, page 05. 
 
Table A.1. Microorganisms and plasmids used in this study 
 
For liquid cultures, aliquots of MYG cultures were diluted (1/100) in the trial 
media and incubated at 30 °C for 2 to 7 days with shaking. MYG, yeast extract-malt 
extract medium (YEME) (31), Difco nutrient broth (DNB), and minimal liquid medium 
(NMMP) (34) were tested. For the induction of phosphonates production with D/L-2-
Strain  Relevant characteristics Source or reference 
Escherichia coli   
    WM4489 E. coli DH10B derivative: mcrA (mrr hsdRMS 
mcrBC) 80(lacM15) lacX74 endA1 recA1 deoR 
(ara-leu)7697 araD139 galU galK nupG rpsL 
attB::pAE12(PrhaB::trfA33 oriR6K-cat::frt5) 
(21) 
    WM2785 Indicator strain 
E. coli BW26678 derivative: lacIq, rrnB3, 
(lacZ4787), hsdR514, attP22(EcoB), 
(araBAD)567, (rhaBAD)568, rph−1, (phnC-P), 
(phoA) 
Expresses the phosphonate uptake system encoded 
by phnCDE under the control of a Ptac promoter 
W. Metcalf, 
Univ. Illinois 
    MMG127 Derivative of WM4489 containing a ppm positive 
fosmid isolated from the S. mauvecolor 
WM6391genomic library 
B. Li and   
W. Metcalf 
 
Bacillus subtilis 
ATCC6633 
 
Indicator strain 
 
ATCCa 
 
Streptomyces 
  
    mauvecolor WM6391 ppm positive strain, Illinois soil isolate W. Metcalf, 
Univ. Illiniois 
    verne WM4235 ppm positive strain, Alaskan soil isolate W. Metcalf, 
Univ. Illinois 
    sp. WM6372 ppm positive strain, Illinois soil isolate W. Metcalf, 
Univ. Illinois 
aATCC, American Type Culture Collection, Manassas, VA.  
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amino-3-phosphonopropionic acid (D/L-phosphonoalanine, D/L-PnAla), ISP4 media 
without agar and substituting K2HPO4 for D/L-PnAla (0.1 g/L, Sigma) was used for the 
initial trials and the bacterial cultures were incubated for 14 days at 30 °C with shaking. 
In the following trials, a modular media composed of freshwater base (NaCl 17.1 mM, 
MgCl2·6H2O 1.97 mM, CaCl2·2H2O 0.15 mM, KCl 6.71 mM), glucose (55 mM) or soluble 
starch (29 mM), NH4Cl (10 mM), Na2SO4 (1 mM), DL-PnAla (4 mM), AEP (10 mM), 
trace elements (FeSO47H2O, 2.1 ppm; MnCl24H2O, 0.1 ppm; CoCl26H2O, 0.19 ppm; 
H3BO3, 0.03 ppm; NiCl26H2O, 0.024 ppm; CuCl2·2H2O, 0.002 ppm; ZnSO47H2O, 0.144 
ppm; Na2MoO42H2O, 0.036 ppm; Na2WO42H2O, 0.025 ppm; Na2SeO35H2O, 0.006 
ppm), and MOPS (50 mM, pH 7.2) as buffering reagent was used and the cultures were 
incubated for 7 days at 30 °C with shaking. See also Notebook IV, page 50. 
The presence of phosphonates was determined using 1H-decoupled 31P-NMR 
spectroscopy. Liquid fractions or culture supernatants were passed through a 0.2 µm 
filter, concentrated (4× to 30×) by lyophilization, and resuspended in H2O supplemented 
with 20% D2O as a lock solvent. The spectra were externally referenced to an 85% 
phosphoric acid standard (0 ppm) and acquired at room temperature on a Varian Unity 
Inova-600 spectrometer equipped with a 5-mm Varian 600DB AutoX probe with 
ProTune accessory and tuned at 242.789 MHz at the Varian Oxford Center for 
Excellence in NMR laboratory at the University of Illinois, Urbana-Champaign.  
To reduce the complexity of the sample, phosphates and cyclophosphate 
nucleotides, which may generate false positive signals in the phosphonate range in 31P 
NMR spectroscopy, were hydrolyzed by incubation with calf intestinal alkaline 
phosphatase (New England Biolabs) and phosphodiesterase I from Crotalus atrox 
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(Sigma) in reaction buffer (HEPES, 25 mM, pH 7.5)  at 37 °C for 4 h. Finally, since the 
C-P bond in phosphonates, but not the C-O-P bond in phosphate esters, is remarkable 
stable under acidic conditions, samples were treated with hydrochloric acid (1 N) at 100 
°C under reflux for 4 h, followed by analysis by 31P NMR spectroscopy as described 
above to confirm the presence of phosphonates. See also Notebook IV, page 62. 
 
A.3. RESULTS AND DISCUSSION 
Genomic DNA library construction of a ppm-positive Streptomyces strain, 
sequencing, and annotation of phosphonate gene clusters 
In collaboration with Dr. Bo Li, a former graduate student in the van der Donk 
laboratory, a fosmid-based genomic DNA library for S. mauvecolor WM6391 in E. coli 
was constructed under the direction of Prof. William Metcalf and Mr. Junkai Zhang. 
Briefly, genomic DNA was isolated in fragments longer than 200 kb and partially 
digested. Then, cloning of 30-50 kb fragments into a cosmid followed by lambda phage 
transduction resulted in a library of fosmid-containing clones in E. coli WM4489. Finally, 
a fraction of the fosmid library was screened by PCR for the ppm gene using 
degenerate primers that recognize conserved nucleotide sequences on the gene and 
three positive clones were isolated. To obtain the sequence of one of the fosmids, a 
library of transposon insertions into the isolated fosmid was prepared and a set of 192 
clones were sequenced using primers binding at each end of the transposon. After 
assembling of the DNA sequences, two contigs were obtained.  
The hypothetical function and location of the putative proteins were determined 
using several bioinformatic tools (Figure A.3). The biosynthetic gene cluster in WM6391 
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contains three genes with high homology to genes already identified in the FR-900098 
cluster and that encode a Ppm (FrbD), a homocitrate synthase for the second step of 
the biosynthesis (FrbC) and an aconitase isomerase for the third step (FrbA) (Figure 
A.4) (21). Thus, this cluster may encode the biosynthesis of a small metabolite and it 
was further characterized by Mr. Joel Cioni, a graduate student in the Metcalf 
laboratory.  
In a collaborative effort, genomic libraries of six additional Streptomyces sp. that 
potentially contain the genetic information for phosphonate biosynthesis were obtained 
by other members of the Mining Microbial Genomes Theme at the Institute for Genomic 
Biology. After sequencing, five of these clusters were assembled and the open reading 
frames encoding proteins involved in the biosynthesis of phosphonates were identified 
(Figure A.6 to A.10). The remaining gene cluster was annotated by Dr. Tyler Johannes, 
a former graduate student in the Zhao laboratory (Figure A.5). 
The gene clusters from the strains S. goshikiensis WM6368, S. virginiae 
WM6349, and Streptomyces sp. WM6373 are similar and may produce identical 
phosphonates (Figures A.5 to A.7). These clusters are likely to produce AEP, a 
common component of the bacterial cell wall (18), that may be tethered to a polyketide 
chain as suggested by the presence of polyketide synthase (PKS) I and II genes in the 
vicinity of the phosphonate cluster (Figure A.5). The cluster from Streptomyces sp. 
WM6352, in addition to phosphonate-related genes encoding for AEP, contains genes 
for the biosynthesis of TDP-L-rhamnose, a common component of exo-polysaccharides 
and glycoproteins (Figure A.8). Two interesting gene clusters from the strains 
Streptomyces sp. WM6372 and S. verne WM4235, presumably involved in the 
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synthesis of non-ribosomal peptides, were selected for further analysis (Figures A.9 and 
A.10, Tables A.2 and A.3). For both clusters, the gaps between the sequences were 
filled by primer walking. 
 
Figure A.3. Workflow for the bioinformatic analysis of the open reading frames identified after 
assembling the DNA sequences (24-30).
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Figure A.4. Open reading frame map of the sequenced fosmid containing the phosphonate gene cluster from S. mauvecolor 
WM6391 (or E. coli MMG127 fosmid) (A) and proposed reactions for the first three biosynthetic steps (B).  
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Figure A.5. Open reading frame map of the sequenced fosmid containing the phosphonate gene cluster from S. goshikiensis 
WM6368 (A) and proposed reactions for the first three biosynthetic steps (B). Annotation by Dr. Tyler Johannes. Green: PKS genes, 
blue: putative phosphonate gene cluster, orange: other genes. 
199 
 
 
 
Figure A.6. Open reading frame map of the sequenced fosmid containing the phosphonate gene cluster from S. virginiae WM6349. 
Open reading frames were assigned using the BLAST program at the NCBI website. Blue: putative phosphonate gene cluster, 
orange: other genes. 
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Figure A.7. Open reading frame map of the sequenced fosmid containing the phosphonate gene cluster from Streptomyces sp. 
WM6373. Open reading frames were assigned using the BLAST program at the NCBI website. Blue: putative phosphonate gene 
cluster, orange: other genes. 
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Figure A.8. Open reading frame map of the sequenced fosmid containing the phosphonate gene cluster from Streptomyces sp. 
WM6352. Open reading frames were assigned using the BLAST program at the NCBI website. Blue: putative phosphonate gene 
cluster, green: TDP-L-rhamnose biosynthesis, orange: other genes. 
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Figure A.9. Open reading frame map of the sequenced fosmid containing the phosphonate gene cluster from Streptomyces sp. 
WM6372. Open reading frames were assigned using the BLAST program at the NCBI website and other bioinformatic tools. 
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Figure A.10. Open reading frame map of the sequenced fosmid containing the phosphonate gene cluster from S. verne WM4235. 
Open reading frames were assigned using the BLAST program at the NCBI website and other bioinformatic tools. 
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Table A.2. Open reading frames analysis of the Streptomyces sp. WM6372 gene cluster using 
BLASTp at the NCBI website.  
Predicted protein Protein homology Identity
Transcriptional 
regulator 
dbj|BAC71516.1|  putative transcriptional regulator  
[S. avermitilis MA-4680] 
47% 
Adenylosuccinate 
lyase 
emb|CAJ89132.1|  putative adenylosuccinate lyase  
[S. ambofaciens ATCC 23877] 
63% 
N-Acetyltransferase emb|CAJ89131.1|  putative acetyltransferase  
[S. ambofaciens ATCC 23877] 
64% 
Hypothetical protein emb|CAJ89135.1|  hypothetical protein  
[S. ambofaciens ATCC 23877] 
33% 
Glu-tRNA amido 
transferase 
gb|ABP54656.1|  Amidase  
[Salinispora tropica CNB-440] 
51% 
Glutamine synthetase emb|CAK51247.1|  putative glutamine synthetase  
[S. ambofaciens] 
54% 
FAD(NAD)-dependent 
oxidoreductase 
dbj|BAC73537.1|  hypothetical protein  
[S. avermitilis MA-4680] 
gb|ABJ69048.1|  Predicted FAD(NAD)-dependent oxidoreductase  
[Lactobacillus casei ATCC 334] 
58% 
 
35% 
Carboxymuconate 
cycloisomerase 
emb|CAK51228.1|  putative 3-carboxymuconate cycloisomerase  
[S. ambofaciens] 
61% 
Thymidylate kinase emb|CAA83856.1|  unknown  
[Pseudomonas syringae] 
gb|ABE54453.1|  Thymidylate kinase-like protein  
[Shewanella denitrificans OS217] 
37% 
 
34% 
MSF transporter gb|ABM09775.1|  putative major facilitator superfamily (MFS) 
transporter  
[Arthrobacter aurescens TC1] 
33% 
Peptidyltransferase emb|CAA60475.1|  orfD - rapamycin gene cluster  
[S. hygroscopicus]   
30% 
N5-glutamine SAM-
dependent 
methyltransferase 
gb|AAK64442.1|AF377339_3  protoporphyrinogen oxidase HemK  
[Myxococcus xanthus] 
emb|CAJ93170.1|  predicted methyltransferase  
[Ralstonia eutropha H16] 
39% 
 
39% 
Oxygenase (FrbJ)  gb|EDP64847.1|  hypothetical protein BAL199_05284  
[alpha proteobacterium BAL199] 
gb|ABB90399.1|  FrbJ  
[S. rubellomurinus] 
34% 
 
28% 
ATP-grasp ligase gb|AAU23668.1|  Carbamoyl-phosphate synthase L chain 
[Bacillus licheniformis ATCC 14580] 
ref|YP_091723.1|  acetyl-CoA carboxylase biotin carboxylase subunit  
[B. licheniformis ATCC 14580] 
29% 
 
29% 
Phosphodiesterase emb|CAJ89340.1|  putative phosphodiesterase  
[S. ambofaciens ATCC 23877] 
54% 
Phosphonopyruvate 
decarboxylase 
emb|CAB45023.1|  putative phosphonopyruvate decarboxylase  
[Amycolatopsis orientalis] 
48% 
Phosphoenolpyruvate 
phosphomutase 
emb|CAN97474.1|  Phosphoenolpyruvate mutase  
[Sorangium cellulosum 'So ce 56'] 
47% 
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Table A.2. Continuation. 
 
Predicted protein Protein homology Identity
Methyltransferase gb|EAV40562.1|  hypothetical protein SIAM614_16737 
 [Stappia aggregata IAM 12614] 
gb|EDQ31853.1|  methlytransferase, UbiE/COQ5 family protein  
[Hoeflea phototrophica DFL-43] 
46% 
 
43% 
Aspargine synthetase emb|CAB16028.1|  asparagine synthetase (glutamine-hydrolyzing)  
[B. subtilis subsp. subtilis str. 168] 
37% 
Metallophospho-
esterase 
emb|CAB41730.1|  putative secreted protein  
[S. coelicolor A3(2)] 
gb|ABL94102.1|  metallophosphoesterase  
[Mycobacterium sp. KMS] 
82% 
 
52% 
Hypothetical protein 
(GatB/YqeY) 
emb|CAB41729.1|  conserved hypothetical protein  
[S. coelicolor A3(2)] 
emb|CAL99661.1|  GatB/YqeY  
[Saccharopolyspora erythraea NRRL 2338] 
83% 
 
56% 
Transpeptidase emb|CAD55325.1|  putative transpeptidase  
[S. coelicolor A3(2)] 
dbj|BAC72295.1|  putative penicillin-binding protein  
[S. avermitilis MA-4680] 
71% 
 
70% 
Transcriptional 
regulator 
emb|CAB43030.1|  hypothetical protein  
[S. coelicolor A3(2)] 
dbj|BAC72296.1|  putative WhiB-family transcriptional regulator 
[S. avermitilis MA-4680] 
88% 
 
87% 
Ion-transporting 
ATPase  
emb|CAB45557.1|  putative ion-transporting ATPase  
[S. coelicolor A3(2)] 
82% 
Ion-transporting 
ATPase  
emb|CAB45559.1|  putative ion-transporting ATPase  
[S. coelicolor A3(2)] 
76% 
Endoribonuclease dbj|BAC72300.1|  hypothetical protein  
[S. avermitilis MA-4680] 
gb|ABY24518.1|  translation initiation inhibitor  
[Renibacterium salmoninarum ATCC 33209] 
84% 
 
74% 
NUDIX hydrolase dbj|BAC72301.1|  hypothetical protein  
[S. avermitilis MA-4680] 
gb|ABL79881.1|  NUDIX hydrolase  
[Nocardioides sp. JS614] 
78% 
 
54% 
Note: Results are from a BLASTp search of the GenBank protein database on January 2008. 
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Table A.3. Open reading frames analysis of the S. verne WM4235 gene cluster using BLASTp 
at the NCBI website.  
Predicted protein Protein homology Identity 
TetR-family transcript. 
regulator 
emb|CAJ88304.1|  putative TetR-family transcriptional regulator  
[S. ambofaciens ATCC 23877] 
74% 
Aldo/keto reductase dbj|BAB50827.1|  oxidoreductase; MocA  
[Mesorhizobium loti MAFF303099] 
gb|ABR61565.1|  aldo/keto reductase 
[Sinorhizobium medicae WSM419] 
81% 
 
79% 
Reductase dbj|BAC70041.1|  putative assimilatory nitrate reductase  
[S. avermitilis MA-4680] 
69% 
Alcohol 
dehydrogenase 
gb|ABN51632.1|  iron-containing alcohol dehydrogenase 
[Clostridium thermocellum ATCC 27405] 
32% 
Phosphoglycerate 
kinase  
gb|EDO62266.1|  hypothetical protein CLOLEP_01127  
[C. leptum DSM 753] 
dbj|BAD39227.1|  phosphoglycerate kinase  
[Symbiobacterium thermophilum IAM 14863] 
29% 
 
33% 
N-acetyl-glutamyl-
phosphate reductase  
gb|EAZ54588.1|  N-acetyl-gamma-glutamyl-phosphate reductase  
[P. aeruginosa C3719] 
42% 
Alcohol 
dehydrogenase  
gb|EAX46939.1|  Alcohol dehydrogenase GroES domain protein 
[Thermosinus carboxydivorans Nor1] 
35% 
Phosphoglycerate 
dehydrogenase  
gb|AAL81518.1|  phosphoglycerate dehydrogenase  
[Pyrococcus furiosus DSM 3638] 
48% 
NRPS, adenylation 
domain  
ref|ZP_00111185.1|  COG1020: Non-ribosomal peptide synthetase 
modules and related proteins  
[Nostoc punctiforme PCC 73102] 
45% 
Dioxygenase gb|ABD89411.1|  Phytanoyl-CoA dioxygenase  
[Rhodopseudomonas palustris BisB18] 
35% 
NRPS, condensation 
domain 
gb|ABJ11576.1|  pyoverdine synthetase D  
[P. aeruginosa UCBPP-PA14] 
24% 
Phosphonopyruvate 
decarboxylase 
gb|ABH03014.1|  IlvB  
[Spirochaeta aurantia] 
gb|AAQ61550.1|  acetolactate synthase  
[Chromobacterium violaceum ATCC 12472] 
35% 
 
36% 
Transketolase, C-
terminal subunit 
gb|ABR61955.1|  Transketolase domain protein  
[S. medicae WSM419] 
49% 
Transketolase, N-
terminal subunit 
gb|ABW09872.1|  Transketolase domain protein  
[Frankia sp. EAN1pec] 
55% 
Phosphoenolpyruvate 
phosphomutase 
emb|CAJ65000.1|  putative Phosphoenolpyruvate phosphomutase 
[Frankia alni ACN14a] 
62% 
MFS transporter gb|ABM09775.1|  putative major facilitator superfamily transporter 
[Arthrobacter aurescens TC1 
34% 
FomD dbj|BAA32492.1|  FomD  
[S. wedmorensis] 
48% 
Synthetase/ligase emb|CAK13564.1|  putative AMP-dependent synthetase/ligase  
[P. entomophila L48] 
41% 
MFS transporter gb|AAD36408.1|AE001788_3  permease, putative 
[Thermotoga maritima MSB8] 
22% 
Acetyl transferase emb|CAJ88185.1|  putative modular polyketide synthase 
[S. ambofaciens ATCC 23877] 
32% 
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Table A.3. Continuation. 
 
Acyl-protein 
synthetase 
emb|CAE16553.1|  unnamed protein product  
[Photorhabdus luminescens subsp. laumondii TTO1] 
51% 
Acyl-CoA reductase gb|ABA74299.1|  conserved hypothetical protein  
[P. fluorescens PfO-1] 
44% 
Glycosyl transferase dbj|BAC72261.1|  putative glycosyltransferase  
[S. avermitilis MA-4680] 
58% 
Siderophore-
interacting protein 
dbj|BAC74424.1|  putative siderophore-interacting protein  
[S. avermitilis MA-4680] 
61% 
Note: Results are from a BLASTp search of the GenBank protein database on January 2008. 
 
In addition to Ppm and phosphonopyruvate decarboxylase (Ppd), an enzyme that 
catalyzes the decarboxylation of PnPy to produce phosphonoacetaldehyde (PnAA), the 
gene cluster from Streptomyces sp. WM6372 contains an ORF encoding a member of 
the ATP-grasp ligase superfamily. This protein might catalyze an ATP-dependent 
ligation of a phosphonate-containing amino acid to another amino acid to produce a 
dipeptide, with the formation of an acylphosphate intermediate as suggested for 
rhizocticins (Figure A.11) (35, 36). The alignment of the predicted protein sequence with 
that of D-alanine D-alanine ligase (Ddl) demonstrates that the most relevant residues 
involved in ATP and metal binding are conserved (37). Two other genes in the cluster 
encode ATP-dependent enzymes that catalyze the formation of carbon-nitrogen bonds: 
a glutamine synthetase homolog and an asparagine synthetase homolog. Gln 
synthetase is involved in the formation of L-Gln from L-Glu and ammonia, while Asn 
synthetase catalyzes the formation of L-Asn from L-Asp and L-Gln (Figure A.12). 
Different roles in the pathway can be proposed for these proteins. For instance, they 
might supply L-Asn for the formation of a peptide with a phosphonate containing amino 
acid; alternatively, they might have a role in self-protection if they encode resistant 
forms of target enzymes as suggested for FR-900098 (21), rhizocticins (36), and 
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cycloserine (38). If this is the case, the phosphonic acid could be an analog of L-Gln as 
in the case of phosphinothricin (20). Interestingly, a gene designated as 
peptidyltransferase, which has no significant primary sequence homology to proteins of 
known function, was found to have high predicted secondary structure similarity to 
FemX, a non-ribosomal peptidyl transferase that catalyzes the transfer of L-Ala from 
aminoacylated tRNA to the ε-amino group of L-Lys of UDP-N-acetyl-muramyl-
pentapeptide (39). This peptidyl transferase could be involved in the formation of an 
additional amide bond as demonstrated before for other enzymes with structural 
homology to FemX proteins in the biosynthesis of pacidamycin (40) and as suggested 
for dehydrophos (22) (Figure A.12). Upstream of this gene, a homolog to an Asp-
tRNA/Glu-tRNA amidotransferase was identified, further supporting the hypothesis of 
the incorporation of L-Gln, L-Asn or an analog into the final metabolite (Figure A.12). 
Additionally, a gene encoding an N5-glutamine SAM-dependent methyltransferase was 
also found, suggesting the incorporation of a methyl group into the molecule (Figure 
A.12). Thus, the putative phosphonate biosynthetic cluster from Streptomyces sp. 
WM6372 encodes for significantly diverse proteins that potentially perform several steps 
involving C-N bond formation. Based on the analysis above, some biosynthetic steps 
can be speculated (Figure A.12). Although experimental evidence is lacking, the 
bioinformatic analysis performed on the gene cluster and the proposed pathway may 
help in the purification and structure elucidation of the final metabolite. Interestingly, two 
genes in the cluster are predicted to encode secretory and non-secretory 
metallophosphoesterases. These proteins could be involved in self-
protection/reactivation mediated by phosphorylation as previously reported for 
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fosfomycin (Figure A.13) (41). The formation of a phosphonate phosphate is consistent 
with the observation of a doublet of doublets in 31P NMR spectra of culture supernatants 
of this strain as described below.  
 
 
Figure A.11. Formation of a dipeptide catalyzed by an ATP-grasp ligase domain with the 
generation of an acylphosphate intermediate. 
 
 
Figure A.12. A potential biosynthetic pathway for the production of a tripeptide phosphonate by 
Streptomyces sp. WM6372. Several proteins catalyzing the formation of C-N bonds are 
encoded by the putative gene cluster. 
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Figure A.13. Phosphorylation of the phosphonate group in fosfomycin as a self-protection 
mechanism by FomA and FomB in S. wedmorensis. 
 
The gene cluster from S. verne WM4235 also contains genes encoding for Ppm 
and Ppd, as expected. Two genes encoding the adenylation and the condensation 
domains of a non-ribosomal peptide synthetase (NRPS) were also identified, suggesting 
the formation of a peptide phosphonate. Alignment of nine of the ten residues predicted  
to define the specificity of the adenylation domain (42) suggests the incorporation of L-
Thr or Dhb (2,3-dehydroaminobutyric acid, Dht, or Dhbu) into the peptide (Figure A.14). 
The downstream gene designated as synthetase/ligase encodes a protein with an AMP-
binding site domain that could be the adenylation domain for activation of a 
phosphonate intermediate before incorporation into the peptide. Interestingly, an alcohol 
dehydrogenase is predicted to be a zinc-dependent oxidoreductase that contains a 
threonine dehydrogenase domain, suggesting that Thr or an analog might be 
incorporated into the peptide by the NRPS and subsequently modified by the 
dehydrogenase.  
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Figure A.14. Amino acid sequence alignment of PheA (1) and the adenylation domain of 
WM4235 (2). Shown in red are the 10 amino acids defined to determine the specificity of the 
adenylation domain (42). Nine of the ten residues in the active site established to recognize for 
Thr or Dhb in other NRPS proteins are conserved. 
 
Screening of conditions for production of novel phosphonates 
The genomic approach described above allows for the identification of strains 
that carry the genetic information for the biosynthesis of potentially novel phosphonates. 
However, to discover new natural products, the biosynthetic pathways have to be 
activated and the metabolites identified. In Streptomyces, the production of antibiotics is 
often temporally correlated with other changes in colony morphology, such as spore 
formation and development of aerial mycelia (43). A variety of conditions, including 
nutrient limitation, can induce Streptomyces to produce secondary metabolites and to 
sporulate in order to compete with other organisms and guarantee preservation under 
hostile conditions. However, the networks of regulatory signals that control these 
changes are quite complex, highly variable among strains and pathways and only 
partially understood (43). For this reason, the isolation of novel phosphonates from 
native host cultures can be quite challenging and requires testing many different 
conditions.  
To induce the production of phosphonates by Streptomyces sp. WM6372 and S. 
verne WM4235, a broad set of conditions (including solid and liquid, rich and minimal 
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media) were tested. In the case of solid media, the agar plates were incubated from 7 to 
15 days at which time the formation of spores and/or the production of pigments were 
normally observed. The agar plates were frozen and then thawed before the liquid 
phase was removed and concentrated tenfold. For liquid media, the cultures were 
grown from 2 to 5 days and aliquots of cell-free supernatant were concentrated 4- to 30-
fold for further analysis. Initially, the samples were analyzed for bioactivity in 
conventional agar diffusion bioactivity assays using a variety of indicator strains, 
including Gram-positive and Gram-negative bacteria and an E. coli strain that has the 
three component phosphonate transporter phnCDE integrated into the chromosome 
under an IPTG inducible promoter (21). For both Streptomyces species, the production 
of at least two different antibiotics was observed (Figure A.15). 
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Figure A.15. Agar diffusion bioactivity assay of samples of cell-free extracts after tenfold 
concentration. Top: Extracts from Streptomyces sp. WM6372 tested on LB agar plates with E. 
coli WM2785 (A) and B. subtilis ATCC6633 (B) as indicator strains. Extracts from minimal 
medium (MM) and from ISP2 were bioactive, ampicillin (+) was used as a positive control. 
Bottom: Extracts from S. verne WM4235 tested on LB agar plates with E. coli WM2785 (C) and 
Enterobacter cloacae C19 (D) as indicator strains. Extracts from minimal medium (MM) and 
from ISP2 were bioactive. 
 
Phosphorus-31 nuclear magnetic resonance spectroscopy (31P NMR) is an 
effective technique to determine the presence of phosphonates in cell-free extracts. In 
31P NMR spectra, the signals due to phosphate esters and orthophosphate are normally 
observed at chemical shifts below 5 ppm, while those of the C-P compounds are 
observed between 6 and 45 ppm. The cell-free extracts of cultures of the strains 
WM6372 and WM4235 were analyzed by 31P NMR spectroscopy and various peaks, 
likely corresponding to phosphonates, were detected. In the case of the strain WM6372 
(Figure A.16), the 1H-decoupled 31P NMR spectrum of an ISP2 extract presents a signal 
ISP2
MM
ISP2
MM
ISP2
A B
C D
+ +
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at 10.6 ppm and a smaller peak at 11.2 ppm. Additional phosphorus-containing 
compounds, most of them not present in the media, were observed, including a 
compound that generates a doublet of doublets at −11.5 ppm (dd, J = 387, 19.2 Hz). 
This compound may be a phosphonate phosphate or a diphosphate produced by one of 
the phosphodiesterases present in the cluster (see above). The 1H-coupled 31P NMR 
spectrum of the same sample was also recorded, and a doublet at 10.6 ppm (d, J  = 17 
Hz) was observed, suggesting that only one proton is bound to the α-carbon (Figure 
A.16). After enzymatic treatment of the sample with a phosphodiesterase (which can 
break down the phosphodiester bond in 2’,3’-cyclophosphate nucleoside derivatives that 
produce a 31P NMR peak in the range of phosphonates (44)) and with an alkaline 
phosphatase to hydrolyze phosphate-containing molecules, the characteristic peak at 
10.6 ppm was still observed in the 31P NMR spectrum. Furthermore, the peak survived 
concentrated hydrochloric acid treatment confirming the expected chemical stability of 
the C-P bond. Thus, this phosphorus-containing compound is most likely a 
phosphonate. Similarly, for the strain WM4235 grown in ISP4 for 15 days the 1H-
decoupled and coupled 31P NMR spectra were recorded and a multiplet around 7.8 ppm 
was observed (Figure A.17). This compound was not detected when the strain was 
grown for shorter incubation periods or in different media and its production may be 
correlated with spore formation.  
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Figure A.16. 31P NMR spectra of concentrated crude extract from strain WM6372 grown on 
ISP2 agar plates. The 1H-decoupled and 1H-coupled (insert) spectra are shown. The signals at 
10.5 ppm at 11.2 ppm are presumably generated by phosphonates. 
 
 
Figure A.17. 31P NMR spectra of concentrated crude extract from strain WM4235 grown on 
ISP4 agar plates. The 1H-decoupled and 1H-coupled (insert) spectra are shown. The signal at 
7.8 ppm is presumably generated by a phosphonate.  
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Production of phosphonates in the presence of phosphonoalanine 
As mentioned above, the identification of suitable conditions for phosphonate 
production can be quite challenging. To facilitate the discovery of novel metabolites 
from ppm-positive strains, the development of a medium that chemically induces the 
production of phosphonates is highly desirable. Since the target strains have the genetic 
potential to convert reversibly PnPy into PEP, a media containing PnPy as the only 
source of phosphorus or carbon may force the expression of the Ppm-encoding gene 
operon or cluster, allowing the host to access a source of PEP and other essential 
phosphates (Figure A.18). The activation of the pathway may simultaneously lead to the 
production of the phosphonate metabolite or its intermediates. Since PnPy is not 
commercially available, D/L-PnAla can be alternatively used, provided non-specific 
aminotransferases in the host catalyze the conversion between them (Figure A.18). 
Indeed, the Ppm activity, which favors the reverse reaction, was successfully used to 
isolate several ppm-positive microorganisms after growing them in an enrichment media 
containing D/L-PnAla as a sole phosphorus source (45, 46).  
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Figure A.18. Conversion of PnAla and AEP into phosphates and phosphonates. The 
expression of PEP mutase (Ppm) and PnPy decarboxylase (Ppd) encoding genes may allow 
the conversion of PnAla and AEP (green) into phosphates (red) and the expected phosphonates 
(blue). 
 
When the strain WM6372 was grown in modified ISP4 medium, without agar and 
with D/L-PnAla as the sole source of phosphorus, two signals at 10.5 ppm and 10.0 ppm 
were observed by 1P NMR spectroscopy (Figure A.19A). A spiking experiment indicated 
that these signals overlap with the peaks generated by the phosphonates produced in 
ISP2 medium (Figure A.19B). One additional peak at 18.5 ppm, which may correspond 
to a biosynthetic intermediate or a degradation product, was also detected. 
Furthermore, no signals in the phosphonate range were observed by 1P NMR 
spectroscopy when K2HPO4 was the source of phosphorus (Figure A.19C), confirming 
that the production of the phosphonates depends on the presence of D/L-PnAla. As 
expected, when both, K2HPO4 or PnAla, were absent in the media, no significant 
bacterial growth was detected. 
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Figure A.19. 1H-decoupled 31P NMR spectra of concentrated crude extract from strain WM6372 
grown on ISP4 medium without agar and with PnAla as the sole source of phosphorus (A). After 
spiking with a sample produced in ISP2 medium, only the signals at 10.5 ppm and 10.0 ppm 
were observed (B). No signals for phosphonates were detected when PnAla was substituted for 
K2HPO4 in the medium (C). The signal at 17.4 ppm corresponds to D/L-PnAla, while the signal at 
18.5 ppm may correspond to a biosynthetic intermediate or a degradation product. 
 
 Although the previous results are promising, PnAla could be preferentially utilized 
for the production of PEP and other phosphates that are essential for bacterial growth 
and the yield of phosphonates may be considerably low. However, an open reading 
frame encoding for Ppd, which catalyzes the conversion of PnPy into PnAA, is present 
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in several of the phosphonate gene clusters, including the strains WM6372 and 
WM4235. Thus, growing the bacteria in a medium containing PnAA (or its equivalent 
AEP), in addition to PnAla, as the sources of phosphorus, may further facilitate the 
production of the desired phosphonates (Figure A.18). Indeed, when a minimal media 
containing glucose or starch as the main carbon sources, NH4Cl as nitrogen source, 
and PnAla with AEP as sources of phosphorus was utilized to grow the strain WM6372, 
significant production of a phosphonate with a chemical shift of 10.5 ppm was observed 
(Figure A.20). Furthermore, due to the higher concentration of phosphonate and the 
relatively simplicity of the sample compared with the sample generated from ISP2 
medium, it was possible to record a 1H-31P gHMBC NMR spectrum using a tenfold 
concentrated sample without any additional treatment. The spectrum revealed only one 
proton coupled to the phosphorus generating a doublet with a chemical shift of 2.7 ppm 
(d, J = 12.1 Hz), although a more complex splitting pattern cannot be discarded at this 
point (Figure A.21). From the previously discovered phosphonate natural products (5), 
fosfomycin shows NMR chemical shifts around 11.9 ppm for the phosphorus (4) and 2.7 
ppm (dd, J = 17-21, 5 Hz) for the α-proton (47), close to the recorded values for the 
main phosphonate produced by WM6372. However, spiking experiments performed by 
Dr. Jiangtao Gao, a current postdoctoral researcher in the van der Donk laboratory, 
confirmed that both compounds are not identical, although similar chemical moieties are 
possible. Alternatively, the phosphonate SF-2312 that contains an oxopyrrolidine ring 
was reported  to show NMR chemical shifts at 13 to 18 ppm for the phosphorus and 2.9 
ppm to 3.1 ppm (ddd, J = 21, 10, 6 Hz) for the α-proton (48, 49). Interestingly, the gene 
cluster for WM6372 encodes for a putative 3-carboxy-cis,cis-muconate cycloisomerase, 
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an enzyme that catalyzes the lactonization of cis,cis-muconate. Thus, the phosphonate 
moiety may be bound to a lactone ring consistent with the NMR spectroscopy data. 
The designed medium containing PnAla and AEP as sources of phosphorus can 
be utilized to obtain relatively large quantities of phosphonates from strain WM6372 
(and maybe others) using small-scale cultures, facilitating the production of isotopically 
labeled compounds and the elucidation of the chemical structures. Importantly, 
phosphonates, including PnAla and AEP, can be utilized as source of phosphorus by a 
variety of microorganisms via several pathways, including the C-P lyase, 
phosphonatase, phosphonopyruvate hydrolase, and the recently characterized 
phosphonoacetaldehyde dehydrogenase-dependent mechanisms (7, 50). Thus, the 
production of phosphonates under the stimulus of PnAla and AEP may rely on the 
absence of alternative degradation pathways in the producer organisms. Further 
optimization of the media composition, including studies with PnPy or enantiomerically 
pure L-PnAla and different strains, are required to develop a general phosphonate-
inducing media that could be utilized to discover novel metabolites. 
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Figure A.20. 1H-decoupled 31P NMR spectra of concentrated crude extract from strain WM6372 
grown on a minimal media containing glucose (A) or starch (B) as the main carbon sources, 
NH4Cl as nitrogen source, and PnAla with AEP as sources of phosphorus. No phosphonate 
signals were observed when K2HPO4 was used instead of PnAla and AEP. The signals at 18.4 
ppm and 18.1 ppm correspond to D/L-PnAla and AEP, while the signals at 21.1 ppm, 20.9 ppm, 
and 14.8 ppm may correspond to biosynthetic intermediates or degradation products. 
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Figure A.21. 1H-31P gHMBC spectrum of a concentrated crude extract from strain WM6372 
grown on a minimal media containing glucose, NH4Cl, PnAla, and AEP. The phosphorus is 
coupled to a single proton in the α-carbon and with a chemical shift of 2.7 ppm.  
 
In summary, natural phosphonates are a relatively unexplored group of 
metabolites that include several biologically active compounds. The screening for ppm-
positive strains by PCR and the construction of genomic DNA libraries are promising 
tools for the identification of organisms that produce phosphonate antibiotics. Utilizing 
this methodology, several phosphonate gene clusters were sequenced and 
characterized. Furthermore, the production conditions for two novel potential 
phosphonates were determined. Although, the ISP2 medium extract of WM6372 was 
shown to inhibit the growth of B. subtilis ATCC6633, whether the inhibition zone is 
produced by a phosphonate or not is not certain. Once purified, the chemical structures 
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and the biological activity can be determined. Currently, it is not possible to assure that 
the sequenced gene cluster encodes the biosynthesis of the detected phosphonate. 
Trials for heterologous production of the phosphonate by S. lividans may provide the 
answer to this question and may also allow the identification of the minimal gene cluster 
as previously performed for fosfomycin (4), phosphinothricin tripeptide (19), FR-900098 
(21), and dehydrophos (22). Deletion of genes, feeding experiments with identified 
intermediates, in vivo complementation experiments, and in vitro reconstitution of 
enzymes in combination with 31P NMR spectroscopy and mass spectrometry may allow 
the elucidation of the biosynthetic route. 
 
A.4. REFERENCES 
 
1. Brundtland, G., World Health Organization Report on Infectious Diseases 2000: 
Overcoming Antimicrobiol Resistance. http://www.who.int/infectious-disease-
report/2000/index.html. Accessed on Sept 30, 2008. 
2. Coates, A., Hu, Y. M., Bax, R., and Page, C. (2002) The future challenges facing 
the development of new antimicrobial drugs, Nat. Rev. Drug Discov. 1, 895-910. 
3. Baltz, R. H. (2006) Marcel Faber Roundtable: is our antibiotic pipeline 
unproductive because of starvation, constipation or lack of inspiration?, J. Ind. 
Microbiol. Biotechnol. 33, 507-513. 
4. Woodyer, R. D., Shao, Z. Y., Thomas, P. M., Kelleher, N. L., Blodgett, J. A. V., 
Metcalf, W. W., Van der Donk, W. A., and Zhao, H. M. (2006) Heterologous 
production of fosfomycin and identification of the minimal biosynthetic gene 
cluster, Chem. Biol. 13, 1171-1182. 
5. Metcalf, W. W., and van der Donk, W. A. (2009) Biosynthesis of phosphonic and 
phosphinic acid natural products, Annu. Rev. Biochem. 78, 65-94. 
6. Hilderbrand, R. L. (1983) The role of phosphonates in living systems, CRC 
Press, Boca Raton, Fla. 
7. White, A. K., and Metcalf, W. W. (2007) Microbial metabolism of reduced 
phosphorus compounds, Annu. Rev. Microbiol. 61, 379-400. 
224 
 
8. Okuhara, M., Kuroda, Y., Goto, T., Okamoto, M., Terano, H., Kohsaka, M., Aoki, 
H., and Imanaka, H. (1980) Studies on new phosphonic acid antibiotics. I. FR-
900098, isolation and characterization, J. Antibiot. 33, 13-17. 
9. Okuhara, M., Kuroda, Y., Goto, T., Okamoto, M., Terano, H., Kohsaka, M., Aoki, 
H., and Imanaka, H. (1980) Studies on new phosphonic acid antibiotics .3. 
Isolation and characterization of FR-31564, FR-32863 and FR-33289, J. Antibiot. 
33, 24-28. 
10. Takahashi, E., Kimura, T., Nakamura, K., Arahira, M., and Iida, M. (1995) 
Phosphonothrixin, a novel herbicidal antibiotic produced by Saccharothrix Sp. St-
888 .1. Taxonomy, fermentation, isolation, and biological properties, J. Antibiot. 
48, 1124-1129. 
11. Bayer, E., Zahner, H., Konig, W. A., Jessipow, S., Gugel, K. H., Hagele, K., and 
Hagenmai.H. (1972) Metabolites of microorganisms 98. Phosphinothricin and 
phosphinothricyl-alanylalanine, Helv. Chim. Acta 55, 224-&. 
12. Park, B. K., Hirota, A., and Sakai, H. (1977) Studies on new antimetabolite 
produced by microorganism .3. Structure of plumbemycin-A and plumbemycin-B, 
antagonists of L-Threonine from Streptomyces plumbeus, Agr. Biol. Chem. 41, 
573-579. 
13. Ogita, T., Gunji, S., Fukazawa, Y., Terahara, A., Kinoshita, T., Nagaki, H., and 
Beppu, T. (1983) The structures of fosfazinomycin-A and fosfazinomycin-B, 
Tetrahedron Lett. 24, 2283-2286. 
14. Watabe, H., JunkoYoshida, Tanaka, E., Ito, M., Miyadoh, S., and Shomura, T. 
(1986) Studies on a new phosphonic acid antibiotic, SF-2312. I. Screening 
method, taxonomy and biological activity., Meiji Seika Kenkyu Nenpo 25, 12. 
15. Hunt, A. H., and Elzey, T. K. (1988) Revised structure of A53868a, J. Antibiot. 
41, 802-802. 
16. Koguchi, T., Yamada, K., Yamato, M., Okachi, R., Nakayama, K., and Kase, H. 
(1986) K-4, a novel Inhibitor of angiotensin-I converting enzyme produced by 
Actinomadura spiculosospora, J. Antibiot. 39, 364-371. 
17. Yamato, M., Koguchi, T., Okachi, R., Yamada, K., Nakayama, K., Kase, H., 
Karasawa, A., and Shuto, K. (1986) K-26, a novel inhibitor of angiotensin-I 
converting enzyme produced by an Actinomycete K-26, J. Antibiot. 39, 44-52. 
18. Barry, R. J., Bowman, E., McQueney, M., and Dunaway-Mariano, D. (1988) 
Elucidation of the 2-aminoethylphosphonate biosynthetic pathway in 
Tetrahymena pyriformis, Biochem. Biophys. Res. Commun. 153, 177-182. 
 
225 
 
19. Blodgett, J. A., Zhang, J. K., and Metcalf, W. W. (2005) Molecular cloning, 
sequence analysis, and heterologous expression of the phosphinothricin 
tripeptide biosynthetic gene cluster from Streptomyces viridochromogenes DSM 
40736, Antimicrob. Agents Chemother. 49, 230-240. 
20. Blodgett, J. A. V., Thomas, P. M., Li, G., Velásquez, J. E., van der Donk, W. A., 
Kelleher, N. L., and Metcalf, W. W. (2007) Unusual transformations in the 
biosynthesis of the antibiotic phosphinothricin tripeptide, Nat. Chem. Biol. 3, 480-
485. 
21. Eliot, A. C., Griffin, B. M., Thomas, P. M., Johannes, T. W., Kelleher, N. L., Zhao, 
H., and Metcalf, W. W. (2008) Cloning, expression, and biochemical 
characterization of Streptomyces rubellomurinus genes required for biosynthesis 
of antimalarial compound FR900098, Chem. Biol. 15, 765-770. 
22. Circello, B. T., Eliot, A. C., Lee, J. H., van der Donk, W. A., and Metcalf, W. W. 
(2010) Molecular cloning and heterologous expression of the dehydrophos 
biosynthetic gene cluster, Chem. Biol. 17, 402-411. 
23. Ntai, I., Phelan, V. V., and Bachmann, B. O. (2006) Phosphonopeptide K-26 
biosynthetic intermediates in Astrosporangium hypotensionis, Chem. Commun., 
4518-4520. 
24. Letunic, I., Copley, R. R., Pils, B., Pinkert, S., Schultz, J., and Bork, P. (2006) 
SMART 5: domains in the context of genomes and networks, Nucleic Acids Res. 
34, D257-260. 
25. Marchler-Bauer, A., Anderson, J. B., Derbyshire, M. K., DeWeese-Scott, C., 
Gonzales, N. R., Gwadz, M., Hao, L., He, S., Hurwitz, D. I., Jackson, J. D., Ke, 
Z., Krylov, D., Lanczycki, C. J., Liebert, C. A., Liu, C., Lu, F., Lu, S., Marchler, G. 
H., Mullokandov, M., Song, J. S., Thanki, N., Yamashita, R. A., Yin, J. J., Zhang, 
D., and Bryant, S. H. (2007) CDD: a conserved domain database for interactive 
domain family analysis, Nucleic Acids Res. 35, D237-240. 
26. Hulo, N., Sigrist, C. J., Le Saux, V., Langendijk-Genevaux, P. S., Bordoli, L., 
Gattiker, A., De Castro, E., Bucher, P., and Bairoch, A. (2004) Recent 
improvements to the PROSITE database, Nucleic Acids Res. 32, D134-137. 
27. Bennett-Lovsey, R. M., Herbert, A. D., Sternberg, M. J., and Kelley, L. A. (2008) 
Exploring the extremes of sequence/structure space with ensemble fold 
recognition in the program Phyre, Proteins 70, 611-625. 
28. Rausch, C., Weber, T., Kohlbacher, O., Wohlleben, W., and Huson, D. H. (2005) 
Specificity prediction of adenylation domains in nonribosomal peptide 
synthetases (NRPS) using transductive support vector machines (TSVMs), 
Nucleic Acids Res. 33, 5799-5808. 
226 
 
29. Krogh, A., Larsson, B., von Heijne, G., and Sonnhammer, E. L. (2001) Predicting 
transmembrane protein topology with a hidden Markov model: application to 
complete genomes, J. Mol. Biol. 305, 567-580. 
30. Emanuelsson, O., Brunak, S., von Heijne, G., and Nielsen, H. (2007) Locating 
proteins in the cell using TargetP, SignalP and related tools, Nat. Protoc. 2, 953-
971. 
31. Hobbs, G., Frazer, C. M., Gardner, D. C. J., Cullum, J. A., and Oliver, S. G. 
(1989) Dispersed growth of Streptomyces in liquid culture, Appl. Microbiol. 
Biotechnol. 31, 272-277. 
32. Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F., and Hopwood, D. A. (2000) 
Practical Streptomyces genetics, John Innes Foundation, Norwich  (England). 
33. Hopwood, D. A. (1967) Genetic analysis and genome structure in Streptomyces 
coelicolor, Bacteriol. Rev. 31, 373-403. 
34. Hodgson, D. A. (1982) Glucose repression of carbon source uptake and 
metabolism in Streptomyces coelicolor A3(2) and its perturbation in mutants 
resistant to 2-deoxyglucose, J. Gen. Microbiol. 128, 2417-2430. 
35. Kino, K., Kotanaka, Y., Arai, T., and Yagasaki, M. (2009) A novel L-amino acid 
ligase from Bacillus subtilis NBRC3134, a microorganism producing peptide-
antibiotic rhizocticin, Biosci. Biotechnol. Biochem. 73, 901-907. 
36. Borisova, S. A., Circello, B. T., Zhang, J. K., van der Donk, W. A., and Metcalf, 
W. W. (2010) Biosynthesis of rhizocticins, antifungal phosphonate oligopeptides 
produced by Bacillus subtilis ATCC6633, Chem. Biol. 17, 28-37. 
37. Galperin, M. Y., and Koonin, E. V. (1997) A diverse superfamily of enzymes with 
ATP-dependent carboxylate-amine/thiol ligase activity, Protein Sci. 6, 2639-2643. 
38. Noda, M., Kawahara, Y., Ichikawa, A., Matoba, Y., Matsuo, H., Lee, D. G., 
Kumagai, T., and Sugiyama, M. (2004) Self-protection mechanism in D-
cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, 
and kinetics of its alanine racemase and D-alanyl-D-alanine ligase, which are 
target enzymes of D-cycloserine, J. Biol. Chem. 279, 46143-46152. 
39. Maillard, A. P., Biarrotte-Sorin, S., Villet, R., Mesnage, S., Bouhss, A., Sougakoff, 
W., Mayer, C., and Arthur, M. (2005) Structure-based site-directed mutagenesis 
of the UDP-MurNAc-pentapeptide-binding cavity of the FemX alanyl transferase 
from Weissella viridescens, J. Bacteriol. 187, 3833-3838. 
40. Zhang, W., Ntai, I., Kelleher, N. L., and Walsh, C. T. (2011) tRNA-dependent 
peptide bond formation by the transferase PacB in biosynthesis of the 
pacidamycin group of pentapeptidyl nucleoside antibiotics, Proc. Natl. Acad. Sci. 
U. S. A. 108, 12249-12253. 
227 
 
41. Kobayashi, S., Kuzuyama, T., and Seto, H. (2000) Characterization of the fomA 
and fomB gene products from Streptomyces wedmorensis, which confer 
fosfomycin resistance on Escherichia coli, Antimicrob. Agents Chemother. 44, 
647-650. 
42. Stachelhaus, T., Mootz, H. D., and Marahiel, M. A. (1999) The specificity-
conferring code of adenylation domains in nonribosomal peptide synthetases, 
Chem. Biol. 6, 493-505. 
43. Walsh, C. (2003) Antibiotics : actions, origins, resistance, ASM Press, 
Washington, D.C. 
44. Lebedev, A. V., and Rezvukhin, A. I. (1984) Tendencies of 31P chemical shifts 
changes in NMR spectra of nucleotide derivatives, Nucleic Acids Res. 12, 5547-
5566. 
45. Ternan, N. G., McGrath, J. W., and Quinn, J. P. (1998) Phosphoenolpyruvate 
phosphomutase activity in an L-phosphonoalanine-mineralizing strain of 
Burkholderia cepacia, Appl. Environ. Microbiol. 64, 2291-2294. 
46. Nakashita, H., Shimazu, A., and Seto, H. (1991) New screening method for C-P 
compound producing organisms by the use of phosphoenolpyruvate 
phosphomutase, Agric. Biol. Chem. 55, 2825-2829. 
47. Voncarstennlichterfelde, C., Fernandezibanez, M., Galvezruano, E., and 
Bellanato, J. (1983) Structural study of fosfomycin [(-)-cis-1,2-
epoxypropylphosphonic acid] salts and related-compounds, J. Chem. Soc. Perkin 
Trans. 2, 943-947. 
48. Hanaya, T., and Itoh, C. (2011) An efficient synthesis of antibiotic SF-2312 (3-
dihydroxyphosphoryl-1,5-dihydroxy-2-pyrrolidone), Heterocycles 82, 1675-1683. 
49. Ohba, K., Sato, Y., Sasaki, T., and Sezaki, M. (1986) Studies on a new 
phosphonic acid antibiotic, SF-2312. II. Isolation, physico-chemical properties 
and structure, Sci. Rep. Meiji Seika Kaisha 25, 18-22. 
50. Borisova, S. A., Christman, H. D., Metcalf, M. E., Zulkepli, N. A., Zhang, J. K., 
van der Donk, W. A., and Metcalf, W. W. (2011) Genetic and biochemical 
characterization of a pathway for the degradation of 2-aminoethylphosphonate in 
Sinorhizobium meliloti 1021, J. Biol. Chem. 286, 22283-22290. 
 
 
